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RESUMEN
Los feocromocitomas y paragangliomas (PPGLs) son tumores derivados de la cresta neural que se 
desarrollan a partir de las células cromafines de la médula adrenal (PCC) o de los paraganglios ubicados 
en la cabeza y cuello, abdomen y tórax (PGL). Aproximadamente un 75% de los PPGLs porta mutaciones 
mutuamente excluyentes, bien germinales (~40%) o somáticas (~30%), en al menos uno de 17 genes de 
susceptibilidad. El alto porcentaje de pacientes en el cual se ha identificado mutaciones germinales ha 
convertido a los PPGLs en los tumores humanos más hereditarios. Sin embargo, aún quedan casos de 
PPGLs con signos clínicos de heredabilidad, tales como tumores múltiples, edad temprana de aparición 
o historia familiar de la enfermedad, que no han sido diagnosticados genéticamente. 
Por ello, el objetivo primordial de esta tesis fue la identificación de nuevos genes de susceptibilidad a 
desarrollar PPGL en pacientes sin mutaciones en los principales genes identificados hasta la fecha.
En el primer proyecto, se aplicó un panel de secuenciación exómica dirigida que incluía genes relacionados 
con el ciclo de los ácidos tricarboxílicos (TCA) a una serie seleccionada de PPGLs hipermetilados. De 
esta forma, se pudieron identificar mutaciones somáticas en genes de susceptibilidad ya conocidos, como 
IDH1 y SDHC, así como alteraciones germinales en dos genes nuevos, GOT2 e IDH3B. Este estudio 
permitió enfatizar la relevancia del ciclo TCA en el desarrollo de PPGL, así como la participación de 
otras enzimas con funciones de intercambio metabólico entre la mitocondria y el citosol.
Entre los tumores seleccionados en el primer proyecto y sin mutaciones en ninguno de los genes 
incluidos en el panel, se encontraba el de una paciente joven con múltiples PGLs pero sin historia 
familiar de la enfermedad. En el segundo proyecto, se llevó a cabo la secuenciación germinal del exoma 
completo de un trio probando-padres, descubriéndose así una mutación de novo activadora en el gen 
DNMT3A (c.896A>T, p.Lys299Ile). La presencia de un fenotipo metilador en diversos tejidos mutados, la 
identificación de mutaciones somáticas subclonales en seis PGLs adicionales y el descubrimiento de una 
segunda mutación germinal (c.952C>T, p.Arg318Trp) en una paciente con historia familiar de PPGL, 
respaldaron el rol patogénico de las alteraciones en DNMT3A.
Finalmente, tras ampliar la serie de pacientes analizados con el panel de genes relacionados con el 
ciclo TCA, identificamos cinco variantes germinales diferentes en el gen DLST en siete pacientes no 
relacionados con PPGL. Se pudo demostrar que una mutación heterocigota recurrente en DLST 
(c.1121G>A, p.Gly374Glu), hallada en cuatro pacientes diferentes, confería susceptibilidad a desarrollar 
PPGL múltiple. La ausencia de proteína DLST salvaje tanto en tumores como en células DLST-KO 
interrumpía la actividad del complejo OGDH, desencadenando la acumulación de metabolitos y un 
perfil homogéneo tanto de expresión como de metilación en los tumores con mutación en DLST.
Resumen/Abstract
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ABSTRACT
Phaeochromocytomas and paragangliomas (PPGLs) are neural crest-derived tumours that arise from the 
chromaffin cells of the adrenal medulla (PCC) or from the paraganglia of the head and neck, abdominal 
or thoracic regions (PGL). Approximately 75% of PPGLs carry mutually exclusive germline (~40%) or 
somatic (~30%) mutations affecting one of at least 17 major susceptibility genes. The high percentage of 
patients for which germline mutations have been found has turned PPGLs into the most heritable of all 
human tumours. However, there are still PPGL cases with clinical signs of heritability, such as multiple 
tumours, early age at onset or family history of the disease, that are genetically undiagnosed. 
Therefore, the principal aim of this thesis was the identification of new PPGL susceptibility genes in 
patients without mutations in any of the main driver genes identified so far. 
In the first project, a targeted exome sequencing panel of tricarboxylic acid (TCA) cycle-related genes 
was applied to a selected series of hypermethylated PPGLs. In this way, it was possible to identify somatic 
mutations in already known PPGL susceptibility genes such as IDH1 and SDHC, as well as germline 
alterations in two new genes, GOT2 and IDH3B. This study further highlighted both the relevance of the 
TCA cycle in PPGL development, as well as the involvement of other metabolic enzymes with a role in 
metabolite exchange between the mitochondria and the cytosol.
Among the tumours selected in the first project without mutations in any of the genes included in 
the panel, there was one from a young patient with multiple PGLs but without family history of the 
disease. In the second project, whole-exome germline sequencing was applied to a parents-proband trio, 
uncovering a de novo germline gain-of-function mutation in the DNMT3A gene (c.896A>T, p.Lys299Ile). 
The presence of a methylator phenotype in several mutated tissues, the identification of subclonal 
somatic mutations in six additional PGLs and the finding of a second DNMT3A germline mutation 
(c.952C>T, p.Arg318Trp) in a patient with family history of PPGL, further supported the pathogenic role 
of alterations in this gene. 
Finally, upon extension of the series of patients analysed with the TCA cycle-related genes panel, we 
identified five different germline DLST variants in seven unrelated PPGL patients. We demonstrated that 
a recurrent heterozygous DLST mutation (c.1121G>A, p.Gly374Glu) found in four different patients, 
conferred susceptibility to develop multiple PPGL. The absence of wild-type DLST both in tumours 
(by germline mutation and loss of heterozygosity due to uniparental disomy) and in DLST-KO cells, 
disrupted the activity of the OGDH complex, triggering the accumulation of metabolites and leading to 
a homogeneous expression and methylation profile in DLST-mutated tumours.
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INTRODUCTION
Introduction
29
1. GENERAL FEATURES OF PHAEOCHROMOCYTOMA AND 
PARAGANGLIOMA
1.1. DISEASE DEFINITION
Phaeochromocytomas (PCCs) and paragangliomas (PGLs), together known as PPGLs, are 
neuroendocrine tumours derived from chromaffin cells of the adrenal medulla and from neural crest 
progenitors of extra-adrenal paraganglia, respectively. Sympathetic PPGLs, including PCCs and thoracic 
and abdominal (A-PGL) PGLs, are predominantly catecholamine-producing tumours. Whereas masses 
derived from parasympathetic paraganglia, mainly located in the head and neck region (HN-PGL) and 
less frequently in the thorax, are principally non-secreting tumours1–3.
1.2. EPIDEMIOLOGY
PPGL is considered a rare disease with an incidence between 2-8 patients per million per year (1000-2000 
new cases diagnosed every year) in the US3, from which 10-20% occur in paediatric cases4. However, it 
remains a fact that up to 25% of PPGLs are discovered as incidentalomas5 and diagnosis may be even 
missed during life; finding undiagnosed tumours in 0.05–0.1% of patients post-mortem6. The prevalence 
of PPGL in hypertensive patients varies between 0.2 and 0.6%7. Despite they can appear at any age, they 
have a peak incidence between the third and fifth decade of life and it occurs equally in men and women8.
1.3. CLINICAL PRESENTATION
The heterogeneous signs and symptoms of PPGLs are attributed to hemodynamic and metabolic actions 
of the catecholamines synthetized and released by these tumours including noradrenaline, adrenaline 
and dopamine9. Patients with a functional PPGL can present with hypertension and tachycardia, and a 
wide range of symptoms, both paroxysmal and sustained, that are indistinguishable from common stress 
disorders. The symptoms include the classic triad: palpitations, headaches, and sweating, as well as many 
others such as flushing, tremors, abdominal or chest pain, nausea, fatigue weight loss, heat intolerance, 
visual disturbance, dizziness, change in bowel habit, and neurological symptoms and an “impending 
sense of doom”10. Additionally, catecholamine release of functional PPGLs7,11 may derive in cardiac 
complications such as stroke, aortic dissection, myocardial infarction, arrhythmias and heart failure12,13. 
Symptoms are also often absent, even in the face of significant elevations of catecholamines or their 
metabolites, and it is frequent an incidentally discovered adrenal mass in PPGL patients. PPGLs enlarge 
over time and specially HN-PGLs may cause mass effect symptoms such as pain and nerve paralysis by 
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encroaching upon or extending into adjacent tissues and organs7.
Despite predominantly benign and cured by surgical removal, PPGLs present a significant morbidity and 
mortality, due to clinical aggressiveness of tumours with multiple recurrences and metastatic disease for 
which therapeutic options remain scarce14. Between 10% (PCC) to up to 40% (PGL) of patients develop 
metastases in distant non-chromaffin tissues11,15 such as lymph nodes (80%), bones (71%), liver (50%), 
and lungs (50%)16.  Metastases are rarely found in the pancreas, breast, central nervous system, or skin. As 
expected, metastatic PPGL (M-PPGL) patients present a shorter overall survival, with a heterogeneous 
5-year survival rate between 40-95% in adults17,18.
1.4. PREDICTORS OF OUTCOME
PPGL risk factors are limited and imprecise. Conventional approaches include histological techniques 
such as the proliferation Ki-67 index, and scoring systems as the PASS (PCC of the adrenal gland scaled 
score) and GAPP (grading system for PPGL); tumour size (>5cm) and location (PGL>PCC) together 
with plasma levels of 3-methoxytyramine19 (dopamine secretion)20. Some of these predictors have 
been included into the new staging classification of PPGLs, TNM (primary tumour size, lymph node 
involvement, and distant metastasis), proposed by the American Joint Committee on Cancer14. 
The best known genetic predictor of M-PPGL is the presence of germline mutations in the SDHB gene. 
Indeed, more than one third of patients with M-PPGL carry a germline SDHB mutation and half of 
SDHB-mutated patients will ultimately develop metastatic disease, having a lower overall survival than 
other M-PPGL patients21.
However, any of the before mentioned predictive factors could help in the differentiation of benign and 
metastatic tumours at early stages, something crucial according to the recommendations of the World 
Health Organization in order to diagnose and treat M-PPGLs beforehand22.
Therefore, it is of high relevance a further understanding of the molecular pathogenesis of the disease 
that would provide new markers of malignancy and may offer effective therapeutic options for tumours 
with negative clinical outcomes.
2. DIAGNOSIS 
Diagnosis of PPGL relies on biochemical evidence of catecholamine release, imaging studies, 
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histopathological classification of the tumours, and identification of genetic syndromes, all of which can 
be used as prognostic markers.
2.1. BIOCHEMICAL
Biochemical testing should be performed in symptomatic patients, patients diagnosed with an 
incidentaloma, and those who have hereditary predisposition (i.e. mutation carriers) or syndromic 
features suggesting hereditary PPGL. Catecholamines are converted into their inactive metabolites 
(metanephrine and normetanephrine) by the catechol-O-methyltransferase present in PPGL tumour 
cells, independently of the exocytotic catecholamine release, and are subsequently released into the 
plasma in a continuous way. Recommended optimal screening should include fractionated metanephrine 
(adrenergic), normetanephrine (noradrenergic), and 3-methoxytyramine (dopaminergic), measured in 
plasma and/or urine. Finally, chromogranin A can be used as an alternative biochemical parameter for 
silent PPGLs23.
2.2. IMAGING
After confirming the diagnosis of PPGL biochemically, imaging studies are critical for primary tumour 
localization, detection of multifocality, and metastases, but there is not a ‘gold-standard’ imaging 
technique for all patients. Despite their cost and availability, a combination of both, anatomical and 
functional imaging has presented with the highest sensitivity for PPGL staging. First line anatomical 
imaging modalities include computed tomography (CT) and magnetic resonance imaging. They provide 
a high sensitivity that allow precise tumour delineation, which is critical for pre-surgical evaluation, but 
a low specificity (75-80%)24,25.
In the current era, PPGL imaging has moved beyond towards functional characterization of tumours, 
which provides a higher specificity and it is particularly recommended for diagno¬sis of multi-focal 
or metastatic disease. Planar scintigraphy, single-photon emission computed tomography (SPECT) and 
positron emission tomography (PET) have improved the sensitivity and spatial resolution. Functional 
imaging takes advantage of radiotracers, ligands that target cell membrane transporters or the vesicular 
catecholamine transport system. For the time being, the choice of ligand should be personalized according 
to features such as tumour location, metastases and underlying genetic mutation, as it has been proposed 
by the Endocrine Society guidelines7.
Norepinephrine membrane transporter
Iodine-123-metaiodobenzylguanidine (123I-MIBG) is a guanidine analogue, similar to noradrenaline, 
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and it is the most frequently used and available ligand for PPGL localization with scintigraphy and 
SPECT. Its sensitivity for PCC detection is excellent (nearly 100%). 18F-fluorodopamine PET/CT has the 
highest sensitivity and specificity across genetically different PGLs (tumours negative or with unknown 
SDHB genotype), and it is the preferred technique for the localization of the primary PGL and to rule out 
metastases, except in HN-PGLs24,26.
Somatostatin receptors (SSTR)
Overexpression of SSTRs was recently shown in SDH-deficient PPGLs, and since then, the use of different 
radiolabelled somatostatin analogues have been re-examined not only for the diagnosis, but also for 
therapeutic uses27. 111In pentetreotide (OctreoscanTM) is used in combination with PET28. Preliminary 
data indicates that 68Ga-DOTATATE shows sensitivities approaching 100% and very high and selective 
affinity for SSTR2, being able to give an excellent diagnostic accuracy, superior to all other functional 
and anatomical imaging modalities in the evaluation of sporadic and SDHB-mutated M-PPGL, and HN-
PGLs29–31.
Glucose membrane transporters
18F-fluorodeoxyglucose (18F-FDG) accumulates in proportion to the glycolytic cellular rate, providing an 
index of intracellular glucose metabolism, a constant feature in PPGL. Sensitivity of 18F-FDG-PET is very 
high for patients with SDHB-related M-PPGL. 
Amino acid transporter system
Dihydroxyphenylalanine (DOPA) is the precursor of all endogenous catecholamines, and PPGL cells 
can take it up through the amino acid transporter system. 18F-FDOPA PET/CT is recommended for the 
localization of non-M-PPGL, especially in HN-PGLs24.
2.3. IMMUNOHISTOCHEMISTRY
After surgery, immunohistochemistry (IHC) can give information on the occurrence of a mutation 
in certain genes but it also can provide a classification of variants of unknown significance (VUS). A 
negative SDHB staining indicates a defect in any of the SDH-related genes (SDHx) with high sensitivity 
and specificity, and it has become a rapid and inexpensive preliminary test for testing SDHx deficiency 
in tumour tissue32.  In a complementary way, SDHA IHC is also used to detect tumours with SDHA 
mutations, as they are negative at IHC for both SDHB and SDHA.
There are other optimized IHC assays, such as the use of MAX antibody for the identification of truncating 
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MAX mutations, and S-(2-succinyl) cysteine staining for tumours deficient in FH. Additionally, tumours 
with mutations in any of the tricarboxylic acid (TCA) cycle genes show loss of 5-hydroxymethylcytosine 
(5-hmC) expression due to the epigenetic impairment of 5-mC hydroxylation33.
2.4. GENETIC DIAGNOSIS
Preventive medicine has been dramatically improved by cancer genetics. The identification of 
susceptibility genes for hereditary forms of cancers in the past decades opened avenues for detection 
of second primary and recurrent tumours. Once a given germline mutation is detected, genotype-
phenotype associations allow the risk stratification and screening of relatives, and thus the diagnosis of 
tumours in an asymptomatic stage in carriers becomes possible. 
Taking into account the high frequency of germline mutations found in patients with apparently sporadic 
PPGL, current guidelines indicate consideration of genetic testing in all patients with PPGL independent 
of a clear family history7. Systematic screening of all PPGL-related genes (including many of them with 
low prevalence) has become a time- and resource-consuming process.
When facing a PPGL patient, genetic testing algorithms have been proposed in order to help the clinician 
in prioritizing one or a few genes that should be tested in first place34,35. Those algorithms take into 
consideration three levels of analysis: biochemical phenotype (catecholamines released by the tumour), 
immunohistochemical characterization, and clinical presentation36,37. Including the latter, age at onset, 
location and number of tumours, family history, presence of metastases, and whether the PPGL is part 
of a syndrome such as neurofibromatosis type 1 (NF1), multiple endocrine neoplasia type 2 (MEN2, 
caused by mutations in the RET gene), von Hippel-Lindau disease (VHL), hereditary PGL (SDHx), 
polycythaemia PGL syndrome (EPAS1) or Reed’s syndrome (FH). In the end, genetic diagnostics in 
PPGLs is a multidisciplinary approach combining the expertise of geneticists, endocrinologists, clinical 
chemists, and pathologists38.
Traditionally, genetic diagnosis of PPGL has been performed by PCR-based amplification followed by 
Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA, MRC-Holland Inc.) 
for large gene rearrangements. However, due to the large number of driver genes identified so far, this 
single-gene testing technology is becoming unfeasible as it is laborious, costly and time consuming37. 
The use of high-throughput DNA sequencing technology or next generation sequencing (NGS), where 
simultaneously multiple genes could be tested, makes the detection of mutations in PPGL predisposing 
genes easier39.
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3. TREATMENT AND MANAGEMENT
Preoperative management of PPGLs requires the administration of α1-adrenergic blocking agents followed 
by β-blockers, both necessary to prevent catecholamine-mediated life-threatening complications40. 
Nevertheless, reports of high-dose toxicity and lack of effectiveness of these drugs makes often necessary 
the administration of additional anti-hypertensive drugs to PPGL patients41.
3.1. SURGERY
The preferred treatment for localized primary PPGLs is early surgical resection by laparoscopic 
approach42. However, if metastases are suspected, open laparotomy is recommended in order to remove 
as much malignant tissue as possible and to prevent tumour rupture43.
In the case of bilateral PCC, the classical outcome would be bilateral adrenalectomy with subsequent 
Addison’s disease and lifelong depending on steroid replacement. Partial adrenalectomy sparing at least 
one of the adrenal cortices is a highly successful treatment option that should be the surgical approach 
of choice to prevent permanent hipercortisolism7,44. HN-PGLs are rarely resected, this is due to their 
generally benign and non-catecholamine production phenotype, the risk of intraoperative vascular 
accidents and postoperative low cranial nerve neuropathy45.
After PPGL resection, follow-up, for at least 10 years, is crucial to detect metachronous PPGLs or 
recurrences as well as new events in carriers of germline mutations in PPGL susceptibility genes3,46.
Patients with M-PPGL are rarely cured by surgery, facing a dismal prognosis. Although symptoms usually 
improve with the different therapies available such as chemotherapy, radiotherapy or with the molecular 
targeted options, it is unclear whether any of the therapies modifies the natural history of M-PPGL or 
prolongs patient survival. Therefore, it is considered an orphan disease for which curative chances are 
very limited47.
3.2. CHEMOTHERAPY
After surgery, M-PPGL are treated with systemic chemotherapy with a combination of cyclophosphamide, 
vincristine and dacarbazine, although patients generally do not have a complete response48. Temozolamide 
(an oral alternative of dacarbazine) in combination with thalidomide, both acting as antiangiogenic 
agents, were effective for one of three M-PPGL patients in a phase II trial49. To note, it has been reported 
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that SDHB mutations are responsible for the association with partial response to temozolamide in 
M-PPGL patients50.
3.3. RADIOTHERAPY
For unresectable tumours detected by 123I-MIBG scintigraphy, radiotherapy with 131I-MIBG is 
recommended51. 131I-MIBG is taken up by the noradrenaline transporter, and inside the tumour cell, 
releases lethal radiation that induces DNA damage and cell death52. The use of histone deacetylase 
(HDAC) inhibitors increases 123I-MIBG uptake, thus enhancing the therapeutic efficacy of the treatment53. 
A phase II clinical trial was performed (some others are ongoing) with the second-line MIBG, Ultratrace 
Iobenguane 131I (AZEDRA®, Progenics Pharmaceuticals, Inc.), a highly specific radiopharmaceutical 
agent that delivers very high levels of radioactivity per dose. Almost all treated patients had a tumour 
response and lower rate of cardiovascular events54. Peptide receptor radionuclide therapies such as 
90Y-DOTATOC and 177Lu-DOTATATE bind to somatostatin receptors and deliver lethal radiation, 
however, initial prospective studies have been disappointing55,56. Remarkably, toxicity associated with 
chemotherapy and radiopharmaceutical agents cannot be underestimated57.
3.4. MOLECULAR TARGETED THERAPIES
Our increasing knowledge on the molecular biology of PPGLs is helping to extend the number of 
promising therapeutic options. Unfortunately, these potential drugs present a shortage of positive results 
as well as different adverse effects.
- Some anti-proliferative agents have been included in specific clinical trials such as everolimus (mTOR 
pathway inhibitor), showed modest efficacy58, or tested only in preclinical models, AZD8055 (ATP-
competitive dual mTORC1/2 inhibitor59), Indotecan/LMP-400 (topoisomerase 1 inhibitor)60, and Hsp90 
inhibitors (tanespimycin and ganetespib). 
- Tyrosine kinase receptor (RTK) inhibitors prevent neoangiogenesis, cell growth, cell migration, 
development of resistance and may induce apoptosis61–63. Sunitinib is the first RTK inhibitor recognized 
as a potential treatment for patients with M-PPGL. It also has a direct cell effect, causing tumour size 
reduction, disease stabilization, and hypertension improvement in some patients22. In a retrospective 
review of a series of 17 patients treated with sunitinib, 47% experienced clinical benefit, being most of 
them carriers of SDHB mutations57. There are several phase II trials, already finished or still ongoing 
(www.clinicaltrials.gov), using multikinase inhibitors which endpoints are response rate and/or 
progression-free survival14: FIRSTMAPPP-sunitinib (recruiting), pazopanib (halted, only 1/7 patients 
had a partial response64), axitinib (active), lenvatinib (recruiting), cabozantinib (recruiting M-PPGL 
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mainly with bone metastasis), and dovitinib (active). Imatinib mesylate (Glivec), a selective inhibitor of 
c-ABL, and the PDGF and stem cell ligand (c-kit) RTKs exhibited no response in two cases65.
- Proteasome inhibitors such as bortezomib in combination with salinosporamid A showed PPGL cell 
death66. 
- DNA methyltransferase inhibitor, Guadecitabine (SGI-110) has been included in a phase II clinical 
trial for the treatment of SDHx-mutated PPGL patients (those exhibiting a CpG island methylation 
phenotype, CIMP profile) (www.clinicaltrials.gov). 
-Immunotherapy drugs that fight hypoxia/pseudohypoxia-derived immune system disarrangements67 
include interferon alpha-2b and octreotide analogues that have been already used routinely in the 
treatment of gastroenteropancreatic neuroendocrine tumours, melanoma, kidney cancer, and occasionally 
M-PPGLs68. A recent retrospective study showed promising results, indicating that immunotherapy 
could have a positive impact on patients with M-PPGL69. Moreover, a phase II clinical trial of the immune 
checkpoint inhibitor pembrolizumab is currently underway for M-PPGL patients.
- HIF2A (hypoxia inducible factor 2 alpha) pathway inhibitors have been tested in cancer patients with 
low success22. However, new potent HIF2A antagonists targeting the cavity of the protein (PT2385 and 
PT2977), are quite promising despite they have not been tested yet for M-PPGL70,71.
- Preclinical studies in other cancers suggest that ATR inhibitors and Wnt antagonists could also have a 
benefit in M-PPGL patients, and therefore they should be explored in clinical trials72.
- Recent findings in SDH- and FH-mutated PPGLs showed that the accumulation of succinate or fumarate 
compromises homologous recombination (HR) DNA repair in the tumours. Thus, those PPGL patients 
could benefit from the vulnerability of tumoural cells to synthetic-lethal targeting with poly(ADP)-
ribose polymerase (PARP) inhibitors73.
4. PPGL GENETIC SCENARIO
PPGLs are considered the tumours with one of the highest degrees of heritability amongst all human 
neoplasms. Approximately 40% of patients suffering from this highly genetically heterogeneous disease 
carry a germline mutation36 in one of 17 different major susceptibility genes. This includes classic driver 
genes such as RET, NF1, VHL, SDHD, SDHC, and SDHB as well as the more recently identified SDHA, 
SDHAF2, TMEM127, MAX, FH, MDH2, EGLN1, EGLN2, KIF1B, MET, and SLC25A1174,75 (Figure 1). 
Furthermore, somatic mutations in some of these driver genes (mainly RET, VHL, NF1 and MAX) and in 
others (EPAS1, HRAS, IDH1, CSDE176, and ATRX77 among others) can be detected in an additional 30% 
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SETD2, TERT, TP53
Methylation status
 Figure 2.  PPGL molecular signatures. Classification according to genotype, clinical and multi-omics data.
of tumours1. Finally, there are also PPGL patients carrying somatic postzygotic mutations that occurs in 
early developmental stages (i.e. in EPAS178 and H3F3A79), and tumours affected by somatic gene fusions 
(i.e. MAML376).
Except for the case of certain oncogenes such as RET, EPAS1, H3F3A, MET, IDH1, and HRAS, most 
PPGL susceptibility genes are tumour suppressor genes. Thus, patients carry an autosomal dominant 
heterozygous germline mutation in one of the PPGL tumour suppressor genes, and tumour development 
occurs following a somatic second hit or loss of the wild-type (WT) allele, that leads to loss of heterozygosity 
(LOH) and to the subsequent inactivation of the gene’s function36,80.
Based on multi-omics data (transcriptomic gene expression, copy number alterations, metabolomics 
signature, miRNA profiles and DNA methylation), PPGLs can be classified in different clusters according 
to their genetic background81–83 (Figure 2). 
This omics-based classification of PPGLs have guided the discovery of novel susceptibility genes during 
the last years. The most studied are the transcriptional clusters (1, 2 and 3), and we will use them in 
this thesis to stratify the different PPGL susceptibility genes. Cluster 1 (hypoxic/angiogenic cluster, 
consisting in tumours with mutations in SDHx, VHL, EPAS1 and FH genes) comprises tumours with 
features resembling the cellular response to hypoxia and a predominantly noradrenergic secretion. 
Cluster 2 (kinase-signalling cluster, which includes tumours carrying mutations in RET, NF1, TMEM127 
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and MAX genes, as well as most of the sporadic tumours) groups tumours, producing both adrenaline 
and noradrenaline, that display a profile of activated tyrosine kinase receptors and increased protein 
translation. Finally, Cluster 3 includes Wnt signalling-related tumours.
4.1. CLUSTER 1: PSEUDOHYPOXIA DRIVEN TUMOURS
A common feature for tumours carrying mutations in Cluster 1 genes, is the aberrant and constitutive 
activation of hypoxia inducible factors (HIFs) even under normal cellular oxygen levels, a condition 
known as pseudohypoxia. HIFs are heterodimeric transcription factors and their inducible components, 
the α-subunits (HIF-1α, -2α and -3α), are tightly regulated by hydroxylation by prolyl hydroxylase domain 
(PHD) proteins: PHD1, PHD2 and PHD3 (encoded by EGLN2, EGLN1 and EGLN3 genes, respectively)84, 
enabling HIF recognition for proteasome-mediated degradation1. Upon pseudohypoxia, HIFs bind DNA 
at hypoxia response elements thereby activating not only the EPO gene but also a broad range of other 
genes that orchestrate adaptation to hypoxia and tumorigenesis when sustained (VEGF, TGFα, GLUT1, 
CCD1, Oct4, CXCR4, etc.). They are thought to have a key role in stimulating angiogenesis, cellular 
proliferation, reduced apoptosis, invasion and metastasis84–86. In these pseudohypoxic tumours, the 
Warburg effect causes downregulation of respiration that is substituted by aerobic glycolysis, resulting 
in increased glucose consumption for energy production85. Beyond genetics, prolonged exposure to 
hypoxia has been reported as an environmental risk factor for PPGL in people living at high altitude87, as 
well as in patients with cyanotic congenital heart disease88,89.
The Cluster 1 can be subdivided, in turn, into Cluster 1A and Cluster 1B.
4.1.1.  CLUSTER 1A
This subcluster comprises tumours carrying mutations in genes encoding energy metabolism enzymes 
such as the succinate dehydrogenase (SDH) subunits (SDHx genes), fumarate hydratase or fumarase 
(FH), malate dehydrogenase 2 (MDH2), isocitrate dehydrogenase 1 (IDH1) or solute carrier family 25 
member 11 (SLC25A11).
In addition to the metabolic re-wiring that occurs after the loss-of-function of TCA cycle enzymes, 
alterations in Cluster 1A genes also lead to the accumulation of “oncometabolites” such as succinate, 
fumarate, malate or 2-hydroxyglutarate (2HG). Among other functions90, these oncometabolites act as 
competitors of αKG to broadly inhibit the activity of αKG-dependent dioxygenases, such as ten-eleven 
translocation DNA hydroxylases and Jumonji (JMJ) histones demethylases91,92. This causes a global 
hypermethylation with a characteristic CIMP profile in the tumours, leading to altered gene expression 
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and contributing to tumorigenesis, something already observed for glioblastomas93 and clear cell renal 
cell carcinomas (ccRCC)94 carrying metabolic alterations such as IDH1/2 and FH/SDHB mutations, 
respectively. Recently, fumarate and succinate have been also found to suppress the HR DNA-repair 
pathway involved in the resolution of DNA double-strand breaks and the maintenance of genomic 
integrity73. 
- SDHx genes
The SDH enzyme complex is a heteroligomer that comprises four structural subunits: two hydrophilic 
catalytic subunits, SDHA and SDHB, and two hydrophobic subunits that anchor the catalytic ones to the 
inner mitochondrial membrane, SDHC and SDHD. The fifth SDH gene, SDHAF2, encodes a cofactor 
responsible for flavination of SDHA. The SDH complex catalyses the oxidative dehydrogenation of 
succinate to fumarate in the TCA cycle95 and it is also functionally involved in the electron transport 
chain forming the mitochondrial complex II96 (Figure 3). Germline mutations in the SDHx genes 
cause disassembly of the mitochondrial complex, with loss of SDH enzymatic activity and therefore 
triggering the accumulation of its substrate, succinate. Apart from the aforementioned CIMP profile, 
this accumulation competitively inhibits prolyl hydroxylases like PHDs, contributing to activation of 
the pseudohypoxic pathway97,98. Moreover, the accumulation of succinate also causes downregulation 
of the enzyme responsible for the conversion of norepinephrine to epinephrine, therefore inducing the 
characteristic noradrenergic phenotype of SDHx tumours92.
Figure 3. Structure of the succinate dehydrogenase enzyme. Adapted from Hederstedt, Science 2003.
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Germline loss-of-function mutations in SDHA, SDHAF2, SDHB, SDHC and SDHD (together accounting 
for 20% of all PPGLs) cause the well-characterized familial PGL syndromes known as PGL599 (MIM: 
#614165), PGL2100 (MIM: #601650), PGL4101 (MIM: #115310), PGL3102 (MIM: #605373) and PGL1103 
(MIM: #168000), respectively. Additional solid tumours such as gastrointestinal stromal tumours 
(GISTs)104, ccRCCs105 and pituitary adenomas106 have been associated, although rarely, with these familial 
PGL syndromes107. Only 30% of SDHx-mutated cases have a family history of the disease mainly due to 
the incomplete penetrance of these syndromes95. 
SDHD became the first metabolic gene whose mutations were associated with the development of 
cancer103. Germline inactivating mutations in this gene show a high penetrance (43.2% at the age of 60 
years95) with maternal genomic imprinting, and are the cause of multiple HN-PGLs, although rarely 
malignant108. On the contrary, SDHB-related tumours are usually diagnosed in patients with single 
PGLs, mutations in this gene show a low penetrance (21.8% by age 60 years95), and they present a high 
risk of malignancy (50%)36 and ccRCC development (4.7% by age 60 years95). As previously mentioned, 
the presence of mutations in SDHB is the best biomarker of poor prognosis and malignancy in PGL 
syndromes21,109. Mutations in SDHB and SDHD account for the great majority (over 60%) of all SDHx-
related PGL patients.
SDHC was the second SDHx gene identified as a cause of PPGLs, however its frequency is much lower 
than SDHB- and SDHD-related PPGLs, accounting for less than 1% of the patients. SDHC mutations 
result primarily in HN-PGLs but have also been identified in patients with sympathetic PGLs. Recently, 
postzygotic epimutations in SDHC promoter were identified in patients with PGLs110, Carney triad 
(MIM: #604287) (GIST, pulmonary chondroma and PGLs)111, and Carney-Stratakis syndrome (MIM: 
#606864) (co-occurrence of PGL and GIST)112.
Familial PPGL related to mutations in SDHA shows a prevalence of 3%, and it has a very low penetrance 
and multifocality113. Finally, mutations in the SDHAF2 subunit have also been reported in HN-PGL with 
maternal imprinting36, common multifocality114, and very low prevalence (0.1%113).
- FH
FH catalyses the reaction that follows SDH complex activity in the TCA cycle, the conversion of fumarate 
to malate. Deficiency in FH activity results in the accumulation of the precursor metabolite, fumarate, 
which, as happens with succinate, affects the function of certain αKG-dependent enzymes91. But in this 
case, both JMJ demethylases inhibition and HIFα accumulation are reactive oxygen species (ROS)-
dependent, with a ROS increased in FH-mutant cells and tumours115. Phenotype of FH affected patients 
(with a prevalence of ~1% in PPGL patients11) is characterized by multifocal PPGLs and a high frequency 
of metastatic disease116.  FH deficiency is also linked to hereditary cutaneous and uterine leiomyomas 
(Reed’s syndrome) and type 2 papillary renal carcinoma (MIM: #150800), being the appearance of PPGLs 
42
Introduction
in these patients exceptional117. 
- MDH2
MDH2 encodes malate dehydrogenase 2, which is essential for the reversible oxidation of malate 
to oxaloacetate in the TCA cycle. This tumour suppressor gene was first reported mutated, with an 
incomplete penetrance, in a single family with multiple malignant PGLs118. Very recently, the same 
mutation has been found in another patient with malignant PCC, and additional pathological variants 
have been also reported accounting for <1% of the patients119.
- IDH1/2
Somatic mutations in the IDH1 gene, frequently found in central nervous system tumours120, have 
been also identified in PPGLs leading to a neomorphic production of D-2HG  that finally causes the 
characteristic CIMP profile. However, they are low frequent events in PPGL (<1%)76,112,121. Very recently, 
a single HN-PGL carrying a somatic mutation in IDH2 has also been reported38.
- SLC25A11
Last year, germline mutations in the tumour suppressor gene SLC25A11 have been identified in seven 
unrelated patients, many of them with metastatic A-PGLs. SLC25A11-mutated tumours showed a 
reduction of αKG levels with the pertinent accumulation of aspartate as a consequence of the malate-
aspartate shuttle disruption. SLC25A11 has been classified into Cluster 1A due to the SDHx-like molecular 
phenotype exhibited by the mutated tumours, including pseudohypoxia and a CIMP profile. SLC25A11 
gene mutations could account for 1% of all PPGL75.
4.1.2.  CLUSTER 1B
Cluster 1B genes such as VHL (encoding a HIF ubiquitin ligase), EPAS1 (encoding HIF-2α itself) 
and EGLN1/EGLN2 (encoding PHD proteins) are themselves constituents of the cellular response to 
hypoxia. Tumours carrying mutations in these “pseudohypoxic genes” show an intermediate methylation 
phenotype utterly different from Cluster 1A.
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- VHL
The VHL (von Hippel-Lindau) gene encodes a member of an E3 ubiquitin ligase complex that 
addresses the α subunits of HIF-1 and HIF-2 proteins to proteasomal degradation under normoxia. 
Loss-of-function mutations in VHL, disrupt the process of HIF-1α degradation. Then, HIF-α molecules 
are stabilised leading to sustained expression of pro-tumorigenic hypoxic genes122. Additionally, in a 
HIF-independent manner, VHL can mediate tumorigenesis through regulation of the extracellular 
matrix, apoptosis, transcription, or stabilizing microtubules123. Germline (predominantly missense 
in PPGL124), mutations in the tumour suppressor gene VHL, occur in the setting of VHL syndrome 
(MIM: #193300)125, where the most common associated tumours are hemangioblastomas of the brain, 
spinal cord, and retina, ccRCC, endolymphatic sac tumours, PPGLs (up to 20% of VHL patients), and 
pancreatic neuroendocrine tumours126. PPGLs tend to occur in younger patients and are frequently 
bilateral and occasionally multifocal, accounting for <10% of all PPGLs127. Somatic mutations of VHL 
are also frequently found in PPGLs (~10%)128.
- EPAS1 
The endothelial PAS domain-containing protein 1 gene (EPAS1), also known as HIF2A, encodes one of 
the members of the HIF family of transcriptional regulators involved in hypoxic response129. Gain-of-
function somatic mutations (found in ~5% of sporadic PPGLs130) at EPAS1 hydroxylation sites disrupt 
the recognition of EPAS1 by members of the PHD family, and therefore its hydroxylation and the 
following degradation by pVHL1. Stabilization and constitutive activation of EPAS1 leads to tumour 
growth in vivo, through a specific sensitivity of chromaffin cells to EPAS1 oncogenic properties such as 
the activation of the oncogene MYC131. Somatic mosaicism caused by postzygotic EPAS1 mutations can 
lead to a non-inherited syndrome presenting with multiple and recurrent PGLs, somatostatinoma and 
congenital polycythaemia (also known as Pacak-Zhuang syndrome)132,133. Additionally, gain-of-function 
somatic mutations of EPAS1 in PPGLs patients presenting with cyanotic congenital heart disease have 
been recently described88.
- EGLN1/2
Germline mutations in Egl-9 Family Hypoxia Inducible Factors (EGLN1: n=2  and EGLN2: n=1; also 
known as PHD2 and PHD1, respectively) have been reported in three patients with PPGL-polycythaemia 
disorder134,135. Mutations in those genes cause substantial loss of protein stability of both PHD1 and 
PHD2, resulting in the upregulation of HIF-α target genes and therefore in the activation of hypoxic 
pathway135.
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4.2. CLUSTER 2: KINASE-SIGNALLING TUMOURS
Tumours from the second main transcription subgroup carry mutations in genes encoding the RET 
receptor, HRAS or its inhibitor NF1, TMEM127 and MAX, all of which led to hypomethylation and 
kinase signalling activation74. Thus, these mutations lead to the activation of RAS/RAF/MAPK, PI3K/
AKT/mTOR or MYC-MAX intracellular pathways that are involved in cell growth, proliferation, survival 
and metastasis136.
- RET
The RET (re-arranged during transfection) gene encodes a transmembrane tyrosine kinase receptor 
for members of the glial cell line-derived neurotropic factor family that is necessary for neural crest 
development137. Germline gain-of-function mutations in the oncogene RET (identified in 5-10% of PPGL 
patients), predispose to a rare autosomal dominant disorder named MEN2 syndromes (types 2A and 
B)138. MEN2A (MIM: #171400), also known as Sipple syndrome, causes medullary thyroid carcinoma, 
PCC and primary hyperparathyroidism, while MEN2B (MIM: #162300) is characterized by medullary 
thyroid carcinoma, PCC, Marfanoid habitus, intestinal and mucosal ganglioneuromatosis, being the 
latest rarer but also the most aggressive form of the disease139. Additionally, somatic RET mutations are 
detected in approximately 5% of sporadic PPGLs128,140. The study of this gene has provided a paradigm 
for heritable acti¬vated oncogenes in cancer predisposition syndromes. Its striking genotype-phenotype 
correlation leads to a better prediction of disease onset and prognosis, and genetic-based personalized 
medical care, for instance, early prophylactic thyroidectomy in MEN2B cases141.
- NF1
The NF1 (neurofibromin 1) gene encodes a GTPase-activating protein that functions as a tumour 
suppressor by promoting the conversion of the active GTP-bound RAS GTPase to the inactive GDP-
bound RAS form, thereby acting as a RAS inhibitor. Germline loss-of-function mutations in NF1 (with 
a prevalence lower than 3% in PPGL patients) predispose to neurofibromatosis type 1 (MIM: #162200), 
a frequently tumour-prone disorder with high penetrance and in which around 5% of patients develop 
PPGLs142,143. The most frequent clinical features of the syndrome are: café-au-lait spots, neurofibromas, 
axillary or inguinal freckling, optic glioma, bone lesion and/or Lisch nodules144. Somatic NF1 mutations, 
most of them truncating, are present in 14% of cases, therefore considered as the foremost-inactivated 
gene in sporadic PPGLs140,145.
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- TMEM127
The transmembrane protein 127 (TMEM127) plays a role in endosomal signalling and it acts as a negative 
regulator of mTOR. Thus, loss-of-function mutations in TMEM127 results in reduced inhibition of 
the mTOR pathway in a RAS/RAF/MAPK and PI3K/AKT independent manner. Germline mutations 
in this tumour suppressor gene (found in around 2% of all PPGLs)113, mainly truncating, present low 
penetrance136,146 and have been also reported in rare cases of ccRCC147.
- MAX
MAX (MYC-associated factor X) mutations were discovered by WES applied to the germline of patients 
with hereditary PCC who lacked a mutation in other susceptibility genes148. MAX is a basic helix–loop–
helix (bHLH) leucine zipper domain-containing protein that is involved in protein–protein interactions 
and DNA binding. MAX is predominantly found in complex with MXD1 and the MYC transcrip¬tion 
factor, a common oncogene in many human cancers149. MYC–MAX heterodimers bind to Ebox  DNA 
recognition sequences in the promoters of many target genes that encode proteins involved in metabolism, 
growth and angiogenesis while MAX-MDX1 heterodimerization antagonizes this transcription. Upon 
MAX alterations affecting the bHLH domain, the ability of MAX to antagonize MYC-dependent cell 
transformation is destroyed, leading to tumour development150. Apart from PPGL, MAX have been found 
subsequently mutated in many other cancer types such as small cell lung cancer151, GIST152, endometrial 
cancer153, and multiple myeloma154 among others.
The second hit observed for MAX-mutated PCCs is the LOH either by paternal uniparental disomy 
(UPD) or by loss of chromosome 14q, which results in a unique transcriptomic signature. Germline 
mutations in this gene, which could also predispose to renal oncocytoma155, appear with very low 
prevalence (0.8%) in patients with PPGL148, though the prevalence amongst patients with bilateral PCC is 
much higher113. Additionally, somatic mutations in MAX have been also reported in an extensive patient 
cohort of sporadic tumours156.
- HRAS
The HRAS (Harvey rat sarcoma viral oncogene homolog) gene encodes a small GTP-binding protein 
that affects multiple downstream pathways related to cell growth and homeostasis. It has been described 
as a common driver event in PPGL pathogenesis (prevalence of ~7%157), with exclusively somatic gain-
of-function mutations in sporadic cases, mainly PCC158,159.
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- KIF1B
The KIF1B (kinesin family member 1B) gene has been found mutated, both somatically and germline, 
in different PPGL cases. It has been reported that KIF1B functions as a tumour suppressor and it is 
necessary and sufficient for neuronal apoptosis160,161.
A small minority of PPGLs show potential driver mutations in other kinesins (apart from KIF1B) such 
as, MERTK germline mutations that may be related to rare RET-negative cases with MEN2-like clinical 
manifestations; germline and somatic mutations in MET; and a somatic oncogenic hotspot in FGFR179. 
Tumours carrying mutations in these genes could probably be grouped with RET-mutated PPGLs in this 
Cluster 2.
Although Cluster 1 and 2 related genes are discussed separately, several of the pathways activated in these 
two major groups are linked. Thus, mTOR can activate HIF162, and there are multiple levels of crosstalk 
between MYC and HIF-2α in oncogenesis163.
4.3. CLUSTER 3: WNT SIGNALLING-RELATED TUMOURS
This recently defined cluster, related to genes not previously associated with PPGLs, comprises sporadic 
and probably more aggressive and hypomethylated tumours carrying mutations that trigger Wnt 
signalling activation.
This group includes PPGLs carrying somatic gene fusions affecting the MAML3 (mastermind like 
transcriptional coactivator 3) transcription factor gene, with increased transcription levels of a chimeric 
MAML3. One of the fusions observed in PPGLs, UBTF-MAML3, leads to the activation of the Wnt target 
expression and Hedgehog signalling pathway, something similar as detected in neuroblastoma, a tumour 
with shared developmental origin with PPGLs. The first study describing MAML3 alterations in PPGL, 
carried out by The Cancer Genome Atlas project, also described somatic loss-of-function mutations in 
CSDE1 (cold shock domain containing E1), that encodes an RNA-binding protein not hitherto associated 
with cancers76.
Moreover, it has been suggested a fourth group that would comprise a minority of PPGLs displaying 
adrenocortical features. The identity of this cluster is less well defined, unlike the other three transcriptional 
groups, since they lack consistent driver mutations, copy number changes, or transcriptome and 
methylome patterns that would help to discern between PPGLs and other cortical tumours. It is currently 
under debate whether this represents a new biological entity or if it is an artefact from cortex tissue 
contamination74,76.
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4.4. OTHER GENES NOT CLEARLY ASSOCIATED TO ANY TRANSCRIPTIONAL 
CLUSTER 
Recent publications have uncovered mutations in chromatin-remodelling genes, highlighting the 
relevance of epigenetic modifications in the development of PPGL. For instance, the presence of somatic 
loss-of-function mutations in ATRX (alpha thalassemia/mental retardation syndrome X-linked) in 
PPGLs was first described in 2015 mostly coexisting with SDHx mutations (and therefore associated to 
Cluster 1A). However, there are also cases without any further driver mutation which are related to the 
Cluster 376,164. Mutations in ATRX have been associated with alternative lengthening of telomeres and 
clinically aggressive behaviour80. 
Postzygotic mosaic mutations in H3F3A (H3 histone family member 3A) cause PPGL together with giant 
cell tumour of the bone, and lead to the upregulation of MYCN oncoprotein165. H3F3A-mutated PPGLs 
have been proposed to be part of Cluster 2, although due to their function, those PPGLs may fit better 
into Cluster 1. Other chromatin-remodelling genes found mutated in PPGLs are: EZH2, HIST1H1T, 
HIST4H4, JMJD1C, KDM2B, KMT2B, or SETD282.
Additionally, commonly mutated genes in different cancer types (such as TERT, TP53 and BRAF) have 
been also involved in PPGL pathogenesis83,166. However, the specific role of many of those genes in PPGL 
development needs to be further clarified.
Mutations in PPGL, either inherited or acquired, are mutually exclusive in the tumours. The presence of 
single driver events in PPGLs highlight the redundancy of the pathways affected1. In this respect, PPGLs 
are more similar to other Mendelian disorders, where a driver mutation can be related to a specific 
phenotype, than to most cancers. As aforementioned, an exception to this rule is the ATRX gene, which is 
mutated preferentially in tumours carrying a germline SDHB mutation74. There are, however, anecdotal 
examples of PPGLs  with mutations in different driver genes (NF1 together with RET o VHL mutations167) 
as well as double monoallelic mutations (EPAS1168).
Despite the past and present genetics/genomics efforts that have led to deciphering the driver causal event 
in around 60% of PPGL patients, there is still a percentage of patients with clinical features indicative of 
a hereditary condition (i.e. early age of onset, tumour multiplicity and/or family history of PPGL), but 
without mutations in any of the known PPGL susceptibility genes74. Therefore, identification of additional 
germline or mosaic disruptions in those genetically undiagnosed patients would have important 
implications in their management, and in the early diagnosis and treatment of at-risk individuals20. 
As established by the NGS in PPGL study group, WES is the preferred method for discovering the 
primary mutation in PPGLs without mutations among the PPGL susceptibility genes37. However, the 
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potential of targeted NGS approaches, which improve the efficiency and accuracy of the detection, is 
higher when there is a candidate list of genes. When planning a NGS-based project, one of the most 
critical steps is the adequate selection of cases that will be included in the study. This selection is usually 
based on the presence of similar phenotypes, distinctive molecular markers or particular clinical features. 
Regarding this, mutations in MAX were discovered thanks to the selection of PCCs showing a common 
and characteristic expression profile. In other example, the gene NF1 was found somatically mutated in 
a surprising high number of PPGLs by selecting tumours with loss of chromosome 17. In this regard, 
previous studies identified that RBP1 (retinol binding protein 1) was amongst the genes silenced by 
promoter hypermethylation not only in TCA cycle-mutated PPGLs (SDHx, FH and MDH292,118), but 
also in gliomas related to IDH1 and IDH2 mutations169. Thus, downregulation of this gene constitutes a 
marker not only of a CIMP profile, but also of a TCA cycle alteration, and the assessment of its expression 
could be used for selection of PPGLs in order to uncover mutations in new candidate susceptibility genes 
implicated in this key metabolic pathway.
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Objectives
The main objective of this thesis was:
1. To identify new PPGL susceptibility genes in selected patients without any mutation in the 
already known driver genes using NGS approaches. Once a new candidate PPGL susceptibility gene was 
identified we aimed:
a) To determine the pathogenicity of the variants found in the identified gene/s using omics data as 
well as in vitro and in silico models.
b) To assess the prevalence of mutations in the new gene/s applying targeted sequencing to larger 
series of PPGL patients, and establish, if any, the associated clinical presentation.
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Predisposing Mutations in Pheochromocytomas and Paragangliomas.
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Mercedes Robledo, and Alberto Cascón
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ABSTRACT
Mutations in phaeochromocytoma and paraganglioma (PPGL) predisposition genes encoding enzymes 
involved in the TCA cycle lead to a particular CpG island hypermethylation phenotype. In this study, we 
used selected tumours with this phenotype for targeted exome sequencing of a home designed panel of 
TCA cycle-related genes in order to find new PPGL susceptibility genes.
We identified for the first time a germline variant in the glutamic-oxaloacetic transaminase 2 gene 
(GOT2), a mitochondrial transporter, in a patient with multiple tumours (n=9) and metastasis. This 
variant increased GOT2 activity and expression, and caused alterations in TCA cycle metabolite ratios, 
both in tumours and in GOT2 KD cells transfected with the variant, suggesting that GOT2 is involved 
in PPGL predisposition. In addition, we found a truncating germline mutation in a new candidate 
susceptibility gene, the isocitrate dehydrogenase 3 (NAD+) Beta (IDH3B), in a patient with a single PGL 
showing an altered a-ketoglutarate/isocitrate ratio. 
Finally, we also identified two extremely rare variants in already known cancer-predisposing genes; the 
third somatic mutation in IDH1 reported until now was identified by sequencing the panel in one patient 
with PGL, and array methylation-based analysis uncovered a somatic epigenetic mutation in SDHC in a 
patient with multiple PGLs and GIST.
This study further attests to the relevance of the TCA cycle in the development of PPGL, some of which 
might be effectively treated with DNA-demethylating agents.
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Abstract
Purpose: Mutations in Krebs cycle genes are frequently found
in patients with pheochromocytomas/paragangliomas. Disrup-
tion of SDH, FH or MDH2 enzymatic activities lead to accumu-
lation of speciﬁc metabolites, which give rise to epigenetic
changes in the genome that cause a characteristic hypermethy-
lated phenotype. Tumors showing this phenotype, but no altera-
tions in the knownpredisposing genes, could harbormutations in
other Krebs cycle genes.
Experimental Design: We used downregulation and methyl-
ation of RBP1, as a marker of a hypermethylation phenotype, to
select eleven pheochromocytomas and paragangliomas for tar-
geted exome sequencing of a panel of Krebs cycle-related genes.
Methylation proﬁling, metabolite assessment and additional
analyses were also performed in selected cases.
Results: One of the 11 tumors was found to carry a known
cancer-predisposing somatic mutation in IDH1. A variant in
GOT2, c.357A>T, found in a patient with multiple tumors, was
associated with higher tumor mRNA and protein expression
levels, increased GOT2 enzymatic activity in lymphoblastic
cells, and altered metabolite ratios both in tumors and in
GOT2 knockdown HeLa cells transfected with the variant. Array
methylation-based analysis uncovered a somatic epigenetic
mutation in SDHC in a patient with multiple pheochromocy-
tomas and a gastrointestinal stromal tumor. Finally, a truncat-
ing germline IDH3B mutation was found in a patient with
a single paraganglioma showing an altered a-ketoglutarate/
isocitrate ratio.
Conclusions: This study further attests to the relevance of the
Krebs cycle in the development of PCC and PGL, and points to a
potential role of other metabolic enzymes involved inmetabolite
exchange between mitochondria and cytosol. Clin Cancer Res; 1–10.
�2017 AACR.
Introduction
Despite their low prevalence, pheochromocytomas (PCC)
and paragangliomas (PGL) represent a paradigm for hereditary
cancer due to the highest degree of heritability of these tumors
among all human neoplasms (1). Up to 40% of individuals
with PCC and/or PGL have a hereditary background due
to germline mutations affecting one of 13 susceptibility genes
(2–13). The mutations result in two broad groups of tumors
characterized by either activation of hypoxia or kinase receptor
signaling pathways (1). Furthermore, somatic mutations in
several of these genes or in two other PCC/PGL predisposition
genes, HIF2A and HRAS (14, 15), are found in an additional
approximately 30% of tumors (16). Finally, the presence of
features of heritability amongst some of the patients without
germline mutations in the known susceptibility genes, strongly
suggests the implication of additional genes in this multige-
netic disease. Of note, more than half of the PCC/PGL predis-
position genes encode enzymes involved in the Krebs cycle
(SDHA, SDHB, SDHC, SDHD, SDHAF2, FH, and MDH2),
which stresses the crucial role of this pathway in PCC/PGL
development and suggests that alterations in other genes from
this pathway could account for more patients. This is even more
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likely for cases showing a noradrenergic or dopaminergic
phenotype, which is associated with the presence of mutations
in the aforementioned Krebs cycle-related genes.
In recent years, the application of high-throughput "omics"
technologies to PCC/PGL research has led to improved under-
standing of the biology of these tumors, and paved the way for
discovery of new predisposing genes (7, 12, 17). It has been
known for years that pseudo-hypoxic PCCs/PGLs, such as SDH-
and VHL-mutated tumors, share a similar transcriptional pro-
ﬁle (18) that can be further segregated into different gene
expression signatures (19). More recently, high-throughput
methylation studies performed in PCCs/PGLs have revealed
a particular CpG island methylation phenotype (CIMP) asso-
ciated with the presence of Krebs cycle gene (SDH, FH, or
MDH2) mutations (11, 12). This CIMP proﬁle is caused by
impaired histone demethylation and 5-mC hydroxylation (5-
hmC) due to the enzymatic inhibition of multiple a-KG–
dependent dioxygenases by the accumulation of succinate and
fumarate (20). In addition, mutations in other Krebs cycle-
related genes (IDH1 and IDH2) also lead to a similar CIMP in
gliomas (21), caused in this case by the accumulation of D-2-
hydroxyglutarate (22). IDH1 has been also found to be somat-
ically mutated in two PGLs (23, 24). Though the majority of
genes that deﬁne the altered methylation proﬁle in PCC/PGL
and gliomas are different, a substantial percentage of them
(�25%) are silenced in both neoplasias (12). That is the case
for RBP1, which is consistently methylated and downregulated
in both types of tumors carrying Krebs cycle mutations (11, 25).
Tumors carrying mutations in other PCC/PGL susceptibility
genes, such as RET, NF1, MAX or TMEM127, all belonging to
the so-called expression cluster 2, do not exhibit methylation of
RBP1 (11).
In the present study, we use the low expression of RBP1
as a marker of hypermethylation to select PCCs and PGLs as
candidates for targeted exome sequencing of a panel of
Krebs cycle-related genes to ﬁnd new PCC/PGL predisposi-
tion genes.
Materials and Methods
Samples
Forty-nine tumors from patients showing noradrenergic or
dopaminergic catecholamine phenotypes or no evidence of cat-
echolamine production (when available), and testing negative for
mutations in the major susceptibility genes (including all known
PCC/PGL Krebs cycle-related genes: SDH, FH and MDH2), were
included in the study. Immunostaining of SDHB was performed
when formalin-ﬁxed parafﬁn-embedded (FFPE) tissues were
available, to rule out hidden mutations affecting the SDH genes,
because negative SDHB immunohistochemistry is associatedwith
the presence of SDH gene mutations in PCC/PGL (26, 27). The
Instituto de Salud Carlos III (ISCIII) ethics committee approved
the study, and all the patients provided written informed consent.
Quantitative real-time PCR
Total RNA was obtained from FFPE or from frozen material
using the RNeasy FFPE (Qiagen) or TriReagent (MRC) Kit, respec-
tively, according to the manufacturers' instructions. cDNA was
prepared from 1 mg of total RNA using oligo (dT) primers and
SuperScript III RT (Invitrogen). RBP1, SDHC and GOT2 mRNA
levels were determined by quantitative PCR on a 7500 fast real-
time PCR system (Applied Biosystems) using the Universal Pro-
beLibrary set (https://www.roche-applied-science.com), as
described by the manufacturer. Relative mRNA levels were esti-
mated by the 2-Ct method (28) and normalized using b-actin
(ACTB) as housekeeping gene. The results are shown as mean þ
SD (n � 3). mRNA obtained from tumors carrying mutations in
other known pheochromocytoma susceptibility genes were used
as controls. Tumors with RBP1 expression below 15 relative units
(RU; n¼ 14) were considered candidates for subsequent analyses.
Pyrosequencing
Speciﬁc primers were used for PCR ampliﬁcation and sequenc-
ing using the PyroMark assay (design version 2.0.01.15) to
interrogate the methylation status of CpG sites from RBP1, as
previously described (11).
Targeted next-generation sequencing
DNA extracted from 11 selected tumor samples was sequenced
for a set of genes involved in the Krebs cycle by TruSight sequenc-
ing technology (Illumina), which comprises oligo probes target-
ing the genes of interest. Themakeup of the panel was planned to
cover the complete coding region of 37 human genes found to be
directly or indirectly involved in the Krebs cycle based on the
KEGG (http://www.genome.jp/kegg/pathway.html) and Gene-
card (http://www.genecards.org/) databases (Supplementary
Table S1). Designstudio software (Illumina) was used to design
the 733 amplicons included in the panel (cumulative Target:
65525 bp and coverage of 99%). This tool avoids designing for
ampliﬁcation primers that include known polymorphisms. Once
the library was prepared following the manufacturer's instruc-
tions, next-generation sequencing was performed using MiSeq
desktop sequencer (Illumina) and sequence alignment was car-
ried out usingMiSeq Reporter and Illumina VariantStudio softwares
(Illumina). Variant calling was performed usingGATK and Somat-
ic Variant Caller, and identiﬁed variants were ﬁltered considering
mapping quality, variant score, depth, strand bias and annotation
quality. To establish a cutoff value to consider a nucleotide
substitution reported in controls as a candidate pathogenic
Translational Relevance
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variant, we used publically available data for SDHB germline
mutations because they have the lowest penetrance amongst
mutations in the known PCC/PGL susceptibility genes (29). The
highest frequency for a knownpathogenic SDHBmutation, found
in the Genome Aggregation Consortium (gnomAD) database
(http://gnomad.broadinstitute.org/), was 1.805 � 10�5, which
was therefore applied as the cutoff value. Targeted regionswithout
appropriate coverage andquality orwith lowmappabilitywere re-
ampliﬁed by Sanger sequencing. The PredictSNP consensus clas-
siﬁer (30) was used to predict the effect of the substitutions that
passed all ﬁltering steps. Tumor DNA samples from a series of 63
unselected patients with PCC or PGL, and negative for germline
mutations in the known susceptibility genes, were tested by
targetednext-generation sequencing for the presence ofmutations
in TCA-related genes.
Methylation assay and data processing
DNA was extracted and puriﬁed from the 11 selected cases,
and from ﬁve SDH gene-mutated controls (two SDHB, one
SDHA, one SDHD, and one SDHC-mutated tumors), using the
DNeasy Blood & Tissue Kit (Qiagen) according to manufac-
turer's recommendations. Bisulﬁte conversion of DNA was
performed using the EZ DNA Methylation Kit (Zymo Research)
and genome-wide DNA methylation was assayed using the
Inﬁnium HumanMethylation450 BeadChip (Illumina) at the
Centro Nacional de Genotipado (CEGEN-ISCIII), as previously
described (31). This BeadChip interrogates more than 485,000
methylation sites per sample. Beta values for each interrogated
CpG were assigned using the Genome Studio Methylation
module. Methylomes from the 19 tumors were proﬁled togeth-
er with 13 additional controls (four non-SDH gene-mutated
and nine SDH gene-mutated tumors) obtained from the GEO
database (accession number GSE43298). We used the cluster-
ing average for linkage and City-block as the distance measure,
and assumed a standard deviation of 0.22.
Immunohistochemistry
Immunohistochemical SDHB (HPA002868, Sigma) analysis
of 3-mm formalin-ﬁxed parafﬁn-embedded (FFPE) tissues was
used for all cases, where tissue was available, to further rule
out the presence of SDH gene mutations, as previously report-
ed (26). Speciﬁc immunohistochemical staining of GOT2
(NBP1-80521, Novus) was performed using FFPE sections from
the two available GOT2-mutated tumors, following standard
procedures; ﬁve tumors carrying mutations in PCC suscepti-
bility genes were used as controls. Finally, immunohistochem-
ical staining of 5-hmc (Active Motif; 39770) was performed
using 3-mm FFPE sections from the IDH3B-mutated tumors,
following standard procedures.
Enzymatic activity analyses
Cytosolic and mitochondrial fractions were obtained after
processing of lymphoblastoid cells obtained from the GOT2-
mutation carrier and from three controls, as previously described
(32). Protein concentrationwas determinedusing Bradfordmeth-
od with BSA as standard. The cytosolic and mitochondrial frac-
tions were used to determine the enzymatic activity of GOT1 and
GOT2, quantiﬁed as a decrease in NADH ﬂuorescence, after the
addition of aspartate, using a BMG plate reader, as previously
described (33). Control and mutant GOT activity in cell fractions
were measured in duplicate at different dilutions in 3 indepen-
dent paired experiments. Lactate dehydrogenase (LDH,measured
as the increase in NADH caused by lactate addition) and citrate
synthase (CS, measured as the increase in absorption of 5,50-
dithiobis-2-nitrobenzoic acid after the addition of OAA) were
assayed using standard procedures (33, 34). GOT2 activity was
corrected by subtracting the estimated cytosolic contamination
(% of LDH present) from the activity measured in the mitochon-
drial fraction.
Mutagenesis
GOT2 c.357A>T and c.223T>G variants and the OGDHL
c.750G>T substitution were generated by mutagenesis using the
QuikChange II Site-Directed Mutagenesis Kit (Stratagene),
according to themanufacturer's instructions.Wild-type andmuta-
genized inserts were veriﬁed by sequencing both strands.
Cell cultures
Lymphocytes from the carrier of the c.357A>T GOT2mutation
were immortalized using Epstein-Barr virus (EBV), as previously
described (35). HeLa cell line (kindly provided by Flow Cyto-
metry Core Unit, CNIO, Madrid) was authenticated by short
tandem repeat proﬁling (GenePrint 10 System, Promega) and
periodically conﬁrmed to beMycoplasma free by qPCR. HeLa cells,
used within 10 passages after authentication, were cultured in
Dulbecco's modiﬁed Eagle medium Gluta MAX (DMEM; Invitro-
gen), supplemented with 10% (v/v) FBS (PAA laboratories), 1%
(v/v) penicillin/streptomycin, and0.6%(v/v) Fungizone (Gibco),
and maintained at 37�C in a humidiﬁed incubator with 5% CO2.
MISSION shRNA lentiviral transduction particles were used to
speciﬁcally knockdown GOT2 (TRCN0000034827; Sigma) and
OGDHL (TRCN0000426732; Sigma). Stable gene knockdown
(KD) was established by cellular resistance to puromycin
(1 mg/mL). Scrambled non-target shRNA control vectors served
as negative controls. HeLa (GOT2 or OGDHL) KD cells were
seeded at 550,000 cells per well on 6-well plates for 24 hours.
Each well was transiently transfected with 2 mg of pCMV6-AC
plasmid containing the full cDNA sequence ofGOT2 (SC127269,
Origene), or OGDHL (RC205225, Origene), or with 2 mg of
pCMV6-AC plasmids carrying the corresponding variant (GOT2
c.357A>T and c.223T>G, or OGDHL c.750G>T) using Lipofecta-
mine 2000 (Invitrogen), according to the manufacturer's recom-
mendations. pCMV6-AC empty vector (EV) was used as a control.
In the proliferation assay, GOT2 KD HeLa cells were transfected
with EV, GOT2-WT or GOT2-c.357A>T cDNA, and were seeded
24 hours post-transfection at 30,000 cells per well on 12-well
plates. Then, cells were trypsinized and counted after 48, 72, and
96 hours post-transfection.
Western blot
To demonstrate the absence of full-length GOT2 or OGDHL
proteins in KD HeLa cells, we performed Western blot analysis
using polyclonal rabbit anti-GOT2 (NBP1-80521; Novus) and
anti-OGDHL (NBP1-91486; Novus) antibodies. Proteins were
separated by 10% SDS-PAGE and transferred to a polyvinylidene
ﬂuoride membrane. The membrane was blocked and then incu-
bated with a 1:2,000 or a 1:1,000 dilution of GOT2 and OGDHL,
respectively, following the manufacturer's instructions. Equal
protein loading was assessed using a 1:12,000 dilution of mono-
clonal anti–b-actin mouse antibody (A5441, Sigma-Aldrich).
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Liquid chromatographic tandem-mass spectrometric
determination of metabolites
Fresh frozen or FFPE tumor tissue (5–10 mg) from available
selected cases and from15 controls,was immersed in 500mL LC/MS
grade methanol containing isotope-labeled internal standards and
processes as previously described (11). For cell cultures, 500,000
cells were cultured, washed 4 times with PBS and extracted in
methanol containing isotope-labeled internal standards. Analysis
of metabolites was carried out using an AB Sciex 5500QTRAPmass
spectrometer coupled to an Acquity ultra–high-performance liquid
chromatographic system (Waters), as previously described (11).
Results
Clinical and molecular features of cases showing
downregulation and methylation of RBP1
Fourteen out of the 49 tumors analyzed by qPCR showed low
(lower than 15 RU) or almost no RBP1 expression levels com-
pared with the remaining 35 assessed tumors and 10 control
tumors carryingmutations in PCC/PGL susceptibility genes (Sup-
plementary Fig. S1A). Pyrosequencing analysis conﬁrmed gene
methylation as the cause of the RBP1 downregulation in 11 out of
the 14 tumors, and therefore further analysis were focused on
these 11 cases. Five of the 11 patients had multiple PCCs/PGLs,
one of them suffering also from a gastrointestinal stromal tumor
(GIST), and one case showed distant metastases (Table 1). Nine
cases showed a positive immunostaining for SDHB that ruled out
the presence of SDHgene causalmutations in these patients.Only
one H&N PGL developed by the patient who also suffered from
GIST tested negative (Supplementary Fig. S1B), suggesting that a
hidden SDH gene alteration could account for this patient.
Next-generation sequencing ﬁndings
Five missense variants, affecting four genes and detected in
three samples, passed the ﬁltering process after excluding vari-
ants found at a frequency >2.471 � 10�5 of controls in gnomAD
(Table 1). Sanger sequencing was used to validate both the
presence of the variants in the corresponding tumor (Fig. 1A),
and the presence/absence of the variant in the germline of the
patients. All variants were found in the germline of the corre-
sponding patient, with the exception of the c.394C>T IDH1
somatic mutation. Three variants were predicted to be deleterious
and two neutral by PredictSNP (data not shown).
Seven variants (six missense and one frameshift), affecting four
genes and found in seven samples, were detected and validated in
the extended series of 63 tumors. When we applied the same
ﬁltering process to that used for the selected series of tumors, only
a novel IDH3B truncating mutation remained (Fig. 1B). The
variant was found in the germline of a patient with a single
non-secreting jugular PGL at age 51 years.
Methylation proﬁling classiﬁed most tumors within the CIMP
cluster
Methylomes from 16 tumors (11 selected cases and ﬁve SDH
gene-mutated controls) were proﬁled together with methylomes
from 13 additional genotyped PCCs/PGLs obtained from GEO.
Ten RBP1-downregulated and methylated tumors showed a
"CIMP-like" proﬁle similar to that observed for PCC/PGLs car-
rying SDH gene mutations, whereas only one case clustered with
hypomethylated tumors carrying mutations in NF1, RET orMAX
(Fig. 1C).Whenwe focused on themethylation status of the Krebs Ta
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cycle genes included in the panel, a tumor (Tumor_4 in Table 1)
was found to show signiﬁcantly higher methylation levels for 11
CpG targets encompassing the SDHC promoter region in 1q23.3
(Fig. 2A). To test for constitutional SDHC methylation in the
patient, we analyzed DNA obtained from blood and found no
silencingof the SDHC locus (Supplementary Fig. S1C). Absence of
SDHC mRNA expression was demonstrated by qPCR for the
tumor-exhibiting methylation of the SDHC promoter, compared
to controls (Fig. 2B).Of note, and asmentioned above, the SDHC-
methylated tumor was the only one from our series that showed
negative SDHB immunohistochemistry. Finally, the methylome
from the IDH3B-mutated tumor also showed a "CIMP-like"
proﬁle (data not shown), further supported by a negative 5-hmC
immunohistochemistry (Supplementary Fig. S1D).
Figure 2.
A, DNA methylation (M_values) for 17
CpG island probes located within the
SDHC locus in the 11 analyzed tumors,
compared with IVD (in vitro
methylated DNA). The results of the
immunostaining for SDHB (SDHB IHC)
are also represented. NA: not
available. B, mRNA expression of
SDHC in the SDHC-methylated tumor
(tumor_4) compared with controls
(n ¼ 5). Error bars represent standard
deviations.
Figure 1.
A, Sanger sequencing validation (in
tumor DNA) of targeted exome
ﬁndings. B, Sanger sequencing
validation (in tumor DNA) of the IDH3B
mutation found in the extended series.
C, Hierarchical clustering of the 11
pheochromocytomas/paragangliomas
showing RBP1 mRNA downregulation,
as well as SDH gene-mutated and non-
SDH gene-mutated controls. Tumors
hybridized and analyzed in the present
study are denoted in black letters,
whereas tumors downloaded from
GEO are denoted in gray. Two clusters
were observed and named CIMP
(including all SDH gene-mutated
controls), and non-CIMP (including all
non-SDH gene-mutated controls).
Tumor_3: tumor carrying the OGDHL
and PCK2 variants; tumor_2: tumor
carrying the c.357A>T GOT2 variant
and tumor_1: tumor carrying the IDH1
and the c.223T>G GOT2 variants.
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Higher GOT2 expression and activity in tissues carrying the
c.357A>T mutation
Because we found two different variants in GOT2 in two
different cases, and both tumors were grouped within the
"CIMP-like" cluster, we assessed the expression of the gene in
the tumors. Two available tumors from the patient carrying the
GOT2 c.357A>T variant (Fig. 3A) showed a signiﬁcantly higher
GOT2 mRNA expression (Fig. 3B), as well as a granular cyto-
plasmic differential immunostaining, compared with controls
(Fig. 3C). Tumor_1 that carried the other GOT2 variant,
c.223T>G, showed normal GOT2 expression. EBV-immortal-
ized lymphoblastoid cells carrying the c.357A>T GOT2 muta-
tion exhibited signiﬁcantly higher GOT2 enzymatic activity
compared with three GOT2–wild-type lymphoblastoid cell
lines (Fig. 3D).
Tumoral metabolite ratios
Liquid chromatographic tandem-mass spectrometric was
applied to all available tissues to assess whether the tumors
carrying the identiﬁed variants showed signiﬁcant alterations
in the metabolites of the Krebs cycle. Amongst the 10 cases
tested (Tumor_9 could not be analyzed) only the tumors
carrying the GOT2 c.357A>T variant (Tumor_2) and the
OGDHL/PCK2 variations (Tumor_3), showed a high succi-
nate/fumarate ratio (Fig. 4A) similar to that observed for SDH
gene-mutated tumors. This abnormal succinate/fumarate ratio
was not associated with SDH alterations in either of the two
tumors, because they resulted positive for SDHB immunohis-
tochemistry (Table 1). In addition, the tumor carrying the
IDH1 c.394C>T mutation, showed an elevated hydroxygluta-
rate/isocitrate ratio compared to controls (n ¼ 8; Fig. 4B),
which is consistent with the presence of pathological IDH1/2
mutations. None of the other tumors (those not carrying these
variants) had altered metabolite ratios. The IDH3B-mutated
tumor showed an elevated a-ketoglutarate/isocitrate ratio
compared to controls (Fig. 4C).
c.357A>T GOT2 introduction in GOT2 KD cells increased
metabolite ratios
To demonstrate the relevance of the c.357A>T variant in GOT2
enzymatic activity, we ﬁrst silenced GOT2 (GOT2 KD) by shRNA
in HeLa cells (Supplementary Fig. S2A). Subsequent transient
introduction of GOT2 cDNA carrying the variant c.357A>T in
GOT2 KD cells triggered a slight increase in the succinate/fuma-
rate ratio and a signiﬁcant increase of a-ketoglutarate/citrate and
aspartate/glutamate ratios, compared with GOT2 KD cells trans-
fected with wild-type GOT2 cDNA (Fig. 4D and E). Moreover, the
growth rate of GOT2 KD cells transfected with c.357A>T-GOT2
was higher (although not signiﬁcantly so) than that observed for
GOT2 KD cells transfected with WT-GOT2, and signiﬁcantly
higher than that observed for KD cells (Supplementary Fig.
S2B). Furthermore, GOT2 KD cells transfected with the c.223T>G
variant showed aspartate/glutamate ratios similar to the control
(Supplementary Fig. S3A).
Depletion of OGDHL had no effect on metabolite ratios
Noalteration in the succinate/fumarate ratiowas observed after
silencing OGDHL in HeLa cells by shRNA, or after transient
introduction of the c.750G>T variant in KD cells (Supplementary
Fig. S3B). Silencing PCK2 in HeLa cells was not possible either by
shRNA or CRISPR-Cas9 technologies (data not shown).
Figure 3.
A, GOT2 c.357A>T variant in the
germline and in two tumors from the
patient revealed by Sanger
sequencing. The asterisk marks the
tumor subjected to exome
sequencing. B, GOT2 mRNA
expression in two tumors (tumor_2A
and tumor_2B) carrying the GOT2
c.357A>T variant, compared with
controls (C1–C5). Expression level was
normalized to b-actin (ACTB) and
presented as mean and standard
deviation (n� 3). Error bars represent
standard deviations. C,
Immunohistochemical staining of
GOT2 in two tumors carrying theGOT2
c.357A>T variant and in one control
with WT-GOT2. Cytoplasmic
aggregates were observed only in
GOT2-mutated tumors. D, GOT2
activity measured in lymphoblastic
GOT2-mutated (c.357A>T) and non-
mutated cells (C1–C3).
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Discussion
PCC/PGL are paradigmatic for illustrating the importance of
human genetics in cancer, not only because of the high degree of
heritability of the tumors and involvement of a large number of
genes (more than 13), but also because these tumors are themain
manifestation of genetic alterations in SDHD. SDHD is a gene that
went down in history as the ﬁrst metabolic gene involved in the
Krebs cycle and the respiratory chain whose mutations were
associated with the development of cancer. Since then, mutations
affecting six additional genes involved in the Krebs cycle energy
pathway have been associated with the development of PCC/PGL
and with a particular hypermethylator phenotype. Herein, we
describe how the selection of samples based on the expression of a
methylation marker, identiﬁes PCCs/PGLs harboring candidate
variants affecting other Krebs cycle-related genes. These results
highlight both the relevance of this pathway in PCC/PGL devel-
opment and the need for marker-based selection of samples for
the discovery of cancer susceptibility genes to avoid genetic
heterogeneity.
To date, only two studies have focused on the involvement of
IDH1/2 in PCC/PGL development, yielding 1/365 and 0/104
tumors carrying a pathogenic mutation affecting IDH1 (23).
Another IDH1 mutation has also been identiﬁed in one PGL
among 173 samples from The Cancer Genome Atlas (http://
www.cbioportal.org/index.do; ref. 24), which further conﬁrms
the low frequency of alterations affecting this gene in PCC/PGL.
The two mentioned IDH1 mutations, as well as the one
reported herein, affect the same amino acid (p.Arg132Cys)
and were found in older patients (>61 years) with PGLs, which
stresses the relevance of this cancer-prone alteration to extra-
adrenal tumors. The accumulation of hydroxyglutarate
observed in the tumor, and the absence of any other somatic
or germline alteration in the known PCC/PGL susceptibility
genes, conﬁrmed the driver role of the IDH1 mutation in this
case and explains its CIMP proﬁle.
Glutamic-oxaloacetic transaminase 2 (GOT2) is a mitochon-
drial enzyme that plays a role in amino acid metabolism and the
urea and Krebs cycles. GOT2 converts oxaloacetate into aspartate
by transamination, with the consequent conversion of glutamate
Figure 4.
A, Succinate/fumarate ratios assessed by liquid chromatographic tandem-mass spectrometry (LC/MS) in 13 tumors assayed in the present study compared
with SDH gene-mutated (n ¼ 9) and non-SDH gene-mutated controls (n ¼ 6). Tumor_1: tumor carrying the IDH1 and the c.223T>G GOT2 variants; tumor_2: tumor
carrying the c.357A>T GOT2 variant; tumor_3: tumor carrying the OGDHL and PCK2 variants; tumor_4: tumor showing DNA methylation of SDHC. The
black lines represent medians. B, Hydroxyglutarate/isocitrate ratios assessed by LC/MS in nine tumors from the present study compared with SDH gene-mutated
(n ¼ 9) and non-SDH gene-mutated controls (n ¼ 6). The IDH1-mutated tumor is indicated. The black lines represent medians. C, a-Ketoglutarate/isocitrate
ratios assessed by LC/MS in the IDH3B-mutated tumor compared with 10 tumors from the present study, nine SDH gene-mutated cases and six non-SDH gene-
mutated controls. The black lines represent medians. D, Aspartate/glutamate ratios assessed by LC-MS in GOT2 KD Hela cells transfected with empty vector (EV),
GOT2 wild-type (WT) cDNA, and GOT2- c.357A>T cDNA. The ratios were reported as mean and standard deviation (n ¼ 3). Error bars represent standard
deviations. A t testwas applied to test for differencesbetweenGOTWTandGOT2- c.357A>T-transfected cells.E,a-Ketoglutarate/citrate ratios assessedby LC-MS in
GOT2 KD Hela cells transfected with EV, GOT2 WT cDNA, and GOT2- c.357A>T cDNA. The ratios were reported as mean and standard deviation (n ¼ 3).
Error bars represent standard deviations. A t test was applied to test for differences between GOT WT and GOT2- c.357A>T-transfected cells.
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to a-ketoglutarate. In SDH-deﬁcient cells, glutamine and gluta-
mate are used to providemetabolic intermediates to the truncated
Krebs cycle, after conversion to a-ketoglutarate by GOT2 or
GLUD1 enzymes (36, 37). It has been recently described that
lysine acetylation of GOT2 enhances the protein association
betweenGOT2 andMDH2, stimulating themalate shuttle activity
and thus promoting pancreatic cell proliferation and tumor
growth in vivo (38). Mutant KRAS promotes the reprogramming
of glutamine metabolism in pancreatic cancer through GOT1/
GOT2-mediated transamination pathway (39).
Both the expression of GOT2 and its enzymatic activity found in
c.357A>T-mutated tissues suggest an activating role of the muta-
tion. Moreover, the high succinate/fumarate ratio observed in the
GOT2-mutated tumor, as well as the slight increment of a-keto-
glutarate compared to controls, could be explained by an excess of
this latter metabolite due to the higher enzymatic activity of
GOT2. Introduction of the mutated p.Glu119Asp variant, but not
p.Tyr75Asp, inGOT2KDHeLa cells recapitulates the accumulation
of metabolites observed in tumors carrying the variant, and
increases cell proliferation. Interestingly, GOT2 knockdown led to
an accumulation of glutamate aswell as to signiﬁcantly lower levels
of Krebs cycle metabolites fumarate and malate in melanoma cells
(40). Thus, it seems plausible that a higher activity of GOT2 could
lead to an increment of anaplerotic incorporation of a-ketogluta-
rate to the Krebs cycle, and hence to the oncogenic accumulation of
succinate. TheabsenceofGOT2variants inunselected cases suggests
their prevalence is low in PCC/PGL patients, which has also
reported for other TCA-related genes (11, 41).
The presence of aberrant hypermethylation of SDHC has been
reported to be a novel mechanism of tumor development in
Carney triad (PGL, GIST, and pulmonary chondroma) patients
(42).Moreover, epimutations in SDHChave alsobeen reported in
hypermethylated SDH-deﬁcient GISTs (43), mainly associated
with Carney triad. Interestingly, in both studies the aberrant
methylation of SDHC occurred exclusively in females. Recently,
epigenetic mutation of the SDHC promoter has been found in
another female with two PGLs (44). As far as we know, the case
reported in the present study is the ﬁrst example of a SDHC
epimutation affecting a patient with Carney-Stratakis syndrome
(co-occurrence of PGL and GIST). Regarding the mechanism
involved in silencing SDHC, a potential role of sex chromosome
or hormone biology has been proposed (43). The patient
described herein is a female, and this explanation could also
account for this case. The complete absence of SDHC expression
in the tumor suggested that, in addition to the observed hemi-
methylation, a second hit affecting the gene was also present.
High-density SNP genotyping performed in the tumor showing
SDHCmethylation revealed no alterations affecting chromosome
1, where SDHC is located (data not shown). Furthermore, the
tumor had a normal DNA copy-number proﬁle, which is consis-
tent with previous ﬁndings describing that DNA copy-number
changes are infrequent in parasympathetic PGLs (45). The
absence of high succinate/fumarate ratio in this tumor could be
due to the lower reliability of measurements of these metabolites
inH&NPGLs (46), presumably due to a higher content of stromal
cells diluting the signal from tumor cells. The absence of aberrant
hypermethylation in known susceptibility genes in the other
tumors analyzed (Supplementary Fig. S4) suggests that this
mechanism is extremely rare in PCC/PGL.
The altered succinate/fumarate ratio observed in a tumor car-
rying two rare variants inOGDHL and PCK2 suggested that either
gene could be involved in the disease. Interestingly, the promoter
of OGDHL is differentially methylated in different tissue types,
and it is thought that inactivation of OGDHL can contribute to
cervical tumorigenesis (47). On the other hand, the mitochon-
drial phosphoenolpyruvate carboxykinase (PCK2) is an enzyme
involved in gluconeogenesis, converting oxaloacetate into phos-
phoenolpyruvate, which also has a cataplerotic function, main-
tainingmetabolic ﬂux through the Krebs cycle by removing excess
oxaloacetate. It has been reported that PCK2 activation mediates
an adaptive response to glucose depletion in lung cancer (48).
Althoughwehave ruled out a link betweenOGDHLdepletion and
an altered succinate/fumarate ratio, we were not able to demon-
strate the relevance of PCK2 in PCC/PGL development.
Homozygous loss-of-function mutations in IDH3B have been
found in two families with retinitis pigmentosa (49), and somatic
mutations in IDH3B have been recently found in acute myelog-
enous leukemia (50). IDH3B encodes the beta subunit of NAD-
speciﬁc isocitrate dehydrogenase 3 (IDH3), which is involved in
the oxidation of isocitrate to a-ketoglutarate in the Krebs cycle. It
has been demonstrated that IDH3 activity in lysates from cells
carrying heterozygous truncating IDH3Bmutationswas only 24%
of that observed in normal controls (49). In addition, the altered
a-ketoglutarate/isocitrate ratio detected in the tumor carrying the
truncating mutation, and the associated CIMP-like proﬁle further
suggest a causative role for this variant in PGL development.
In summary, basedonour selectionof cases for exome sequenc-
ing of Krebs cycle genes and whole-genome DNA methylation
assessment, we have identiﬁed rare pathological alterations in
knownPCC/PGL susceptibility genes (SDHC and IDH1), and two
new candidate genes possibly involved in the hereditary predis-
position (GOT2 and IDH3B). This study further strengthens the
evidence for the relevance of the Krebs cycle in the development of
PCC and PGL, and points to other enzymes involved in metab-
olite exchange between mitochondria and cytosol.
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ABSTRACT
The high percentage of patients carrying germline mutations makes phaeochromocytomas and 
paragangliomas (PPGL) the most heritable of all tumours. However, there are still PPGL cases that are 
not explained by mutations in the already known susceptibility genes. Therefore, in this study we aimed 
to identify the genetic cause in a selected patient strongly suspected of having hereditary PPGL due to the 
presence of multiple PGLs and early age at diagnosis, but without family history of the disease.
Whole-exome sequencing was applied to the germline DNA of the parents-proband trio identifying 
a single, novel de novo mutation in the DNA methyltransferase 3A gene (DNMT3A). This mutation 
(c.896A>T; p.Lys299Ile) was affecting a highly conserved residue of the protein located close to the 
aromatic cage that binds to trimethylated histone H3. 
Upon genome-wide methylome analysis of DNMT3A-mutated tissues from the patient we could observe a 
characteristic CpG island methylator phenotype (CIMP) profile as well as a significant hypermethylation 
of homeobox-containing genes (FDR<0.15), suggesting an activating role of the mutation.  CRISPR/Cas9 
gene editing was used to reproduce the knock-in in HeLa cells. The DNMT3A mutation was leading 
to global changes in methylation in those cells, therefore providing evidence of the methyltransferase 
altered function. Additionally, an extension of the study applying targeted deep sequencing to a series 
of PPGL patients and tumours, revealed the presence of somatic subclonal mutations affecting the same 
residue in six additional PPGL cases, all of them paragangliomas. Finally, a second germline DNMT3A 
mutation (c.952C>T; p.Arg318Trp) was found in a patient with family history of PCC, and it also caused 
global tumour DNA hypermethylation similar to the one identified in the tumour from the c.896A>T 
mutation carrier.
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The mutations described herein not only increases the number of paraganglioma susceptibility genes, but 
also represents, to the best of our knowledge, the first example of gain-of-function mutations affecting a 
DNA methyltransferase gene involved in cancer predisposition.
Personal contribution:
I participated in the conception and design of the study. I performed in vitro experiments using the 
CRISPR/Cas9 technology in HeLa cells as well as I collaborated in the identification and characterization 
of additional DNMT3A-mutated PPGL cases through targeted deep sequencing and DNA methylation 
analysis. I also took part in the drafting and the revision of the article.
Gain-of-function mutations in DNMT3A in patients with
paraganglioma
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Purpose: The high percentage of patients carrying germline
mutations makes pheochromocytomas/paragangliomas the most
heritable of all tumors. However, there are still cases unexplained by
mutations in the known genes. We aimed to identify the genetic cause
of disease in patients strongly suspected of having hereditary tumors.
Methods: Whole-exome sequencing was applied to the germlines of a
parent–proband trio. Genome-wide methylome analysis, RNA-seq,
CRISPR/Cas9 gene editing, and targeted sequencing were also performed.
Results:We identified a novel de novo germline mutation in DNMT3A,
affecting a highly conserved residue located close to the aromatic cage that
binds to trimethylated histone H3. DNMT3A-mutated tumors exhibited
significant hypermethylation of homeobox-containing genes, suggesting
an activating role of the mutation. CRISPR/Cas9-mediated knock-in in
HeLa cells led to global changes in methylation, providing evidence of the
DNMT3A-altered function. Targeted sequencing revealed subclonal
somatic mutations in six additional paragangliomas. Finally, a second
germline DNMT3A mutation, also causing global tumor DNA
hypermethylation, was found in a patient with a family history of
pheochromocytoma.
Conclusion: Our findings suggest that DNMT3Amay be a susceptibility
gene for paragangliomas and, if confirmed in future studies, would
represent the first example of gain-of-function mutations affecting a DNA
methyltransferase gene involved in cancer predisposition.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-0003-y
Keywords: DNMT3A; paraganglioma; exome sequencing;
hypermethylation; CRISPR/Cas9 gene editing
INTRODUCTION
Approximately 75% of neural crest-derived pheochromocy-
tomas (PCCs) and paragangliomas (PGLs) (OMIM 171300)
carry mutually exclusive germline (~40%) or somatic
(~35%) mutations affecting 1 of at least 20 genes.1 The
high percentage of patients for which germline mutations
have been found in recent years has turned PCCs and PGLs
into the most heritable of all tumors. In addition to the
known hereditary cases, there is still a subset of PCC/PGL
patients showing clinical features of heritability without
germline mutations in the susceptibility genes identified so
far. The presence of multiple tumors in some of these
patients, in the absence of a family history of the disease,
strongly suggests the presence of de novo alterations,
recessive inheritance, imprinting, or somatic mosaicism
involving precursor cells.
More than one-third of the PCC/PGL disease-causing genes
(SDHA, SDHB, SDHC, SDHD, SDHAF2, FH, MDH2 and
IDH1) encode Krebs cycle enzymes. Recently, gene expression
and methylation profiling have shown that tumors carrying
mutations in Krebs cycle-related genes exhibit an identifiable
CpG island methylator phenotype (CIMP), caused by the
accumulation of specific metabolites.2 These oncometabolites
lead to inactivation of DNA demethylases such as TET2 and
lysine demethylases, giving rise to epigenetic alterations in the
genome that cause global gene expression changes similar to
those found in glioblastomas carrying mutations in IDH1 and
IDH2.3 In addition, mutations affecting chromatin
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Purpose: The high percentage of patients carrying germline
mutations makes pheochromocytomas/paragangliomas the most
heritable of all tumors. However, there are still cases unexplained by
mutations in the known genes. We aimed to identify the genetic cause
of disease in patients strongly suspected of having hereditary tumors.
Methods: Whole-exome sequencing was applied to the germlines of a
parent–proband trio. Genome-wide methylome analysis, RNA-seq,
CRISPR/Cas9 gene editing, and targeted sequencing were also performed.
Results:We identified a novel de novo germline mutation in DNMT3A,
affecting a highly conserved residue located close to the aromatic cage that
binds to trimethylated histone H3. DNMT3A-mutated tumors exhibited
significant hypermethylation of homeobox-containing genes, suggesting
an activating role of the mutation. CRISPR/Cas9-mediated knock-in in
HeLa cells led to global changes in methylation, providing evidence of the
DNMT3A-altered function. Targeted sequencing revealed subclonal
somatic mutations in six additional paragangliomas. Finally, a second
germline DNMT3A mutation, also causing global tumor DNA
hypermethylation, was found in a patient with a family history of
pheochromocytoma.
Conclusion: Our findings suggest that DNMT3Amay be a susceptibility
gene for paragangliomas and, if confirmed in future studies, would
represent the first example of gain-of-function mutations affecting a DNA
methyltransferase gene involved in cancer predisposition.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-0003-y
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INTRODUCTION
Approximately 75% of neural crest-derived pheochromocy-
tomas (PCCs) and paragangliomas (PGLs) (OMIM 171300)
carry mutually exclusive germline (~40%) or somatic
(~35%) mutations affecting 1 of at least 20 genes.1 The
high percentage of patients for which germline mutations
have been found in recent years has turned PCCs and PGLs
into the most heritable of all tumors. In addition to the
known hereditary cases, there is still a subset of PCC/PGL
patients showing clinical features of heritability without
germline mutations in the susceptibility genes identified so
far. The presence of multiple tumors in some of these
patients, in the absence of a family history of the disease,
strongly suggests the presence of de novo alterations,
recessive inheritance, imprinting, or somatic mosaicism
involving precursor cells.
More than one-third of the PCC/PGL disease-causing genes
(SDHA, SDHB, SDHC, SDHD, SDHAF2, FH, MDH2 and
IDH1) encode Krebs cycle enzymes. Recently, gene expression
and methylation profiling have shown that tumors carrying
mutations in Krebs cycle-related genes exhibit an identifiable
CpG island methylator phenotype (CIMP), caused by the
accumulation of specific metabolites.2 These oncometabolites
lead to inactivation of DNA demethylases such as TET2 and
lysine demethylases, giving rise to epigenetic alterations in the
genome that cause global gene expression changes similar to
those found in glioblastomas carrying mutations in IDH1 and
IDH2.3 In addition, mutations affecting chromatin
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remodeling genes have recently been found either in the
germline or in tumor cells of patients with PCC/PGL.4
However, though global methylation changes are closely
related to the development of a substantial subset of PCCs
and PGLs, to date no alterations in DNA methyltransferase
genes, which are frequently disrupted in cancer, have been
reported in PCC/PGL.
In the present study, we identified a de novo germline
mutation in the DNA (cytosine-5-)-methyltransferase 3
alpha (DNMT3A) gene in a patient with multiple (n= 7)
PGLs. The same mutation was also found subclonally in six
additional PGLs. A second germline mutation was identified
in a patient with a family history of the disease. The altered
methylation profile exhibited by DNMT3A-mutated tissues
(both PGLs and lymphocytes) and HeLa cells carrying one
of the mutations, and the location of the altered amino acids
close to the aromatic cage responsible for binding
trimethylated histone H3, together suggest a gain of
alternative activities (referred to as gain-of-function) caused
by these alterations.
MATERIALS AND METHODS
Index patient
Whole-exome sequencing was applied to DNA samples from
a parent–proband trio. The index case, a 22-year-old woman,
was referred to hospital because of persistent dysphonia for 3
years. Multiple laryngeal PGLs (T1) and a right carotid PGL
(T2) were detected by single photon emission computed
tomography (CT), magnetic resonance imaging (MRI), and
octreoscan, and the patient underwent surgery at the age of 23
years. Four additional PGLs were diagnosed subsequently,
two jugulotympanic, one in the left carotid, and one
normetanephrine-producing paracardiac tumor presenting
with impaired fasting glucose and high blood pressure. One
jugulotympanic PGL was treated with radiosurgery at age 28
years, and the other was embolized, surgically removed (T3),
and treated with radiosurgery at ages 29 and 30 years. The
paracardiac and left carotid PGLs were treated with external
radiation therapy at ages 30 and 32 years, respectively. The
patient reported no family history of PCC or PGL.
Whole-exome sequencing analysis
Whole-exome sequencing was carried out at the National
Centre for Genomic Analysis (CNAG) using germline DNA
samples obtained from the patient and her parents using
FlexiGene DNA kit (Qiagen). Briefly, the Covaris S2 System
(Covaris) was used for DNA fragmentation. Exome capture
was performed using the SureSelect XT HumanAllExon 50-
Mb kit (Agilent Technologies). Exome sequencing at a mean
coverage >50× was performed by 75-bp paired-end technol-
ogy using a HiSeq2000 sequencer (Illumina). The GEM5 and
BFAST programs were used to align the reads against the
whole human genome (hg19 assembly). To identify single-
nucleotide substitutions and small insertions and deletions
(indels) the SAMtools program was used (http://samtools.
sourceforge.net). Filtering was applied to exclude noncoding
substitutions and variants in genomic regions with low
mappability, with low depth readings, with the alternative
allele present in <20% of reads, or with the alternative allele
present only in forward or reverse reads. Variants with
genotype quality (GQ) lower than 90% in any of the three
exomes were also excluded. The GQ for a variant is a measure,
derived from the Phred quality scores, of the probability that
the genotype is correct. The higher the GQ value (highest
possible value= 99%), the more likely it is that the genotype is
correct. Three inheritance models were assessed: de novo,
recessive, and dominant with incomplete penetrance. Manual
curation using Integrative Genomics Viewer (IGV) software
was also applied in the de novo analysis to exclude variants
present in at least one of the progenitors or caused by a
sequencing artifact. The PredictSNP consensus classifier6 was
used to predict the effect of the only nucleotide substitution
that passed all filtering steps.
Extended study of PCC/PGL patients
Sanger sequencing of the two exons (8 and 9) encompassing
the complete proline–tryptophan–tryptophan–proline
(PWWP) domain of DNMT3A was applied to screen for
additional germline mutations in a selected series of patients
(n=35) without germline alterations in known susceptibility
genes and who were strongly suspected of having hereditary
PCC/PGL due to the presence of multiple tumors and/or
familial antecedents of the disease. The Instituto de Salud
Carlos III (ISCIII) ethics committee approved the study, and
all the patients provided written informed consent. Also
studied for mutations within the PWWP domain of DNMT3A
were 95 tumors (52 head and neck PGLs, 28 PCCs, and 15
thoracic–abdominal PGLs) that tested negative for mutations
in the known PCC/PGL susceptibility genes and, when it
could be assessed, positive for SDHB immunostaining (to rule
out the presence of hidden mutations affecting the SDH
genes). To test for subclonal DNMT3A mutations, targeted
deep sequencing (Illumina) of an amplicon containing the
c.896A>T mutation was applied to the 95 tumor DNA
samples. Once the library was prepared following the
manufacturer’s instructions, next-generation sequencing was
performed using the MiSeq desktop sequencer (Illumina).
Sequence alignment was carried out using MiSeq Reporter
and Illumina VariantStudio software (Illumina). Variant
calling was performed using GATK7 and Somatic Variant
Caller (Illumina) and identified variants were filtered
considering mapping quality, variant score, depth, strand
bias, and annotation quality.
DNA methylation assay
DNA from peripheral blood leukocytes and formalin-fixed
paraffin-embedded (FFPE) PCCs/PGLs was obtained using the
DNeasy kit (Qiagen), following the manufacturer’s instructions.
Bisulfite conversion of DNA was performed using the EZ DNA
Methylation Kit (Zymo Research) and genome-wide DNA
methylation was assayed using the Infinium MethylationEPIC
BeadChip (Illumina) at the Centro Nacional de Genotipado
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(CEGEN-ISCIII) (www.cegen.org), as previously described.8
This BeadChip interrogates over 850,000 methylation sites per
sample. Beta values for interrogated CpGs were assigned using
the Genome Studio Methylation module and transformed into
M values by applying the formula: log2[Beta value/(1-Beta
value)]. Negative M values indicate less than 50% methylation
and positive M values indicate more than 50% methylation. M
values were used for all statistical analyses. The Infinium
MethylationEPIC BeadChip (Illumina) was also used to
identify specific methylated probes related to the DNMT3A
genetic alteration. Three c.896A>T DNMT3A-mutated PGLs
(T1, T2, and T3) from the index patient were used for
supervised analysis, along with 17 controls (5 SDHB-, 2 HRAS-,
1 NF1-, 1 RET-, 1 VHL-, and 1 IDH3B-mutated PCCs/PGLs,
and 6 tumors without a known mutation). Differentially
methylated probes were identified using a t test (limma) carried
out as implemented in POMELO II.9 To account for multiple
hypothesis testing, the significance level (P) was adjusted using
Benjamini’s FDR correction.10 Probes with an FDR < 0.05 were
considered differentially methylated between classes. Gene
functional annotation analysis was performed by applying the
web-based applications DAVID (the Database for Annotation,
Visualization, and Integrated Discovery).11 and Enrichr.12 to
the genes annotated to significantly methylated probes
obtained in the supervised analysis. After accounting for
duplicate genes (i.e., various probes targeting the same gene),
1,285 individual human genes were recognized by DAVID and
included in further analysis. Hierarchical clustering, performed
using GeneCluster 2.013 on the 3,092 probes found to be
significantly differentially methylated in the supervised analysis,
was used to interrogate first the EPIC methylation data from
the three DNMT3A-mutated tumors (T1–T3) from the index
patient, the c.952C>T DNMT3A-mutated PGL plus the 17
control tumors previously described; and second, EPIC
methylation data from lymphocyte DNAs from the c.896A>T
DNMT3A-mutated carrier (average of two samples) and her
parents (I1 and I2), the c.952C>T DNMT3A-mutated patient,
and eight controls (C1–C8). Additionally, we used the same list
of probes to interrogate Illumina 450k methylation data from
26 acute myeloid leukemia (AML) samples carrying DNMT3A
mutations compared with 30 DNMT3A wild-type (WT)
cases.14 Finally, supervised analysis was performed to identify
differentially methylated probes between HeLa knock-in
(c.896A>T) and HeLa WT cells. The reliability of the clusters
obtained with DNMT3A-mutated and no-mutated PCCs/PGLs
was verified by consensus clustering, a method that obtains the
consensus across multiple runs of a clustering algorithm and
assess the stability of the discovered clusters by using
resampling techniques.
Reverse-transcriptase PCR and qPCR
Total RNA was isolated from peripheral blood lymphocytes
from both DNMT3A-mutation carriers and the parents of the
index case using the TriReagent kit (MRC), following the
manufacturer’s instructions. First strand complementary
DNA (cDNA) was synthesized from 1 μg of total RNA by
oligo (dT) 14 primer reverse transcription using Superscript II
Reverse Transcriptase (Invitrogen) following the manufac-
turer’s instructions. Three genes, HOXD13, IRX5, and NKX2-4,
were selected for messenger RNA (mRNA) quantification
because several CpGs annotated to them were found
amongst the differentially methylated in DNMT3A-mutated
tumors. HOXD13, IRX5, and NKX2-4 mRNA levels were
determined by quantitative polymerase chain reaction (PCR)
on a 7500 fast real-time PCR system (Applied Biosystems)
using the Universal ProbeLibrary set (https://www.roche-
applied-science.com), as described by the manufacturer.
Relative mRNA levels were estimated using the 2-CT method15
and normalized using β-glucuronidase (GUS) and β-actin
(ACTB) as housekeeping genes. The results are shown as mean
± s.d. (n ≥ 2).
CRISPR/Cas9
A HeLa cell line (provided by Flow Cytometry Core Unit,
CNIO, Madrid) was authenticated by short tandem repeat
profiling (GenePrint 10 System, Promega) and periodically
confirmed to be mycoplasma-free by qPCR. HeLa cells were
cultured in Dulbecco’s modified Eagle medium Gluta MAX
(DMEM; Invitrogen); supplemented with 10% (v/v) fetal
bovine serum (FBS, PAA Laboratories), 1% (v/v) penicillin/
streptomycin, and 0.6% (v/v) Fungizone (Gibco); and
maintained at 37 °C in a humidified incubator with 5%
CO2. Recombinant Cas9 protein and two single-guide RNAs
(sgRNAs) (sgRNA-1: AACTGCGGGGCTTCTCCTGGTGG;
sgRNA-2: CTGGTGTGGGGGAAACTGCGGGG) were used
as previously described.16 Briefly, sgRNAs were designed
using the CRISPR MIT software tool (http://crispr.mit.edu)
and transcribed in vitro through runoff reactions by T7 RNA
polymerase using the HiScribe T7 high-yield RNA synthesis
kit (NEB). Transcribed sgRNAs were purified with a column
purification kit (RNeasy mini kit, Qiagen, Hilden, Germany),
quantified, and quality-checked by denaturing RNA gel
electrophoresis. RNP complexes were generate by premixing
Cas9 protein (1–8 μg, Integrated DNA Technologies, CA)
with in vitro transcribed sgRNA (0.5–8 μg) for 10 min at
room temperature. A single-stranded oligodeoxynucleotide
with the nucleotide change c.896A>T was purchased from
IDT as an ultramer oligo (available upon request). For
electroporation, we employed the Neon Transfection System
(ThermoFisher Scientific, Waltham, MA). Confluent HeLa
cells were trypsinized and washed twice with DPBS, counted,
and resuspended in 10 µl Buffer T (ThermoFisher Scientific)
per well. In each reaction approximately 100,000 cells were
electroporated under the following conditions: 2 pulses of 35-
ms width and 1,005 V. Cells were then seeded in a 96-well
plate with prewarmed medium. The following day the media
was replaced with fresh DMEM. After culture expansion, cells
were sorted to a 96-well plate to establish single-cell clones.
Detection of knock-in cell clones was performed using Sanger
sequencing. Genomic DNA extraction, PCR amplification,
and purification of PCR product were performed following
standard procedures.
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(CEGEN-ISCIII) (www.cegen.org), as previously described.8
This BeadChip interrogates over 850,000 methylation sites per
sample. Beta values for interrogated CpGs were assigned using
the Genome Studio Methylation module and transformed into
M values by applying the formula: log2[Beta value/(1-Beta
value)]. Negative M values indicate less than 50% methylation
and positive M values indicate more than 50% methylation. M
values were used for all statistical analyses. The Infinium
MethylationEPIC BeadChip (Illumina) was also used to
identify specific methylated probes related to the DNMT3A
genetic alteration. Three c.896A>T DNMT3A-mutated PGLs
(T1, T2, and T3) from the index patient were used for
supervised analysis, along with 17 controls (5 SDHB-, 2 HRAS-,
1 NF1-, 1 RET-, 1 VHL-, and 1 IDH3B-mutated PCCs/PGLs,
and 6 tumors without a known mutation). Differentially
methylated probes were identified using a t test (limma) carried
out as implemented in POMELO II.9 To account for multiple
hypothesis testing, the significance level (P) was adjusted using
Benjamini’s FDR correction.10 Probes with an FDR < 0.05 were
considered differentially methylated between classes. Gene
functional annotation analysis was performed by applying the
web-based applications DAVID (the Database for Annotation,
Visualization, and Integrated Discovery).11 and Enrichr.12 to
the genes annotated to significantly methylated probes
obtained in the supervised analysis. After accounting for
duplicate genes (i.e., various probes targeting the same gene),
1,285 individual human genes were recognized by DAVID and
included in further analysis. Hierarchical clustering, performed
using GeneCluster 2.013 on the 3,092 probes found to be
significantly differentially methylated in the supervised analysis,
was used to interrogate first the EPIC methylation data from
the three DNMT3A-mutated tumors (T1–T3) from the index
patient, the c.952C>T DNMT3A-mutated PGL plus the 17
control tumors previously described; and second, EPIC
methylation data from lymphocyte DNAs from the c.896A>T
DNMT3A-mutated carrier (average of two samples) and her
parents (I1 and I2), the c.952C>T DNMT3A-mutated patient,
and eight controls (C1–C8). Additionally, we used the same list
of probes to interrogate Illumina 450k methylation data from
26 acute myeloid leukemia (AML) samples carrying DNMT3A
mutations compared with 30 DNMT3A wild-type (WT)
cases.14 Finally, supervised analysis was performed to identify
differentially methylated probes between HeLa knock-in
(c.896A>T) and HeLa WT cells. The reliability of the clusters
obtained with DNMT3A-mutated and no-mutated PCCs/PGLs
was verified by consensus clustering, a method that obtains the
consensus across multiple runs of a clustering algorithm and
assess the stability of the discovered clusters by using
resampling techniques.
Reverse-transcriptase PCR and qPCR
Total RNA was isolated from peripheral blood lymphocytes
from both DNMT3A-mutation carriers and the parents of the
index case using the TriReagent kit (MRC), following the
manufacturer’s instructions. First strand complementary
DNA (cDNA) was synthesized from 1 μg of total RNA by
oligo (dT) 14 primer reverse transcription using Superscript II
Reverse Transcriptase (Invitrogen) following the manufac-
turer’s instructions. Three genes, HOXD13, IRX5, and NKX2-4,
were selected for messenger RNA (mRNA) quantification
because several CpGs annotated to them were found
amongst the differentially methylated in DNMT3A-mutated
tumors. HOXD13, IRX5, and NKX2-4 mRNA levels were
determined by quantitative polymerase chain reaction (PCR)
on a 7500 fast real-time PCR system (Applied Biosystems)
using the Universal ProbeLibrary set (https://www.roche-
applied-science.com), as described by the manufacturer.
Relative mRNA levels were estimated using the 2-CT method15
and normalized using β-glucuronidase (GUS) and β-actin
(ACTB) as housekeeping genes. The results are shown as mean
± s.d. (n ≥ 2).
CRISPR/Cas9
A HeLa cell line (provided by Flow Cytometry Core Unit,
CNIO, Madrid) was authenticated by short tandem repeat
profiling (GenePrint 10 System, Promega) and periodically
confirmed to be mycoplasma-free by qPCR. HeLa cells were
cultured in Dulbecco’s modified Eagle medium Gluta MAX
(DMEM; Invitrogen); supplemented with 10% (v/v) fetal
bovine serum (FBS, PAA Laboratories), 1% (v/v) penicillin/
streptomycin, and 0.6% (v/v) Fungizone (Gibco); and
maintained at 37 °C in a humidified incubator with 5%
CO2. Recombinant Cas9 protein and two single-guide RNAs
(sgRNAs) (sgRNA-1: AACTGCGGGGCTTCTCCTGGTGG;
sgRNA-2: CTGGTGTGGGGGAAACTGCGGGG) were used
as previously described.16 Briefly, sgRNAs were designed
using the CRISPR MIT software tool (http://crispr.mit.edu)
and transcribed in vitro through runoff reactions by T7 RNA
polymerase using the HiScribe T7 high-yield RNA synthesis
kit (NEB). Transcribed sgRNAs were purified with a column
purification kit (RNeasy mini kit, Qiagen, Hilden, Germany),
quantified, and quality-checked by denaturing RNA gel
electrophoresis. RNP complexes were generate by premixing
Cas9 protein (1–8 μg, Integrated DNA Technologies, CA)
with in vitro transcribed sgRNA (0.5–8 μg) for 10 min at
room temperature. A single-stranded oligodeoxynucleotide
with the nucleotide change c.896A>T was purchased from
IDT as an ultramer oligo (available upon request). For
electroporation, we employed the Neon Transfection System
(ThermoFisher Scientific, Waltham, MA). Confluent HeLa
cells were trypsinized and washed twice with DPBS, counted,
and resuspended in 10 µl Buffer T (ThermoFisher Scientific)
per well. In each reaction approximately 100,000 cells were
electroporated under the following conditions: 2 pulses of 35-
ms width and 1,005 V. Cells were then seeded in a 96-well
plate with prewarmed medium. The following day the media
was replaced with fresh DMEM. After culture expansion, cells
were sorted to a 96-well plate to establish single-cell clones.
Detection of knock-in cell clones was performed using Sanger
sequencing. Genomic DNA extraction, PCR amplification,
and purification of PCR product were performed following
standard procedures.
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RNA sequencing (RNA-seq)
PolyA+ fraction from total RNA samples was purified and
randomly fragmented, converted to double-stranded cDNA,
and processed using the TruSeq Stranded mRNA Library Prep
Kit (Illumina). Adapter-ligated library was completed by PCR
and the resulting purified cDNA library was applied to a flow
cell for cluster generation and sequenced on a HiSeq 2500
instrument, following manufacturer protocols. Image analysis,
basecalling, and quality score assignment was performed with
Real Time Analysis software (Illumina), and Illumina2bam
tool, BamToFastq (Bedtools), and SAMtools (http://samtools.
sourceforge.net/) were used to convert the files to BAM,
FASTQ, and SAM format, respectively. FASTQ files contain-
ing the Illumina reads (length= 50) of the samples were
submitted to the Nextpresso v.1.8 pipeline using the default
parameters. Clustering average for linkage and Euclidean as
the distance measure were applied in the hierarchical
clustering using Genecluster 2.0, and a standard deviation of
0.5 was assumed.
Immunohistochemistry
An automated immunostaining platform was used (Ventana
Discovery XT, Roche) for immunohistochemistry of H3(K9)
in 3-μm FFPE sections from the DNMT3A-mutated tumors.
Antigen retrieval was first performed with RiboCC (pH6) and
endogenous peroxidase was blocked (peroxide hydrogen at
3%). Then, slides were incubated with rabbit polyclonal anti-
H3(K9) (1/500; Abcam, ab8898) and following with the
corresponding visualization system (OmniMap antirabbit,
Ventana, Roche) conjugated with horseradish peroxidase.
Immunohistochemical reaction was developed using 3,30-
diaminobenzidine tetrahydrochloride (DAB) (ChromoMap
DAB, Ventana, Roche). Nuclei were counterstained with
Carazzi’s hematoxylin. Finally, the slides was dehydrated,
cleared, and mounted with a permanent mounting medium
for microscopic evaluation.
RESULTS
Exome sequencing findings
First, we focused on heterozygous gene-coding single-
nucleotide substitutions and small insertions and deletions
that were present in blood DNA from the patient but absent
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Fig. 1 Exome sequencing findings, trimethylated histone H3 interactions, and immunohistochemical staining. (a) Schematic representation of
the coding variants passing all filtering steps (with a genotype quality ≥90) that were found in the father (orange square), the mother (green circle), and the
patient (blue circle) exomes. Manual curating by the integrative genomic viewer (IGV) excluded 4 of the 5 variants because they were either found in at least
one of the progenitors or because they were probably the result of a sequencing artifact. The single de novo variant found (c.896A>T in DNMT3A) was
confirmed by Sanger sequencing. (b) PyMOL representation of the interactions between the PWWP domain of DNMT3B and trimethylated K36 in histone
H3 (structure deposited in the Protein Data Base with accession code 5CIU). The histone peptide is shown in yellow and the aromatic cage residues in blue.
The represented residues are fully conserved in DNMT3A. The lysine residue 232 is equivalent to lysine 299 in DNMT3A and is represented in magenta. The
dashed line depicts a hydrogen bond interaction between Lys232 and the carbonyl oxygen of a phenylalanine within the same loop. (c) Highly positive
immunohistochemical staining for H3K9me3 in one representative c.896A>T DNMT3A-mutated tumor from the de novo patient (upper panel) compared to
a DNMT3A wild-type tumor staining negative (lower panel). The scale bars represent 50 µm
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in germline DNA from both of her parents, following a de
novo model. The filtering process applied uncovered a single
de novo missense variant (c.896A>T; p.Lys299Ile) in
DNMT3A, which was subsequently validated by Sanger
sequencing (Fig. 1a). The substitution was not found in the
>120,000 exomes in the gnomAD database (http://gnomad.
broadinstitute.org/), 570 population-matched unrelated Span-
ish exomes from the CIBERER Spanish Variant Server (http://
csvs.babelomics.org/), or the database of Epigenetic Modifiers
(dbEM; http://crdd.osdd.net/raghava/dbem/). The lysine resi-
due affected by the mutation (Lys299) is located within the
highly conserved PWWP domain of the protein (Fig. 1b), and
all in silico algorithms predict the change to be deleterious
(Supplementary Figure S1). In addition, high levels of
H3K9me3 were observed in the c.896A>T DNMT3A-mutated
tumor compared with controls (Fig. 1c). Though recessive
and autosomal dominant with incomplete penetrance models
of inheritance were also considered, we gave priority to the de
novo model because we found a single mutation in a gene
previously associated with various cancers.
Extended study of PCC/PGL patients and tumors
Considering the recurrence of activating mutations affecting
oncogenes, Sanger sequencing–based screening for germline
mutations was performed on the sequence encompassing the
PWWP domain of DNMT3A. A missense mutation
(c.952C>T; p.Arg318Trp) (Supplementary Figure S2A) affect-
ing a highly conserved residue was identified in germline
DNA from a woman (54 yr) with two head and neck PGLs
and a family history of the disease (her mother was diagnosed
with bilateral head and neck PGL). The arginine 318 amino
acid is highly conserved, and the mutation (predicted to be
deleterious) (Supplementary Figure S2B) introduces a trypto-
phan that could alter the binding of DNMT3A to trimethy-
lated histone H3 (Fig. 2a). Further study of the PWWP
domain in a series of 94 tumors identified three cases with a
small mutation peak affecting the same nucleotide as that
mutated in the original patient (Table 1). Subsequent analysis
by targeted deep sequencing showed a clonal effect, ranging
between 14 and 36% of reads, in all three cases, and identified
three additional carriers that hadn’t been detected by Sanger
sequencing. All c.896A>T DNMT3A mutations were found in
head and neck PGLs. The analysis of the corresponding
germline DNA showed in all available cases that the mutation
was somatic. All available DNMT3A-mutated PGLs showed
high immunostaining of H3K9me3.
Methylation and expression profiles of DNMT3A-mutated
tissues
Supervised DNA methylation analyses revealed 3,092 probes
differentially methylated (FDR <0.05) in tumors carrying the
c.896A>T DNMT3A mutation, compared with controls.
Amongst the differentially methylated probes, an enrichment
of homeobox-containing genes (n= 90), dopaminergic neu-
rogenesis, neural crest differentiation, and pattern specifica-
tion and embryonic morphogenesis processes (Supplementary
Table S1), was observed. Probes from 26 Hox genes were
amongst those methylated in c.896A>T DNMT3A-mutated
tumors. Twenty-one probes targeting the HOXD9-13locus,
nine of them targeting HOXD13, were significantly more
methylated (Supplementary Figure S3). Downregulation of
three of the differentially methylated homeobox-containing
genes (HOXD13, NKX2-4, and IRX5) was found by qPCR in
c.896A>T DNMT3A-mutated lymphocytes compared with
controls (Supplementary Figure S4A). Hierarchical clustering,
using data from the 3,092 probes significantly differentially
methylated, grouped all the tumors carrying DNMT3A
mutations together; the three c.896A>T-mutated tumors,
previously used in the supervised comparison, and the tumor
carrying the c.952C>T mutation (Fig. 2b). Additionally,
following a similar profiling, lymphocyte DNAs from the
two DNMT3A mutation carriers were also clustered together
and separated from different controls (Supplementary
Figure S4B). Moreover, a different global expression profile
was observed in c.896A>T DNMT3A-mutated lymphocytes
compared with controls by RNA-seq (Supplementary Fig-
ure S4C). On the whole, these results demonstrate that both
DNMT3A mutations led to a similar and characteristic
methylation profile, being independent of the tissue of origin.
Finally, based on the same list of differentially methylated
probes, all but two AML samples carrying the recurrent
DNMT3A mutation affecting p.Arg882 (Supplementary
Figure S5A) clustered together. This result suggests that
either c.896A>T or c.952C>T and p.Arg882 DNMT3A
mutations cause opposite effects on DNA methylation in
PCC/PGL and AML, respectively.
The p.Lys299Ile mutation increases DNMT3A DNA
methylation capabilities in HeLa cells
CRISPR/Cas9-mediated knock-in introduction of the
DNMT3A p.Lys299Ile mutation in HeLa cells caused
genome-wide alterations in DNA methylation. Thus, more
than 16,000 probes, targeting more than 6,000 different genes,
were found differentially methylated (FDR <0.05; fold change
>|3.5|) in HeLa cells carrying the mutation compared with
WT controls (represented in Supplementary Figure S5B).
Amongst probes that were differentially hypermethylated
upon the introduction of the mutation, an enrichment of
those targeting homeobox-containing genes (n= 52), nervous
system development, neuronal system, and signaling genes
was observed compared to WT HeLa cells (adjusted p < 0.05)
(Supplementary Table S2).
DISCUSSION
DNMT3A encodes one of the two de novo DNA methyl-
transferases, DNMT3A and DNMT3B, that establish DNA
methylation patterns during embryonic development and
gametogenesis in mammals.17 Somatic inactivating mutations
in DNMT3A were first described causing global hypomethy-
lation in acute myeloid leukemia (AML),18 and later most
types of hematological malignancies.19 Other recurrent
somatic alterations affecting genes involved in epigenetic
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in germline DNA from both of her parents, following a de
novo model. The filtering process applied uncovered a single
de novo missense variant (c.896A>T; p.Lys299Ile) in
DNMT3A, which was subsequently validated by Sanger
sequencing (Fig. 1a). The substitution was not found in the
>120,000 exomes in the gnomAD database (http://gnomad.
broadinstitute.org/), 570 population-matched unrelated Span-
ish exomes from the CIBERER Spanish Variant Server (http://
csvs.babelomics.org/), or the database of Epigenetic Modifiers
(dbEM; http://crdd.osdd.net/raghava/dbem/). The lysine resi-
due affected by the mutation (Lys299) is located within the
highly conserved PWWP domain of the protein (Fig. 1b), and
all in silico algorithms predict the change to be deleterious
(Supplementary Figure S1). In addition, high levels of
H3K9me3 were observed in the c.896A>T DNMT3A-mutated
tumor compared with controls (Fig. 1c). Though recessive
and autosomal dominant with incomplete penetrance models
of inheritance were also considered, we gave priority to the de
novo model because we found a single mutation in a gene
previously associated with various cancers.
Extended study of PCC/PGL patients and tumors
Considering the recurrence of activating mutations affecting
oncogenes, Sanger sequencing–based screening for germline
mutations was performed on the sequence encompassing the
PWWP domain of DNMT3A. A missense mutation
(c.952C>T; p.Arg318Trp) (Supplementary Figure S2A) affect-
ing a highly conserved residue was identified in germline
DNA from a woman (54 yr) with two head and neck PGLs
and a family history of the disease (her mother was diagnosed
with bilateral head and neck PGL). The arginine 318 amino
acid is highly conserved, and the mutation (predicted to be
deleterious) (Supplementary Figure S2B) introduces a trypto-
phan that could alter the binding of DNMT3A to trimethy-
lated histone H3 (Fig. 2a). Further study of the PWWP
domain in a series of 94 tumors identified three cases with a
small mutation peak affecting the same nucleotide as that
mutated in the original patient (Table 1). Subsequent analysis
by targeted deep sequencing showed a clonal effect, ranging
between 14 and 36% of reads, in all three cases, and identified
three additional carriers that hadn’t been detected by Sanger
sequencing. All c.896A>T DNMT3A mutations were found in
head and neck PGLs. The analysis of the corresponding
germline DNA showed in all available cases that the mutation
was somatic. All available DNMT3A-mutated PGLs showed
high immunostaining of H3K9me3.
Methylation and expression profiles of DNMT3A-mutated
tissues
Supervised DNA methylation analyses revealed 3,092 probes
differentially methylated (FDR <0.05) in tumors carrying the
c.896A>T DNMT3A mutation, compared with controls.
Amongst the differentially methylated probes, an enrichment
of homeobox-containing genes (n= 90), dopaminergic neu-
rogenesis, neural crest differentiation, and pattern specifica-
tion and embryonic morphogenesis processes (Supplementary
Table S1), was observed. Probes from 26 Hox genes were
amongst those methylated in c.896A>T DNMT3A-mutated
tumors. Twenty-one probes targeting the HOXD9-13locus,
nine of them targeting HOXD13, were significantly more
methylated (Supplementary Figure S3). Downregulation of
three of the differentially methylated homeobox-containing
genes (HOXD13, NKX2-4, and IRX5) was found by qPCR in
c.896A>T DNMT3A-mutated lymphocytes compared with
controls (Supplementary Figure S4A). Hierarchical clustering,
using data from the 3,092 probes significantly differentially
methylated, grouped all the tumors carrying DNMT3A
mutations together; the three c.896A>T-mutated tumors,
previously used in the supervised comparison, and the tumor
carrying the c.952C>T mutation (Fig. 2b). Additionally,
following a similar profiling, lymphocyte DNAs from the
two DNMT3A mutation carriers were also clustered together
and separated from different controls (Supplementary
Figure S4B). Moreover, a different global expression profile
was observed in c.896A>T DNMT3A-mutated lymphocytes
compared with controls by RNA-seq (Supplementary Fig-
ure S4C). On the whole, these results demonstrate that both
DNMT3A mutations led to a similar and characteristic
methylation profile, being independent of the tissue of origin.
Finally, based on the same list of differentially methylated
probes, all but two AML samples carrying the recurrent
DNMT3A mutation affecting p.Arg882 (Supplementary
Figure S5A) clustered together. This result suggests that
either c.896A>T or c.952C>T and p.Arg882 DNMT3A
mutations cause opposite effects on DNA methylation in
PCC/PGL and AML, respectively.
The p.Lys299Ile mutation increases DNMT3A DNA
methylation capabilities in HeLa cells
CRISPR/Cas9-mediated knock-in introduction of the
DNMT3A p.Lys299Ile mutation in HeLa cells caused
genome-wide alterations in DNA methylation. Thus, more
than 16,000 probes, targeting more than 6,000 different genes,
were found differentially methylated (FDR <0.05; fold change
>|3.5|) in HeLa cells carrying the mutation compared with
WT controls (represented in Supplementary Figure S5B).
Amongst probes that were differentially hypermethylated
upon the introduction of the mutation, an enrichment of
those targeting homeobox-containing genes (n= 52), nervous
system development, neuronal system, and signaling genes
was observed compared to WT HeLa cells (adjusted p < 0.05)
(Supplementary Table S2).
DISCUSSION
DNMT3A encodes one of the two de novo DNA methyl-
transferases, DNMT3A and DNMT3B, that establish DNA
methylation patterns during embryonic development and
gametogenesis in mammals.17 Somatic inactivating mutations
in DNMT3A were first described causing global hypomethy-
lation in acute myeloid leukemia (AML),18 and later most
types of hematological malignancies.19 Other recurrent
somatic alterations affecting genes involved in epigenetic
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regulation are common in myeloid malignancies.20 In fact, the
crosstalk between genomic alterations and deregulation of
epigenetic pathways is a well-known cause of cancer that is
not limited to hematologic malignancies. Thus, alterations in
genome-wide gene expression caused by somatic disruption of
epigenetic modifying genes lead to the development of several
solid tumors, including PCC/PGL.4 However, to date no
constitutional alteration of an epigenetic regulator has been
reported as a cause of hereditary cancer. As far as we know,
the case described herein might be the first example of a
Mendelian disorder caused by an alteration of the epigenetic
machinery involved exclusively in cancer predisposition. In
addition, our finding of subclonal somatic mutations in a
substantial number of cases points to the importance of
DNMT3A alterations in PGL, especially for tumors located in
the head and neck region. However, due to the low allele
frequencies of the DNMT3A mutation, it is unlikely that this
mutation is the cancer initiating event in these sporadic cases.
Variant p.Lys299Ile affects a highly conserved residue
within the PWWP motif of DNMT3A that is involved in
both DNA binding and targeting the protein to trimethyl
lysine marks (on lysine 36 and 9) in histone H3 (H3K36me3
and H3K9me3, respectively).21,22 The lysine 299 residue is one
of the most conserved amino acids within the PWWP
domain.23 It is part of the positively charged surface of the
protein that interacts with DNA22 It also interacts with the
aromatic cage of DNMT3A involved in binding methyllysine
histones,22,23 presumably through a hydrogen bond with one
of the amino acids. NMR perturbation experiments per-
formed on histone-binding PWWP motifs of two proteins,
Pdp1 and BRPF1, showed a high chemical shift for the
equivalent lysine residue in both.24,25 The specific methylation
of homeobox-containing genes observed in c.896A>T
DNMT3A–mutated tissues (PGLs and blood from the
patient), further suggests that, instead of a loss of function,
the p.Lys299Ile variation is associated with different
DNMT3A-related DNA methylation capabilities. The high
level of H3K9me3 observed in DNMT3A-mutated tumors,
something also found in SDH- and FH-mutated PCC/PGL,26
provides further evidence for the transcriptional repression
role of the mutation. The effect on DNA methylation caused
by the introduction of the p.Lys299Ile mutation in HeLa cells
supports the role of this mutation in changing DNMT3A
function, which is consistent with the hypermethylated profile
observed in PCC/PGL.
Germline de novo loss-of-function mutations in DNMT3A
cause overgrowth syndrome with intellectual disability,27
while inherited compound heterozygous or homozygous
mutations in DNMT3B are the most common cause of the
ICF (immunodeficiency, centrosome instability, and facial
anomalies) syndrome in humans.28 The patient described
herein did not have any clinical feature related to the
overgrowth or ICF syndromes. Overgrowth syndromes
are also caused by constitutional mutations in two
well-known AML-related genes that encode important
histone methyltransferases: EZH2 (Weaver syndrome)29 and
NSD1 (Sotos syndrome and Beckwith–Wiedemann syn-
drome).30 Moreover, germline de novo inactivating mutations
in ASXL1, which are frequently found in myelodysplastic
syndromes and in AML, also cause a growth disorder called
ba
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Fig. 2 Arg318 location in a DNMT3A 3D structural model and methylation profile for DNMT3A-mutated tumors. (a) PyMOL representation of the
interactions between the PWWP domain of DNMT3B and trimethlyated K36 in histone H3 (similar to the one depicted in Fig. 2a). The histone peptide is
shown in yellow and the aromatic cage residues in blue. The tryptophan that substitutes the arginine 318 amino acid (equivalent to lysine 251 in DNMT3B)
in the mutated Arg318Trp-DNMT3A sample is represented in dark red. (b) Hierarchical clustering using methylation data from the 3,092 probes significantly
differentially methylated (FDR <0.05) between c.896A>T DNMT3A-mutated and nonmutated tumors. T1–T3: c.896A>T DNMT3A-mutated PGLs. H&N head
and neck, PGL paraganglioma, PCC pheochromocytoma, TAP thoracic, abdominal or pelvic
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Bohring–Opitz syndrome.31 In all cases of these syndromes,
genome-wide hypomethylation was observed and no cancer
development was reported. Taken together, our data suggest
that, unlike constitutional inactivation of DNMT3A,
DNMT3A gain-of-function might be associated with PCC/
PGL development. Interestingly, both gain-of-function and
loss-of-function EZH2 mutations occur in cancers with
distinct subtypes,32 including PCC.4
Several Hox family genes, which encode crucial players
during embryogenesis, neural crest patterning, and hemato-
poietic development, are hypomethylated and upregulated in
hematological malignancies carrying somatic DNMT3A
mutations,33,34 and have been proposed as targets for
DNMT3A-dependent methylation. However, Hox genes could
be important for both oncogenesis and tumor suppression,
depending on the context. Thus, hypermethylation of several
Hox genes has been widely found in breast, lung, prostate,
urothelial, and ovarian tumors,35 and methylation of HOXA9
has been found in both neuroblastoma and PCC.36 The
presence of methylation of 26 Hox genes in DNMT3A-
mutated tumors suggests that these transcription factors may
have a tumor suppressor role in PCC/PGL. Our results are
also suggestive of a critical role of methylation of homeobox-
containing genes in PCC/PGL development. So far, ~300
homeobox genes have been identified in the human genome
and the aberrant expression of several members of this
superfamily of transcription factors has been implicated in
tumor initiation and metastasis in many human tumors.37
Both losses and gains of homeobox gene expression are
related to tumorigenesis, and DNMT3A mutations are known
to be associated with altered expression of homeobox-
containing genes.38 Of note, this latter is also observed in
our model of HeLa cells carrying the DNMT3A p.Lys299Ile
mutation. Interestingly, 65 differentially methylated
homeobox-containing genes found in c.896A>T DNMT3A-
mutated tumors were found differentially methylated in
FLT3-ITD/DNMT3A-mutated compared with FLT3-ITD/
DNMT3A-WT AMLs.38 The methylation described herein
in DNMT3A-mutated PGLs and blood samples of mamma-
lian key neural crest determination genes, such as PAX3,
FOXD3, WT1, and the ZIC genes, stresses the relevance of
repression of autonomic lineage cell differentiation in PCC/
PGL, which is also observed in HIF2A-mutated PCCs.39
In summary, we describe herein the first example of gain-
of-function mutations affecting a DNA methyl transferase
gene potentially involved in cancer predisposition. More cases
and further studies, such as mutation segregation analysis and
additional functional assays, are necessary to more precisely
determine the role of DNMT3A alterations in PCC/PGL
susceptibility.
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Bohring–Opitz syndrome.31 In all cases of these syndromes,
genome-wide hypomethylation was observed and no cancer
development was reported. Taken together, our data suggest
that, unlike constitutional inactivation of DNMT3A,
DNMT3A gain-of-function might be associated with PCC/
PGL development. Interestingly, both gain-of-function and
loss-of-function EZH2 mutations occur in cancers with
distinct subtypes,32 including PCC.4
Several Hox family genes, which encode crucial players
during embryogenesis, neural crest patterning, and hemato-
poietic development, are hypomethylated and upregulated in
hematological malignancies carrying somatic DNMT3A
mutations,33,34 and have been proposed as targets for
DNMT3A-dependent methylation. However, Hox genes could
be important for both oncogenesis and tumor suppression,
depending on the context. Thus, hypermethylation of several
Hox genes has been widely found in breast, lung, prostate,
urothelial, and ovarian tumors,35 and methylation of HOXA9
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presence of methylation of 26 Hox genes in DNMT3A-
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have a tumor suppressor role in PCC/PGL. Our results are
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containing genes in PCC/PGL development. So far, ~300
homeobox genes have been identified in the human genome
and the aberrant expression of several members of this
superfamily of transcription factors has been implicated in
tumor initiation and metastasis in many human tumors.37
Both losses and gains of homeobox gene expression are
related to tumorigenesis, and DNMT3A mutations are known
to be associated with altered expression of homeobox-
containing genes.38 Of note, this latter is also observed in
our model of HeLa cells carrying the DNMT3A p.Lys299Ile
mutation. Interestingly, 65 differentially methylated
homeobox-containing genes found in c.896A>T DNMT3A-
mutated tumors were found differentially methylated in
FLT3-ITD/DNMT3A-mutated compared with FLT3-ITD/
DNMT3A-WT AMLs.38 The methylation described herein
in DNMT3A-mutated PGLs and blood samples of mamma-
lian key neural crest determination genes, such as PAX3,
FOXD3, WT1, and the ZIC genes, stresses the relevance of
repression of autonomic lineage cell differentiation in PCC/
PGL, which is also observed in HIF2A-mutated PCCs.39
In summary, we describe herein the first example of gain-
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VGMLVWHKHKKYPFWPAVVKSVRQRDKKA------------SVLYIEGHMNPK--MKGFTVSLKSLKHFDCKEKQT-------------
TGMIVWFKYQKYPFWPAVIKSIRRKERKA------------SVLFVEANMNSE--KKGIRVNFRRLKKFDCKEKQM-------------
VGDIVWAKIYGFPWWPARILTITV----------------------SRKDNGLLVRQEARI-----SWFGSP-TTSFLALSQLSPFLEN
VGDIVWGKIHGFPWWPARVLDISL----------------------GQKEDGEPSWREAKV-----SWFGSP-TTSFLSISKLSPFSEF
PGSIIWAKQYGYPWWPGMIESDPD-----------------LGEYFLFTSHLDSLPSKYHV-----TFFGETVSRAWIPVNMLKNFQEL
LGSLVLVKLQNWPSWPGILCPDRF-----------------KGKYVTY--DPDGNVEEYHI-----EFLGDPHSRSWIKATFVGHYSIT
PLKVVWAKCSGYPSYPALIIDPKMPRVPGHHNGVTIPAPPLDVLKIGEHMQTKSDEKLFLV-----LFFDNKRSWQWLPKSKMVPLGID
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::  *      :*                                                    :                                       
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Supplementary Table S1. Enrichment for the 3092 probes (1378 genes) differentially methylated in DNMT3A -mutated tumors
Enrichr-based enrichment for 1378 input gene IDs
WikiPathway (Homo sapiens)* P-value Adjusted p-value
Dopaminergic Neurogenesis_Homo sapiens_WP2855 2.95E-08 4.96E-06
Neural Crest Differentiation_Homo sapiens_WP2064 6.50E-08 7.27E-06
Endoderm Differentiation_Homo sapiens_WP2853 1.02E-06 6.85E-05
Heart Development_Homo sapiens_WP1591 2.01E-06 1.13E-04
Focal Adhesion_Homo sapiens_WP306 1.22E-04 3.73E-03
*Only the top 5 significant WikiPathways are shown
GO Biological Process (2015)# P-value Adjusted p-value
pattern specification process (GO:0007389) 2.781E-34 1.164E-30
embryonic morphogenesis (GO:0048598) 9.636E-32 2.017E-28
regionalization (GO:0003002) 1.07E-30 1.493E-27
organ morphogenesis (GO:0009887) 5.527E-25 5.785E-22
anterior/posterior pattern specification (GO:0009952) 3.849E-20 2.686E-17
embryonic organ morphogenesis (GO:0048562) 4.582E-21 3.837E-18
neuron differentiation (GO:0030182) 6.008E-20 3.428E-17
tissue morphogenesis (GO:0048729) 5.414E-19 2.267E-16
cell fate commitment (GO:0045165) 6.55E-20 3.428E-17
regulation of neuron differentiation (GO:0045664) 5.892E-18 2.243E-15
#Only the top 10 significant Biological processes are shown
Supplementary Table S2. Enrichr-based enrichment for the 3,094 genes with probes differentially methylated in DNMT3A  knock-in HeLa cells
GO Biological Process P-value Adjusted p-value
nervous system development (GO:0007399) 2.07E-11 4.93E-08
chemical synaptic transmission (GO:0007268) 4.16E-06 2.53E-03
retina layer formation (GO:0010842) 4.25E-06 2.53E-03
synapse assembly (GO:0007416) 6.22E-06 2.96E-03
membrane depolarization during action potential (GO:0086010) 3.36E-06 2.53E-03
branching involved in ureteric bud morphogenesis (GO:0001658) 1.32E-05 5.22E-03
positive regulation of dendrite extension (GO:1903861) 2.52E-05 8.56E-03
neuronal action potential (GO:0019228) 4.65E-05 1.38E-02
Reactome*
Neuronal System Homo sapiens R-HSA-112316 6.57E-06 6.05E-03
Cardiac conduction Homo sapiens R-HSA-5576891 9.25E-06 6.05E-03Transmission across Chemical Synapses Homo sapiens R-HSA-
112315 9.14E-05 2.39E-02
Ion channel transport Homo sapiens R-HSA-983712 6.01E-05 1.96E-02
Phase 0 - rapid depolarisation Homo sapiens R-HSA-5576892 4.34E-05 1.89E-02Interaction between L1 and Ankyrins Homo sapiens R-HSA-
445095 1.66E-04 2.76E-02Neurotransmitter Receptor Binding And Downstream
Transmission In The Postsynaptic Cell Homo sapiens R-HSA- 1.74E-04 2.76E-02
Muscle contraction Homo sapiens R-HSA-397014 1.77E-04 2.76E-02
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ABSTRACT
Hereditary phaeochromocytoma and paraganglioma (PPGL) is a genetically heterogeneous disease 
caused by germline mutations affecting one of seventeen major susceptibility genes, many of which 
encode enzymes involved in the tricarboxylic acid (TCA) cycle. Therefore, in this study we aimed to 
identify novel disease-related TCA cycle genes that could explain additional patients without mutations 
in any of the known susceptibility genes. 
For that, we applied targeted sequencing of several TCA cycle-related genes to genetically undiagnosed 
patients’ samples. This way, we identified five germline variants affecting the dihydrolipoamide 
S-succinyltransferase (DLST) gene in seven unrelated patients, all except one diagnosed with multiple 
PPGLs. A recurrent mutation (c.1121G>A; p.Gly374Glu) was found to disrupt the TCA cycle triggering 
the accumulation of 2-hydroxyglutarate, both in tumours and in a cell-based 13C5-glutamate labelling 
assay. In addition, p.Gly374Glu-DLST tumours exhibited loss of heterozygosity (by means of uniparental 
disomy), as well as homogeneous expression and methylation patterns. 
We also found DLST IHC as a useful tool for identifying tumours carrying alterations not only in DLST 
but also in any of the other TCA cycle-associated genes.
Together, these findings not only unravel DLST as a new PPGL susceptibility gene, but they also further 
strengthen the relevance of the TCA cycle in disease development.
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Abstract 
 
Pheochromocytomas and paragangliomas (PPGLs) provide some of the clearest genetic evidence for the 
critical role of metabolism in the tumorigenesis process. Approximately 40% of PPGLs are caused by driver 
germline mutations in 16 known susceptibility genes, and approximately half of these encode members of the 
tricarboxylic acid (TCA) cycle. Taking as a starting point the involvement of the TCA cycle in PPGL development, 
we aimed to identify unreported mutations in genes involved in this key metabolic pathway that could explain 
additional individuals lacking mutations in known susceptibility genes. For that, targeted sequencing of thirty-
seven TCA cycle-related genes was applied to DNA from 104 PPGL individuals with no mutations in the major 
known predisposing genes. Omics-based analyses, TCA-related metabolite determination and 13C5-glutamate 
labeling assays were also performed. We identified five germline variants affecting DLST in eight unrelated 
individuals (~7%), all except one diagnosed with multiple PPGLs. A recurrent variant, p.Gly374Glu, found in 
four of the eight individuals, triggered accumulation of 2-hydroxyglutarate, both in tumors and in a 
heterologous cell-based assay designed to functionally evaluate DLST variants. p.Gly374Glu-DLST tumors 
exhibited loss of heterozygosity and consistent methylation and expression profiles similarly to EPAS1-
mutated PPGLs, suggesting a link between DLST disruption and pseudohypoxia. Moreover, we found positive 
DLST immunostaining exclusively in tumors carrying TCA cycle mutations and in cases with EPAS1 mutations. 
In summary, this study reveals DLST as a PPGL susceptibility gene, and further strengthens the relevance of 
the TCA cycle in PPGL development.  
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Introduction 
 
Pheochromocytomas and paragangliomas, together called PPGLs (MIM: 171300), are rare neuroendocrine 
tumors derived from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. 
PPGLs have one of the highest heritability rates of all neoplasms in humans. Approximately 40% of individuals 
with this genetically heterogeneous disease carry a germline mutation in one of 16 different susceptibility 
genes (FH [MIM: 136850], KIF1B [MIM: 605995], MAX [MIM: 154950], MDH2 [MIM: 154100], NF1 [MIM: 
613113], EGLN2 [MIM: 606424], EGLN1 [MIM: 606425], RET [MIM: 164761], SDHA [MIM: 600857], SDHAF2 
[MIM: 613019], SDHB [MIM: 185470], SDHC [MIM: 602413], SDHD [MIM: 602690], SLC25A11 [MIM: 604165], 
TMEM127 [MIM: 613403] and VHL [MIM: 608537]).1,2 However, there is still an important fraction of 
individuals with clinical features indicative of a hereditary condition, such as a family history of PPGL, 
multifocal tumors, or an early age of onset, without mutations in any of the known PPGL susceptibility genes. 
Based on many expression and methylation profiling studies (for a review, see3), PPGLs can be 
classified into two main clusters; one of them (cluster 1) is enriched in tumors carrying mutations in genes 
encoding tricarboxylic acid (TCA) cycle enzymes, such as the SDH genes, FH, MDH2 and IDH1 [MIM: 147700]. 
These alterations lead to disruption of the TCA cycle, which results in the accumulation of “oncometabolites” 
like succinate, fumarate and 2-hydroxyglutarate (2HG). These oncometabolites contribute to PPGL 
tumorigenesis through abrogating the function of α-ketoglutarate (αKG)-dependent dioxygenases such as Tet 
methylcytosine dioxygenase 2 or histone N-methyl-lysine demethylases. This leads to a hypermethylation 
signature, also known as the CpG island methylator phenotype (CIMP) profile, similar to the ones observed in 
glioblastomas4 and renal cell carcinomas5,6 carrying metabolic alterations such as gain-of-function IDH1/2 and 
loss-of-function (LoF) FH/SDHB mutations, respectively. Interestingly, there are still PPGLs that exhibit a CIMP-
like profile, but have no alteration in any of the known TCA cycle-related susceptibility genes.7 
Most PPGLs are benign, but 10-20% of PPGL individuals develop metastases in distant non-chromaffin 
tissues like the liver, bones, lymph nodes and lungs.8,9 Despite limited knowledge of markers of malignancy, it 
is known that PPGLs carrying mutations in TCA cycle-related genes, such as SDHB or FH, show particularly high 
rates of malignancy and lower survival rates.10 Therefore, a better understanding of the molecular 
pathogenesis of this disease may determine the appropriate management of affected individuals or the 
treatment strategy. 
Considering the relevance of the TCA cycle in PPGL development, we hypothesized that other genes 
involved in this metabolic pathway could be responsible for the disease in genetically as yet uncharacterized 
cases. In the present study, we identified a PPGL susceptibility gene by sequencing thirty-seven TCA cycle-
related genes in a series of affected individuals without known mutations. We found four different missense 
mutations and one splice-site variant in the dihydrolipoamide S-succinyltransferase (DLST [MIM: 126063]) 
 
 
gene in eight unrelated individuals, suggesting a pathogenic role of the disruption of the αKG dehydrogenase 
(OGDH) complex activity. The characteristic methylation profile and the accumulation of 2HG found in tumors 
and cells carrying the recurrent variant p.Gly374Glu suggest that DLST may be a PPGL susceptibility gene, and 
further supports the importance of TCA cycle alterations in PPGL development.   
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Material and Methods 
 
Research subjects 
One hundred and four index affected individuals, without mutations in known PPGL susceptibility genes (RET, 
VHL, NF1, MAX, TMEM127, SDHA, SDHB, SDHC, SDHD, SDHAF2, MDH2, FH, EPAS1 [MIM: 603349], and HRAS 
[MIM: 190020]), were included in the study. A summary of the clinical data of the affected individuals is shown 
in Table S1. Immunostaining of SDHB was performed when formalin-fixed paraffin-embedded (FFPE) tumor 
tissues were available, in order to rule out hidden mutations affecting the SDH genes.11 Genomic DNA was 
extracted from peripheral blood leukocytes using the Maxwell® 16 Blood DNA purification system (Promega). 
Tumor DNA was obtained using the DNeasy Blood and Tissue kit (Qiagen) for frozen tissues, and the Covaris 
S2 System (Covaris) for FFPE tissues, following the manufacturers' instructions. The Instituto de Salud Carlos 
III (ISCIII) ethics committee (Spain) approved the study, and all individuals provided written informed consent 
to participate in this study. 
 
Targeted next-generation sequencing (NGS)  
DNA extracted from the selected samples was sequenced for a set of thirty-seven genes involved in the TCA 
cycle (Table S2) by TruSight sequencing technology using a previously reported NGS panel.7 In brief, the NGS 
panel was designed using Designstudio software (Illumina) and DNA samples were sequenced using a MiSeq 
desktop sequencer, as previously described.7 Identified coding and splice-site variants were filtered 
considering mapping quality, variant score, depth, strand bias, annotation quality, and predicted effect. The 
cutoff applied to consider a nucleotide substitution as a candidate pathogenic variant was 1.805x10-5, which 
is the highest frequency of a known pathogenic SDHB mutation in the Genome Aggregation Consortium 
(gnomAD) database. The PredictSNP consensus classifier12 was used to predict the effects of the substitutions 
that passed all filtering steps, and Multalin software was used to study and visualize the conservation of 
specific residues in multiple aligned sequences from different species. 
 
Structural modeling of DLST catalytic domain and predictions on variants   
The full-length amino acid sequence of hDLST was submitted to the Phyre2 server for structure prediction.13 
Fourteen templates were selected to model the protein based on heuristics to maximize confidence, 
 
 
percentage identity and alignment coverage. Of these, 13 templates were used to model the biotin/lipoyl 
attachment domain. The E. coli dihydrolipoamide succinyltransferase structure (PDB ID 1SCZ, 60% identity, 
74% similarity) was used to model the catalytic domain. Nine residues were modeled ab initio. The final model 
of the protein had 98% of its sequence modeled at >90% confidence. The hDLST protein has been shown to 
be active as a trimer in vivo.14 The trimeric structure was generated using the E. coli dihydrolipoamide 
succinyltransferase structure crystallized in a trigonal space group (PDB ID 1C4T) as a template. The steric 
clashes generated during modeling and trimerization were removed using the program Chiron.15 The active 
site of the catalytic domain was localized using the known catalytic residues (His424 and Ser372). The binding 
site of the substrate was predicted using the dihydrolipoyl transacetylase structure of A. vinelandii crystallized 
in the presence of 6,8-dimercapto-octanoid acid amide and coenzyme A (PDB ID 1EAB). Images were 
generated using PyMOL.16 
 
Loss of heterozygosity (LOH) and SNP array analyses 
LOH analysis of the DLST locus was performed on samples for which tumor DNA was available. Sanger 
sequencing of tumor DNA using specific primers that amplified DLST regions containing the mutations 
identified was performed in eight tumor samples from five individuals. To characterize the mechanism of LOH, 
high-density SNP-array analysis was performed on DNA of sufficient quality from two tumors (#4 and #5a). A 
genome-wide scan was conducted on 250 ng of tumor DNA using the Illumina Human610-Quad BeadChip 
(Illumina) according to the manufacturer’s specifications. Image data was analyzed using the Chromosome 
Viewer tool contained in GenomeStudio 2010.2 (Illumina). The metric used was the log-R ratio, which is the 
binary logarithm of the ratio of the observed to expected normalized R values for a given SNP.17 In addition, 
the allele frequency was estimated for all SNPs. Microsatellite analysis was carried out on DNA from an 
additional case (#3). Primers for three polymorphic markers located in chromosome 14 and chromosome 2 
(used as control) were designed and labeled (5’ 6-FAM). Genomic and tumor DNA were amplified separately 
by means of a multiplex PCR kit (Qiagen, GmbH, Hilden, Germany), and PCR amplification products were used 
for fragment analysis on an ABI PRISMTM 310 capillary sequencer (Applied Biosystems, Foster City, CA, USA), 
and analyzed using Peak ScannerTM Software v1.0 (Applied Biosystems), as previously described.18 
 
Lentiviral constructs and techniques 
Overexpression of cDNA constructs were made in the pLVX-EF1a-IRES-neo vector, which was derived from the 
pLVX-EF1a-IRES-puro vector (631988, Clontech) by exchanging the selection cassettes. All DLST cDNA 
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constructs were untagged. All constructs were confirmed by sequencing. A catalytically dead DLST mutant was 
designed based on the crystal structure of the E.coli DLST ortholog (PDB ID: 1SCZ), and His375 was selected as 
critical for the deprotonation of the thiol group of coenzyme A. The corresponding human residue, His424, 
was selected for mutagenesis. Lentivirus-based constructs were made using the standard protocol of The RNAi 
Consortium from the Broad Institute. In order to evaluate the role of DLST variants, we used H838 DLST-KO 
cells previously generated by CRISPR/Cas9 technology19. To infect, H838 DLST-KO cells were centrifuged for 1 
hour in the presence of the viruses and 8 µgg/ml Polybrene (H9268, Sigma). Media was replaced after the spin, 
and drug selection was started 24 hours later. Selection was carried out until all uninfected control cells were 
dead. 
 
13C5 -glutamate labeling studies in DLST-KO cancer cells  
Labeling studies and liquid chromatography-mass spectrometry (LC-MS) methods were conducted as 
previously described.19  Briefly, cells were plated at 60%–70% confluency in triplicate in fresh RPMI-1640 
media and incubated overnight. The next day, media was replaced with media containing 2 mM 13C5-
glutamate. Labeling was done for 3 hours, after which the cells were washed three times with PBS (pH 7.4) 
and metabolites were extracted by the addition of ice-cold 80% methanol. Cell debris was removed by 
centrifugation and samples were dried under a stream of nitrogen. Internal standard (L-Glutamic acid-13C5, 
15N,2,3,3,4,4-d5, 749850, Sigma-Aldrich) was added at 1 mg/mL during the extraction step. In all labeling 
studies, the reported amounts of labeled species were corrected for natural isotope abundance.  
 
Immunoblotting 
Immunoblotting was conducted as previously described.19 Briefly, cells were harvested in 1X RIPA buffer (BP-
115, Boston BioProducts) containing a phosphatase and protease inhibitor cocktail (5872S, Cell Signaling 
Technology). Adherent cells were scraped into lysis buffer and sonicated briefly to solubilize. Cell lysates were 
cleared by centrifugation for 10 min at 4⁰C. Protein quantification was done using the Pierce BCA Assay Kit 
(23225, Life Technologies). Primary antibodies used were anti-DLST (HPA003010; rabbit polyclonal 1:1000, 
Sigma) and anti-GAPDH (97166, 1:10,000, Cell Signaling Technology). Results were visualized using the 
Odyssey imaging system (LI-COR) and the following secondary antibodies: IRDye 680RD Donkey anti-Rabbit 
(926-68073, LI-COR) and IRDye 800CW Donkey anti-Mouse (926-32212, LI-COR). 
 
Liquid chromatographic-tandem mass spectrometric determination of TCA-related metabolites 
 
 
Fresh frozen or FFPE tumor tissue (5-10 mg) from four available cases (#1, #3a,b,c, #4, and #5a,b) (Table 1) 
and from 51 controls (DLST-WT PPGLs), were immersed in 500 μl LC-MS/MS-grade methanol containing 
isotope-labeled internal standards and processed as previously described.20 Analysis of metabolites was 
carried out using an AB Sciex 5500 QTRAP mass spectrometer coupled to an Acquity ultra-high performance 
liquid chromatographic system (Waters), as previously described.20 
 
DNA methylation array 
Bisulfite conversion of DNA was performed using the EZ DNA Methylation Kit (Zymo Research) and genome-
wide DNA methylation was assayed using the Infinium MethylationEPIC BeadChip Kit (Illumina) at the Centro 
Nacional de Genotipado (CEGEN-ISCIII), as previously described.21 This BeadChip interrogates over 850,000 
methylation sites per sample at single-nucleotide resolution. Beta values for interrogated CpGs were assigned 
using the Genome Studio Methylation module and transformed into M values by applying the formula: 
log2[beta value/(1-beta value)]. Negative M values indicate less than 50% methylation and positive M values 
indicate more than 50% methylation.22 M-values were used for statistical analyses. Hierarchical clustering of 
methylation data from three unrelated DLST-mutated tumors and 13 PPGLs carrying known mutations in 
major susceptibility genes (four SDHB-, two DNMT3A-, two HRAS-, one NF1-, two MAX-, one EPAS1-, and one 
RET- mutated tumors) was performed using GeneCluster 2.0.23. A second unsupervised analysis was 
performed using a list of 125,112 probes corresponding to 4,662 genes with CpG sites reported as significantly 
hypermethylated in SDHx-mutated (M1) PPGLs.24 We used the complete linkage as clustering method and the 
city-block metric as the distance measure in the unsupervised comparisons. The methylomes used in the 
analysis have been deposited in the National Center for Biotechnology Information GEO database, under 
accession numbers GSE111336 and GSE123185. 
 
Gene expression array 
The Agilent Whole Human Genome platform (4x44K) was used for competitive hybridization of labeled and 
amplified cDNAs obtained from Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) and from RNAs 
extracted from PPGL tumor samples, as previously described.25 To identify a transcriptional profile related to 
DLST alteration, we used gene expression data from two available DLST-mutated tumors and from 67 controls 
harboring mutations in other PPGL susceptibility genes (GEO database accession number GSE19422). Tumor 
samples were grouped according to their expression profiles by unsupervised clustering, and a supervised 
analysis was used to identify specific transcripts related to the presence of DLST mutations. For the hierarchical 
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clustering, we used expression data from a previously reported list of 451 genes (572 probes) differentially 
expressed in SDHx-, VHL- and RET/NF1/TMEM127-mutated PPGLs.26 Differentially expressed genes were 
identified by a t-test (limma) carried out using POMELO II software.27 To account for multiple hypothesis 
testing, the estimated significance level (P) was adjusted using the Benjamini false discovery rate (FDR) 
correction.28 Genes with an FDR<0.05 were considered to be differentially expressed between tumor classes. 
The transcriptome from tumor #5a (data from tumor #4 are already included in GSE19422) has been deposited 
in GEO, under accession number GSE123344. 
 
Quantitative real-time PCR 
Total RNA was obtained from FFPE or frozen material using the RNeasy FFPE (Qiagen) or TriReagent (MRC) kit, 
respectively, according to the manufacturers’ instructions. cDNA was prepared from 1 µg of total RNA using a 
mix of oligo-dT and random primers and qScriptTM cDNA Synthesis Kit (#95047-100, Quanta Biosciences). 
mRNA levels from genes of interest were determined by quantitative PCR on a 7500 fast real-time PCR system 
(Applied Biosystems) using the Universal ProbeLibrary set;  each sample was analyzed in triplicate. Relative 
mRNA levels were estimated by the ΔΔCt method29 and normalized using β-actin (ACTB) as housekeeping 
gene. The results are shown as mean+SD. mRNAs obtained from frozen/FFPE tumors carrying mutations in 
other known PPGL susceptibility genes were used as controls.  
 
Immunohistochemistry 
Immunohistochemical (IHC) staining of DLST (11954; rabbit monoclonal 1:150, Cell Signaling Technology) was 
performed using 3 μm FFPE sections from six DLST-mutated tumor samples available, following standard 
procedures. Eighty-two tumors carrying mutations in other PPGL susceptibility genes were used as controls. 
  
 
 
Results 
 
TCA-targeted NGS findings 
In order to identify additional genes mutated in PPGL affected individuals, we applied targeted sequencing of 
thirty-seven TCA cycle-related genes to individuals with PPGL and without mutations in the major known 
predisposing genes. Targeted NGS identified nine germline LoF and non-synonymous coding variants, affecting 
five different genes in thirteen unrelated affected individuals from the 104 cases analyzed (Table S3). All 
substitutions were validated by Sanger sequencing. One of the variants was found in a recently reported PPGL 
susceptibility gene (SLC25A11; GenBank: NM_003562 [MIM: 604165])2, and the remaining changes affected 
genes that encode different subunits of TCA cycle enzymes (DLST and SUCLG1; GenBank: NM_001933 [MIM: 
126063] and NM_003849 [MIM: 611224], respectively), a cytosolic TCA cycle-related protein (IDH1; GenBank: 
NM_001282387 [MIM: 147700]), and a mitochondrial carrier (SLC25A10: GenBank: NM_012140 [MIM: 
606794]). The only recurrently mutated gene was DLST, in which we found five different variants in seven 
unrelated individuals (Table 1). In addition, upon revisiting 14 whole exomes from PPGL individuals, we found 
another person carrying a germline DLST mutation (#6). We therefore focused our further research on the role 
of this gene in PPGL development. 
 
DLST is recurrently mutated in individuals with multiple PPGLs 
The five different DLST variants consisted of four missense mutations (c.1121G>A, p.Gly374Glu [in four 
individuals]; c.692G>A, p.Arg231Gln; c.910G>A, p.Asp304Asn; and c.1265A>G, p.Tyr422Cys) and one intronic 
splice site variant (c.1060-3T>A) (Figure 1A and Table 1). None of the individuals with a DLST mutation had a 
family history of the disease and two of them also had non-PPGL tumors. Seven of the eight individuals carrying 
DLST mutations presented with tumors in multiple locations (significantly higher than 21/97 non-DLST-
mutated cases; p<0.001), especially in the thoracic-abdominal region (p<0.001). One of the affected 
individuals developed distant metastasis, and all functional tumors produced normetanephrine (Table 1). 
Three of the four DLST missense substitutions were predicted as deleterious by PredictSNP (Figure S1A) and 
affected highly-conserved protein residues located close to amino acids predicted to be critical for protein 
functions (Figure 1B): Gly374 and Tyr422 are part of a pocket where the succinyl group fits in E. coli, and Tyr422 
is close to the active site of the protein (Figure 1C).30 All DLST variants were absent or found in at most 3 
controls in gnomAD (out of more than 122,000 individuals) (Table S3), and two of them (p.Asp304Asn and 
p.Gly374Glu) were found as somatic variants in other cancers (Figure S1B). The number of heterozygous LoF 
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mutations per coding nucleotide found in gnomAD for DLST (n=12) was significantly lower (p<0.05) than that 
observed for SDHB (n=25), and similar to that observed for FH (n=18). Assuming that disease-causing genes 
are more intolerant of rare LoF variants,31 this suggests that the presence of heterozygous DLST LoF variants 
could have phenotypic consequences. 
 
The DLST variants locate in a region critical for functional activity 
Structural analysis revealed that all missense variants detected map in regions of DLST involved in its catalytic 
activity. A structural model of human DLST was generated based on a comparison with available crystal 
structures from prokaryotic homologs. The structures of the N- and C-terminal domains were predicted with 
significant confidence due to their high conservation, but the spatial relationship between the two domains 
cannot be predicted accurately since there seems to be a poorly structured region connecting both domains. 
There is evidence of flexibility from the structures of related complexes,14 which would be allowed by the 
linker connecting the catalytic and Biotin/Lipoyl attachment domains. The family of dehydrogenase 
multienzyme complexes that includes DLST functions as trimeric complexes with the catalytic domain formed 
by residues from two adjacent subunits.32 Gly374 locates within the pocket where the succinyl group fits, but 
also in the region of interaction between two monomers. The recurrent p.Gly374Glu substitution introduces 
a large and negatively-charged side chain, compared to the Gly-containing structure, which could interfere 
with either binding to the succinyl group and/or oligomerization (Figure 1C). 
 
p.Gly374Glu-DLST tumors show LOH due to uniparental disomy 
Sanger sequencing revealed LOH of the WT DLST allele in six tumors from three independent individuals, all of 
them carrying the p.Gly374Glu variant (Table 1 and Figure S2A). Genome-wide SNP array and microsatellite 
analysis revealed that uniparental disomy (UPD) of chromosome 14q, on which DLST is located, caused LOH in 
tumors from three available individuals carrying the p.Gly374Glu variant (Figure 2). One of the tumors also 
showed loss of chromosomes 11 and 3q. The other two showed clonal gains in chromosomes 6p, 7p, and 22 
and no chromosomal alterations in PPGL-predisposing loci (i.e. loss of chromosomes 1p, 11 and 3, and gain of 
chromosome 2p). In addition, a paternal origin of the UPD was determined in the three individuals carrying 
the p.Gly374Glu variant based on the methylation status (data obtained from the methylation arrays) of a 
maternally expressed imprinted gene, MEG3, which is located at the distal part of chromosome 14q (Figure 
2). Collectively, the observed pattern of genetic changes at this locus suggests a tumor suppressor role for 
 
 
DLST. Two additional DLST-mutated tumors, carrying substitutions different from the recurrent p.Gly374Glu 
variant, showed no LOH (Table 1). 
 
Functional evaluation of DLST variants  
To assess the impact of the missense variants on DLST function, we conducted 13C5-glutamate labeling studies 
to trace the carbon flow in the TCA cycle (Figure 3A). The individual DLST mutants (see Table 1), along with the 
corresponding WT DLST control, were introduced in H838 DLST-KO cells. These cells do not demonstrate 
dramatic DLST-associated growth defects probably due to significant activity of compensatory metabolic 
pathways 19. The complete inhibition of oxidative TCA in these cells, demonstrated by loss of 13C4-succinate, 
13C4-fumarate and 13C4-malate fractions, provides a robust assay for the evaluation of DLST variants. We also 
included a predicted catalytically-dead DLST mutant, p.His424Ala. The prediction was based on homology 
modeling of the E.coli DLST ortholog (PDB: 1SCZ) and the critical role this histidine plays in deprotonation of 
the coenzyme A thiol group. An equivalent protein level was achieved for all DLST constructs (Figure 3B).  
As expected, DLST-KO cells displayed a significant block in carbon flow in the TCA cycle as evidenced 
by negligible levels of labeled downstream metabolites, such as 13C4-succinate, 13C4-fumarate, 13C4-malate, and 
13C4-aspartate (Figure 3C). Reintroduction of WT DLST was able to effectively rescue this metabolic phenotype 
and the predicted catalytically-dead mutant, p.His424Ala, had dramatically diminished activity. Of the four 
variants identified in our PPGLs, only p.Gly374Glu showed partially compromised activity as compared to WT 
DLST. Importantly, all cells displayed equivalent levels of precursor labeling, as evidenced by 13C5-glutamate 
and 13C5-αKG levels. Confirmatory results were obtained using the 13C5-2HG readout, where DLST-KO cells 
displayed significant levels of 2HG accumulation (L-2HG/D-2HG>25) that was decreased by reintroduction of 
WT DLST. Only two mutants, p.His424Ala and p.Gly374Glu, showed a behavior consistent with diminished 
enzymatic activity (Figure 3D). Collectively, these results indicate that the p.Gly374Glu variant results in a 
functionally compromised DLST protein. Considering this result, and due to tissue limitations, we focused our 
further research on the p.Gly374Glu-DLST- tumors. 
 
p.Gly374Glu-DLST tumors accumulate αKG and 2HG  
Liquid chromatography tandem-mass spectrometry revealed a significantly higher αKG/fumarate ratio 
(21.48±23.65; n=5) in p.Gly374Glu-DLST tumors as compared to WT-DLST tumors (2.27±4.99; n=51, p<0.001) 
(Figure 4A). Additionally, p.Gly374Glu-DLST tumors presented a significantly higher 2HG/fumarate ratio 
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(24.64±21.40; n=5) than PPGLs due to other mutations (1.97±0.87; n=6) (p<0.05) (Figure 4B). The levels of L-
2HG, the 2HG enantiomer generated from αKG by promiscuous activity of lactate and malate dehydrogenases, 
were >2.3 times higher than D-2HG levels in three p.Gly374Glu-DLST tumors available for the measurement 
(data not shown). Since this ratio reflects normally found proportions of L-2HG to D-2HG and since IDH1/2 
mutations are associated with a complete reversal to many fold higher D-2HG to L-2HG concentrations33, the 
data suggest that the increase in 2HG was not related to IDH1/2 neomorphic mutations. All this data suggests 
that disruption of the TCA cycle in p.Gly374Glu-DLST tumors leads to aberrantly elevated αKG/fumarate and 
2HG/fumarate ratios. 
  
p.Gly374Glu-DLST tumors show a characteristic methylation profile 
To understand the impact of DLST mutations on the global methylation patterns in PPGLs tumors, we profiled 
three tumors from unrelated individuals carrying the p.Gly374Glu-DLST variant and 14 tumors harboring 
known mutations in other PPGL susceptibility genes. The three DLST-mutated cases consistently clustered 
together within the non-CIMP methylation cluster, together with tumors with EPAS1 and MAX mutations, 
close to tumors carrying RET/NF1/HRAS mutations, and separated from tumors carrying SDHx and DNMT3A 
mutations (Figure S2B). This relatively uniform methylation profile further supports the relevance of the 
p.Gly374Glu DLST variant, and is in agreement with previous studies that showed the importance of the driver 
mutation on PPGL methylation profiles. Hierarchical clustering using methylation data from 125,112 probes 
corresponding to 4,662 genes reported as significantly hypermethylated in SDHx-mutated tumors, grouped 
the four SDHB- and the two DNMT3A-mutated tumors together in a CIMP cluster, while HRAS-, NF1-, RET- and 
MAX-mutated cases and the only EPAS1-mutated tumor clustered in the non-CIMP cluster (Figure S2C). This 
unsupervised analysis clustered the three p.Gly374Glu-DLST tumors together and within the non-CIMP cluster. 
Thus, despite a very homogeneous methylation profile, p.Gly374Glu-DLST tumors do not show the CIMP 
profile associated with other TCA-cycle related mutations. Rather, DLST-mutated tumors clustered with the 
only M2 tumor (i.e. PPGLs showing an intermediate methylation phenotype) included in the analysis, which 
questions the role of the observed accumulation of metabolites as the mediators of tumorigenesis in DSLT-
mutated PPGLs. 
    
HIF3A is overexpressed in DLST-mutated tumors 
Hierarchical clustering of whole gene expression data from 69 frozen tumors grouped the two (#4 and #5a) 
p.Gly374Glu-DLST tumors together, suggesting a common transcriptional profile. A second unsupervised 
 
 
clustering using a list of 451 genes differentially expressed in PPGLs with different genetic backgrounds 
grouped all VHL- and SDHx-mutated tumors in cluster 1, and all tumors carrying mutations in 
TMEM127/MAX/NF1/HRAS genes in cluster 2. Interestingly, the two p.Gly374Glu-DLST cases (#4 and #5a) 
were grouped in cluster 1 together with all, except one, tumors carrying mutations in EPAS1 (Figure 4C). This 
result suggests a consistent impact of the potential driver mutation on gene expression, and a link between 
p.Gly374Glu-DLST variant and pseudohypoxia. The supervised analysis revealed 132 probes significantly 
differentially expressed in DLST-mutated tumors compared to tumors carrying known mutations in other PPGL 
susceptibility genes (Table S4). The most representative probes targeted signal transduction and 
hematopoiesis genes such as JAK3 [MIM: 600173], ERBB4 [MIM: 600543] or LEPR [MIM: 601007], neural 
proteins like MAP7D1, SPTBN5 [MIM: 605916], GABRA4 [MIM: 137141], ZIC4 [MIM: 608948] and FRMD7 
[MIM: 300628], and seven nucleosome genes. Moreover, four different probes targeting HIF3A [MIM: 609976] 
were found differentially overexpressed and were ranked amongst the five most significant ones. mRNA 
expression of HIF3A, measured by RT-qPCR, showed an overexpression of HIF3A in p.Gly374Glu-DLST tumors 
(#3a,c; #4 and #5a) when compared to controls (n=18) (Figure 4D), which  further suggests a link between 
DLST disruption and pseudohypoxia.  
 
DLST- and TCA cycle-mutated PPGLs show positive DLST immunostaining 
Immunohistochemical (IHC) staining of DLST in all available DLST-mutated tumors revealed that this enzyme 
was more abundant in these samples as compared to DLST-WT PPGLs (Figure 5A). A strong staining was also 
observed in all tumors carrying mutations in genes encoding TCA cycle enzymes (n=33) compared with control 
PPGLs carrying mutations in other PPGL susceptibility genes (p<0.001) (Figure 5B). Four of the control tumors 
without TCA cycle mutations showed an intense IHC staining (IHC score=3), and two of them carried a mutation 
in EPAS1. Therefore, we extended the IHC study to six additional EPAS1-mutated tumors and found a positive 
staining in all of them (Figure 5B). This data suggests DLST immunohistochemistry as a useful tool to identify 
tumors from the pseudohypoxic cluster 1 carrying alterations either in TCA cycle-related genes or in EPAS1. 
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Discussion 
 
The identification of heterozygous germline mutations in more than ten genes that are directly or indirectly 
involved in the TCA cycle point to this metabolic pathway as one of the main drivers for the development of 
PPGLs. Thus, the assessment of TCA cycle status has become a routine part of the genetic diagnosis of PPGL 
and has fueled intense interest in this pathway to identify therapeutic targets. In the present study, we have 
found variants affecting DLST in more than 6% of affected individuals (most of them with multiple tumors) 
without mutations in other PPGL-related genes. Moreover, we have demonstrated the deleterious effect for 
DLST function of one recurrently mutated residue (found in ~3% of the whole series of affected individuals) 
and therefore propose DLST as a PPGL susceptibility gene. 
DLST encodes the E2 subunit of the mitochondrial αKG dehydrogenase (OGDH) complex, which has 
two additional subunits: E1 (encoded by OGDH [MIM: 613022]) and E3 (encoded by DLD [MIM: 238331]). The 
OGDH complex catalyzes the overall conversion of αKG to succinyl-CoA and CO2. Depletion of any of the OGDH 
complex subunits leads to impaired enzymatic activity and αKG accumulation, and it has been demonstrated 
that DLST is a non-redundant member of the OGDH complex.34 Dlst KO mice are embryonically lethal and while 
some DLST-KO cells can grow, they exhibit a complete disruption of the oxidative TCA cycle.19,35 Any condition 
causing even a modest variation in the cytosolic levels of αKG may affect different pathways, promoting either 
oncogenic or tumor suppressive responses: increase of fatty acid biosynthesis or promotion of aberrant 
mammalian target of rapamycin 1 (mTORC1) activation (Figure S3). 36–38. In addition, DLST mutation causing 
loss of OGDH complex nuclear translocation capacity, may lead to altered overall gene expression (Figure S3). 
39 The increased αKG to fumarate ratio in p.Gly374Glu-mutated tumors suggests that this variant leads to a 
disruption of OGDH complex activity. Moreover, the accumulation of significant levels of  L-2HG in DLST-KO 
cells reconstituted with p.Gly374Glu-DLST mutant protein further suggests a functional impairment of this 
mutant DLST, since an increase in L-2HG has been previously noted in other experimental models upon OGDH 
complex disruption.34  
In contrast to D-2HG, which can be generated by neomorphic mutations in IDH1 or IDH2 [MIM: 
147650],40 the stereospecific production of L-2HG is driven by the reduction of mitochondrial αKG by both 
malate dehydrogenases (MDH1 and MDH2) and mainly by lactate dehydrogenase A (LDHA)42, which specific 
inhibition prevents the accumulation of L-2HG in OGDH null cells. 34 This promiscuous substrate usage of αKG 
occurs specifically under conditions of increased  αKG  as a result of TCA cycle dysfunction, increased 
mitochondrial reducing potential, or oxygen limitation.34,41,42 The labeling studies with 13C5-glutamate revealed 
that the p.Gly374Glu-DLST variant is functionally compromised, as it was not able to reconstitute WT-DLST 
function in the context of DLST-KO cells. The location of Gly374 close to Ser372, an amino acid described to 
be essential for catalysis,32 reinforces the hypothesis that distortion introduced by the Gly to Glu substitution 
 
 
could interfere with the catalytic activity of DLST. The remaining substitutions, although two of them affect 
residues that are highly conserved and were predicted to be deleterious, displayed similar behavior to WT-
DLST in our cellular model. Moreover, Tyr422 is very close to the critical residue of the active site (His424) of 
the protein. It is important to note that we cannot exclude the possibility that these variants affect other less-
explored DLST functions, such as the biogenesis of the respiratory chain,43 or that they manifest defects in a 
more physiologically relevant context not recapitulated by our heterologous system.  
The presence of multiple tumors in most of the individuals with DLST mutations, similar to other 
hereditary cancer syndromes, supports the pathological role of DLST germline variants. On the other hand, 
the lack of family history of the disease in these particular individuals (Figure S4) points to a de novo or low 
penetrance inheritance; this latter mechanism is frequently observed in PPGL.20,44 It is interesting to note that 
one of the individuals also harbored a pituitary adenoma, a pathology that has been described to co-occur in 
some persons with PPGL.45 However, given the singularity of this observation, further studies in a larger 
number of affected individuals will be needed to elucidate the functional contribution of DLST. 
To the best of our knowledge, there are no DLST or OGDH complex germline mutations reported in 
individuals with cancer. However, mutations in DLD result in an atypical form of αKG dehydrogenase 
deficiency,46 and recessive variants in DHTKD1 [MIM: 614984] and OGDHL [MIM: 617513], encoding proteins 
similar to subunits of the OGDH complex, have been found in individuals with neurodegenerative 
phenotypes,38,47 and a decline in OGDH complex activity has also been associated with neurodegeneration.48 
Moreover, it is well known that homozygous or compound heterozygous mutations in TCA cycle-related genes 
(e.g. SDH genes, FH, MDH2, ACO2 [MIM: 100850], IDH3A [MIM: 601149] or SLC25A10), lead to encephalopathy 
and neurodegeneration.49–53 Thus, taking into account the evidences linking intermediary metabolism, 
tumorigenesis and neurodegeneration, it is not surprising to find mutations in DLST leading to cancer. 
LOH of chromosomal regions is crucial in tumor progression and has been successfully used to map 
the locations of tumor suppressor genes. Since disease-causing genes appear to be more intolerant of rare LoF 
variants,31 the presence of heterozygous DLST LoF variants could have phenotypic consequences. On the other 
hand, six tumors carrying the recurrent p.Gly374Glu variant showed LOH, suggesting a tumor suppressor role 
for DLST. Moreover, we were able to demonstrate in all individuals carrying the p.Gly374Glu-DLST variant that 
the chromosomal loss observed in their tumors was due to a paternal chromosome 14q UPD, a second-hit 
mechanism previously reported in PPGLs carrying mutations in the susceptibility gene MAX.18 Interestingly, 
hierarchical genome-wide expression analysis of two DLST-mutated tumors showed that they had similar 
expression patterns that were also alike to MAX-mutated PPGLs. We studied these tumors in more detail and 
were able to rule out the presence of rare promoter or deep intronic MAX mutations (data not shown). The 
existence of a particular MAX-like expression profile has been previously reported in PPGL,54 and it was 
suggested that certain unknown genes could phenocopy MAX-mutant tumors. Our findings suggest that DLST 
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existence of a particular MAX-like expression profile has been previously reported in PPGL,54 and it was 
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may be one of these genes and that the gene expression alterations caused by paternal chromosome 14q UPD 
is the cause of this characteristic expression profile, underscoring the relevance of this mechanism for PPGL 
pathogenesis. Finally, the absence of somatic rearrangements in other PPGL susceptibility loci, and the finding 
of 14q UPD as the only common chromosomal alteration in p.Gly374Glu-DLST mutated tumors further 
supports the role of DLST in tumor development. 
Previous methylome analyses on PPGLs identified stable clusters associated with distinct clinical 
features and mutational status.22,24,55 The homogeneous methylation profile exhibited by the PPGLs carrying 
the p.Gly374Glu-DLST variant rules out a CIMP profile, and it further points to a driver role of this DLST 
mutation in these tumors. Moreover, the expression profile shared by DLST-mutated tumors further suggests 
that they carry a similar driver genetic alteration. Depletion of DLST leads to increased endogenous HIF1A 
[MIM: 603348] levels by L-2HG-mediated inhibition of enzymatic prolyl hydroxylase activities.34 The expression 
profile similar to that of EPAS1-mutated tumors and the consistent upregulation of HIF3A mRNA observed in 
p.Gly374Glu-DLST tumors further strengthen the connection of tumors harboring TCA mutations to the 
induction of a pseudo-hypoxic state. 25,56 Moreover, it is known that HIF3A overexpression in pancreatic cancer 
tissues is correlated with a shorter survival time and increased local invasion and distant metastasis.57 Further 
studies of HIF3A in this context are warranted.  
Finally, the strong DLST immunostaining observed in DLST-mutated tumors may suggest that, as 
occurs with SDHD and the SDH complex,58 the presence of mutations in DLST disrupt OGDH complex assembly 
and make the DLST epitope more accessible. This could also explain the high intensity of DLST immunostaining 
found in PPGLs carrying other mutations in TCA cycle-related genes, since these mutations also lead to 
disruption of the cycle. The positive DLST staining observed in EPAS1-mutated tumors suggests that the 
activation of this pseudohypoxic pathway could also provoke changes in the assembly of TCA cycle enzymes. 
This is in agreement with the proposed regulatory network between the TCA cycle and the hypoxia response 
in which each of the pathways reciprocally affects the other. 56 Although the mechanism remains unexplained, 
our data suggests that DLST immunohistochemistry may be useful to help in the classification of variants of 
unknown significance in genes related to the TCA cycle.  
In summary, we have identified a recurrent germline variant (p.Gly374Glu) that functionally 
compromises DLST function. Tumors harboring this alteration display altered methylation and transcriptional 
profiles similar to the ones observed in EPAS1-mutated tumors, suggesting a connection between DLST 
functional abrogation and pseudohypoxia. Therefore, we propose DLST as a PPGL susceptibility gene.  
  
 
 
Accession Numbers 
The transcriptome from tumor #5a and the methylomes used in the analysis have been deposited in the 
National Center for Biotechnology Information GEO database under the accession numbers GSE123344 
GSE111336 and GSE123185. 
 
Supplemental Data 
Supplemental data include five figures and four tables. 
 
 
 
Declaration of interests 
David Pirman, Christopher E. Mahoney, Giovanni Cianchetta and Gromoslaw A. Smolen are employees of and 
have ownership interest in Agios Pharmaceuticals. The other authors declare no competing interests. 
 
 
 
Acknowledgments 
 
This work was supported by the Instituto de Salud Carlos III (ISCIII), through the “Acción Estratégica en Salud” 
(AES) (projects PI15/00783 and PI17/01796, to A.C. and M.R., respectively, cofounded by the European 
Regional Development Fund (ERDF)), and the Deutsche Forschungsgemeinschaft (DFG RI2684/1-1 to S.R.). The 
Human Genotyping Unit is a member of CeGen, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 
2013-2016, funded by ISCIII and ERDF. 
  
 
 
Accession Numbers 
The transcriptome from tumor #5a and the methylomes used in the analysis have been deposited in the 
National Center for Biotechnology Information GEO database under the accession numbers GSE123344 
GSE111336 and GSE123185. 
 
Supplemental Data 
Supplemental data include five figures and four tables. 
 
 
 
Declaration of interests 
David Pirman, Christopher E. Mahoney, Giovanni Cianchetta and Gromoslaw A. Smolen are employees of and 
have ownership interest in Agios Pharmaceuticals. The other authors declare no competing interests. 
 
 
 
Acknowledgments 
 
This work was supported by the Instituto de Salud Carlos III (ISCIII), through the “Acción Estratégica en Salud” 
(AES) (projects PI15/00783 and PI17/01796, to A.C. and M.R., respectively, cofounded by the European 
Regional Development Fund (ERDF)), and the Deutsche Forschungsgemeinschaft (DFG RI2684/1-1 to S.R.). The 
Human Genotyping Unit is a member of CeGen, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 
2013-2016, funded by ISCIII and ERDF. 
  
 
 
Web resources 
Centro Nacional de Genotipado (CEGEN-ISCIII): www.cegen.org. 
Genome Aggregation Consortium database: http://gnomad.broadinstitute.org. 
Multalin software: http://multalin.toulouse.inra.fr. 
National Center for Biotechnology Information GEO database: https://www.ncbi.nlm.nih.gov/geo/. 
Online Mendelian Inheritance in Man: http://www.omim.org. 
Phyre2 server: http://www.sbg.bio.ic.ac.uk/phyre2. 
RNAi Consortium from the Broad Institute: http://portals.broadinstitute.org/gpp/public/resources/protocols. 
Universal ProbeLibrary set: https://www.roche-applied-science.com.  
 
  
 
 
References 
1. Toledo, R. a., Burnichon, N., Cascon, A., Benn, D.E., Bayley, J.-P., Welander, J., Tops, C.M., Firth, H., Dwight, 
T., Ercolino, T., et al. (2017). Consensus Statement on next-generation-sequencing-based diagnostic testing of 
hereditary phaeochromocytomas and paragangliomas. Nat. Rev. Endocrinol. 13, 233–247. 
2. Buffet, A., Morin, A., Castro-Vega, L.-J., Habarou, F., Lussey-Lepoutre, C., Letouzé, E., Lefebvre, H., Guilhem, 
I., Magalie, H., Raingeard, I., et al. (2018). Germline mutations in the mitochondrial 2-oxoglutarate/malate 
carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res. 78, 1914–1922. 
3. Dahia, P.L.M. (2014). Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic 
heterogeneity. Nat. Rev. Cancer 14, 108–119. 
4. Turcan, S., Rohle, D., Goenka, A., Walsh, L. a., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W.M., Lu, C., Ward, 
P.S., et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 
479–483. 
5. The Cancer Genome Atlas Research Network (2016). Comprehensive Molecular Characterization of Papillary 
Renal-Cell Carcinoma. N. Engl. J. Med. 374, 135–145. 
6. Ricketts, C., Killian, J.K., Vocke, C.D., Sourbier, C., Yang, Y., Merino, M.J., Meltzer, P.S., and Linehan., W.M. 
(2016). Abstract 2660: A renal CpG island methylator phenotype (R-CIMP) in kidney tumors associated with 
germline mutations of FH and SDHB. Cancer Res. 76,. 
7. Remacha, L., Comino-Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, 
A., Torres-Pérez, R., Honrado, E., et al. (2017). Targeted Exome Sequencing of Krebs Cycle Genes Reveals 
Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clin. Cancer Res. 23, 
6315–6324. 
8. Björklund, P., Pacak, K., and Crona, J. (2016). Precision medicine in pheochromocytoma and paraganglioma: 
current and future concepts. J. Intern. Med. 280, 559–573. 
9. Lussey-Lepoutre, C., Buffet, A., Gimenez-Roqueplo, A.P., and Favier, J. (2017). Mitochondrial deficiencies in 
the predisposition to paraganglioma. Metabolites 7, 1–13. 
10. Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., 
Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007). Succinate dehydrogenase B gene mutations predict 
survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 
3822–3828. 
11. van Nederveen, F.H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. a., de Bruyn, E.M., Sleddens, H.F., 
Derkx, P., Rivière, J., Dannenberg, H., et al. (2009). An immunohistochemical procedure to detect patients with 
paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective 
and prospective analysis. Lancet Oncol. 10, 764–771. 
12. Bendl, J., Stourac, J., Salanda, O., Pavelka, A., Wieben, E.D., Zendulka, J., Brezovsky, J., and Damborsky, J. 
(2014). PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations. 
PLoS Comput. Biol. 10, 1–11. 
13. Kelley, L. a, Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J.E. (2015). Europe PMC Funders Group 
The Phyre2 web portal for protein modelling , prediction and analysis. Nat. Protoc. 10, 845–858. 
14. Zhou, Z.H., McCarthy, D.B., O’Connor, C.M., Reed, L.J., and Stoops, J.K. (2001). The remarkable structural 
and functional organization of the eukaryotic pyruvate dehydrogenase complexes. Pnas 98, 14802–14807. 
15. Ramachandran, S., Kota, P., Ding, F., and Dokholyan, N. V. (2011). Automated minimization of steric clashes 
in protein structures. Proteins Struct. Funct. Bioinforma. 79, 261–270. 
16. The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
17. Simon-Sanchez, J., Scholz, S., Fung, H.C., Matarin, M., Hernandez, D., Gibbs, J.R., Britton, A., de Vrieze, 
 
 
References 
1. Toledo, R. a., Burnichon, N., Cascon, A., Benn, D.E., Bayley, J.-P., Welander, J., Tops, C.M., Firth, H., Dwight, 
T., Ercolino, T., et al. (2017). Consensus Statement on next-generation-sequencing-based diagnostic testing of 
hereditary phaeochromocytomas and paragangliomas. Nat. Rev. Endocrinol. 13, 233–247. 
2. Buffet, A., Morin, A., Castro-Vega, L.-J., Habarou, F., Lussey-Lepoutre, C., Letouzé, E., Lefebvre, H., Guilhem, 
I., Magalie, H., Raingeard, I., et al. (2018). Germline mutations in the mitochondrial 2-oxoglutarate/malate 
carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res. 78, 1914–1922. 
3. Dahia, P.L.M. (2014). Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic 
heterogeneity. Nat. Rev. Cancer 14, 108–119. 
4. Turcan, S., Rohle, D., Goenka, A., Walsh, L. a., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W.M., Lu, C., Ward, 
P.S., et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 
479–483. 
5. The Cancer Genome Atlas Research Network (2016). Comprehensive Molecular Characterization of Papillary 
Renal-Cell Carcinoma. N. Engl. J. Med. 374, 135–145. 
6. Ricketts, C., Killian, J.K., Vocke, C.D., Sourbier, C., Yang, Y., Merino, M.J., Meltzer, P.S., and Linehan., W.M. 
(2016). Abstract 2660: A renal CpG island methylator phenotype (R-CIMP) in kidney tumors associated with 
germline mutations of FH and SDHB. Cancer Res. 76,. 
7. Remacha, L., Comino-Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, 
A., Torres-Pérez, R., Honrado, E., et al. (2017). Targeted Exome Sequencing of Krebs Cycle Genes Reveals 
Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clin. Cancer Res. 23, 
6315–6324. 
8. Björklund, P., Pacak, K., and Crona, J. (2016). Precision medicine in pheochromocytoma and paraganglioma: 
current and future concepts. J. Intern. Med. 280, 559–573. 
9. Lussey-Lepoutre, C., Buffet, A., Gimenez-Roqueplo, A.P., and Favier, J. (2017). Mitochondrial deficiencies in 
the predisposition to paraganglioma. Metabolites 7, 1–13. 
10. Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., 
Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007). Succinate dehydrogenase B gene mutations predict 
survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 
3822–3828. 
11. van Nederveen, F.H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. a., de Bruyn, E.M., Sleddens, H.F., 
Derkx, P., Rivière, J., Dannenberg, H., et al. (2009). An immunohistochemical procedure to detect patients with 
paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective 
and prospective analysis. Lancet Oncol. 10, 764–771. 
12. Bendl, J., Stourac, J., Salanda, O., Pavelka, A., Wieben, E.D., Zendulka, J., Brezovsky, J., and Damborsky, J. 
(2014). PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations. 
PLoS Comput. Biol. 10, 1–11. 
13. Kelley, L. a, Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J.E. (2015). Europe PMC Funders Group 
The Phyre2 web portal for protein modelling , prediction and analysis. Nat. Protoc. 10, 845–858. 
14. Zhou, Z.H., McCarthy, D.B., O’Connor, C.M., Reed, L.J., and Stoops, J.K. (2001). The remarkable structural 
and functional organization of the eukaryotic pyruvate dehydrogenase complexes. Pnas 98, 14802–14807. 
15. Ramachandran, S., Kota, P., Ding, F., and Dokholyan, N. V. (2011). Automated minimization of steric clashes 
in protein structures. Proteins Struct. Funct. Bioinforma. 79, 261–270. 
16. The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
17. Simon-Sanchez, J., Scholz, S., Fung, H.C., Matarin, M., Hernandez, D., Gibbs, J.R., Britton, A., de Vrieze, 
 
 
F.W., Peckham, E., Gwinn-Hardy, K., et al. (2007). Genome-wide SNP assay reveals structural genomic 
variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum. Mol. Genet. 
16, 1–14. 
18. Comino-Méndez, I., Gracia-aznárez, F.J., Schiavi, F., Landa, I., Leandro-garcía, L.J., Letón, R., Honrado, E., 
Ramos-medina, R., Caronia, D., Pita, G., et al. (2011). Exome sequencing identifies MAX mutations as a cause 
of hereditary pheochromocytoma. Nat. Genet. 43, 663–667. 
19. Allen, E.L., Ulanet, D.B., Pirman, D., Mahoney, C.E., Coco, J., Si, Y., Chen, Y., Huang, L., Ren, J., Choe, S., et 
al. (2016). Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. 
Cell Rep. 17, 876–890. 
20. Cascón, A., Comino-Méndez, I., Currás-Freixes, M., De Cubas, A. a., Contreras, L., Richter, S., Peitzsch, M., 
Mancikova, V., Inglada-Pérez, L., Pérez-Barrios, A., et al. (2015). Whole-exome sequencing identifies MDH2 as 
a new familial paraganglioma gene. J. Natl. Cancer Inst. 107, 1–5. 
21. Bibikova, M., Le, J., Barnes, B., Saedinia-Melnyk, S., Zhou, L., Shen, R., and Gunderson, K.L. (2009). Genome-
wide DNA methylation profiling using Infinium® assay. Epigenomics 1, 177–200. 
22. De Cubas, A. a., Korpershoek, E., Inglada-Pérez, L., Letouzé, E., Currás-Freixes, M., Fernández, A.F., Comino-
Méndez, I., Schiavi, F., Mancikova, V., Eisenhofer, G., et al. (2015). DNA methylation profiling in 
pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers. Clin. Cancer Res. 21, 
3020–3030. 
23. Reich, M., Ohm, K., Angelo, M., Tamayo, P., and Mesirov, J.P. (2004). GeneCluster 2.0: An advanced toolset 
for bioarray analysis. Bioinformatics 20, 1797–1798. 
24. Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., 
Nguyen, A., Benit, P., et al. (2013). SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. 
Cancer Cell 23, 739–752. 
25. López-Jiménez, E., Gómez-López, G., Leandro-García, L.J., Muñoz, I., Schiavi, F., Montero-Conde, C., de 
Cubas, A. a., Ramires, R., Landa, I., Leskelä, S., et al. (2010). Research Resource: Transcriptional Profiling 
Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Mol. Endocrinol. 
24, 2382–2391. 
26. Burnichon, N., Vescovo, L., Amar, L., Libé, R., de Reynies, A., Venisse, A., Jouanno, E., Laurendeau, I., Parfait, 
B., Bertherat, J., et al. (2011). Integrative genomic analysis reveals somatic mutations in pheochromocytoma 
and paraganglioma. Hum. Mol. Genet. 20, 3974–3985. 
27. Morrissey, E.R., and Diaz-Uriarte, R. (2009). Pomelo II: Finding differentially expressed genes. Nucleic Acids 
Res. 37,. 
28. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., and Golani, I. (2001). Controlling the false discovery rate in 
behavior genetics research. Behav. Brain Res. 125, 279–284. 
29. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time 
quantitative PCR and. Methods 25, 402–408. 
30. Knapp, J.E., Mitchell, D.T., Yazdi, M. a, Ernst, S.R., Reed, L.J., and Hackert, M.L. (1998). Crystal structure of 
the truncated cubic core component of the Escherichia coli 2-oxoglutarate dehydrogenase multienzyme 
complex. J. Mol. Biol. 280, 655–668. 
31. Ruderfer, D.M., Hamamsy, T., Lek, M., Karczewski, K.J., Kavanagh, D., Samocha, K.E., Daly, M.J., Macarthur, 
D.G., Fromer, M., and Purcell, S.M. (2016). Patterns of genic intolerance of rare copy number variation in 
59,898 human exomes. Nat. Genet. 48, 1107–1111. 
32. Wang, J., Nemeria, N.S., Chandrasekhar, K., Kumaran, S., Arjunan, P., Reynolds, S., Calero, G., Brukh, R., 
Kakalis, L., Furey, W., et al. (2014). Structure and function of the catalytic domain of the dihydrolipoyl 
acetyltransferase component in Escherichia coli pyruvate dehydrogenase complex. J. Biol. Chem. 289, 15215–
15230. 
 
 
33. Richter, S., Gieldon, L., Pang, Y., Peitzsch, M., Huynh, T., Leton, R., Viana, B., Ercolino, T., Mangelis, A., 
Rapizzi, E., et al. (2018). Metabolome-guided genomics to identify pathogenic variants in isocitrate 
dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and 
paraganglioma. Genet. Med. 0,. 
34. Burr, S.P., Costa, A.S.H., Grice, G.L., Timms, R.T., Lobb, I.T., Freisinger, P., Dodd, R.B., Dougan, G., Lehner, 
P.J., Frezza, C., et al. (2016). Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase 
Complex Controls HIF1α Stability in Aerobic Conditions. Cell Metab. 24, 740–752. 
35. Yang, L., Shi, Q., Ho, D.J., Starkov, A. a., Wille, E.J., Xu, H., Chen, H.L., Zhang, S., Stack, C.M., Calingasan, 
N.Y., et al. (2009). Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to 
mitochondrial toxins. Neurobiol. Dis. 36, 320–330. 
36. Suzuki, J., Yamada, T., Inoue, K., Nabe, S., Kuwahara, M., Takemori, N., Takemori, A., Matsuda, S., Kanoh, 
M., Imai, Y., et al. (2018). The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting 
mTORC1-dependent metabolic activation. Nat. Commun. 9,. 
37. Vatrinet, R., Leone, G., De Luise, M., Girolimetti, G., Vidone, M., Gasparre, G., and Porcelli, A.M. (2017). 
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer Metab. 5, 3. 
38. Yoon, W.H., Sandoval, H., Nagarkar-Jaiswal, S., Jaiswal, M., Yamamoto, S., Haelterman, N.A., Putluri, N., 
Putluri, V., Sreekumar, A., Tos, T., et al. (2017). Loss of Nardilysin, a Mitochondrial Co-chaperone for α-
Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration. Neuron 93, 115–131. 
39. Wang, Y., Guo, Y.R., Liu, K., Yin, Z., Liu, R., Xia, Y., Tan, L., Yang, P., Lee, J.H., Li, X.J., et al. (2017). KAT2A 
coupled with the α-KGDH complex acts as a histone H3 succinyltransferase. Nature 552, 273–277. 
40. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M. a., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, 
S., Keenan, M.C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 
739–744. 
41. Oldham, W.M., Clish, C.B., Yang, Y., and Loscalzo, J. (2015). Hypoxia-Mediated Increases in l-2-
hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab. 22, 291–303. 
42. Intlekofer, A.M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A.S., Salah, S., Gunner, 
M.R., Chodera, J.D., Cross, J.R., et al. (2017). L-2-Hydroxyglutarate production arises from noncanonical 
enzyme function at acidic pH. Nat. Chem. Biol. 13, 494–500. 
43. Kanamori, T., Nishimaki, K., Asoh, S., Ishibashi, Y., Takata, I., Kuwabara, T., Taira, K., Yamaguchi, H., 
Sugihara, S., Yamazaki, T., et al. (2003). Truncated product of the bifunctional DLST gene involved in biogenesis 
of the respiratory chain. EMBO J. 22, 2913–2923. 
44. Schiavi, F., Milne, R.L., Anda, E., Blay, P., Castellano, M., Opocher, G., Robledo, M., and Casc??n, A. (2010). 
Are we overestimating the penetrance of mutations in SDHB? Hum. Mutat. 31, 761–762. 
45. Dénes, J., Swords, F., Rattenberry, E., Stals, K., Owens, M., Cranston, T., Xekouki, P., Moran, L., Kumar, A., 
Wassif, C., et al. (2015). Heterogeneous genetic background of the association of 
pheochromocytoma/paraganglioma and pituitary adenoma: Results from a large patient cohort. J. Clin. 
Endocrinol. Metab. 100, E531–E541. 
46. Odièvre, M.-H., Chretien, D., Munnich, A., Robinson, B.H., Dumoulin, R., Masmoudi, S., Kadhom, N., Rötig, 
A., Rustin, P., and Bonnefont, J.-P. (2005). A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit 
gene (DLD) resulting in an atypical form of α-ketoglutarate dehydrogenase deficiency. Hum. Mutat. 25, 323–
324. 
47. Danhauser, K., Sauer, S.W., Haack, T.B., Wieland, T., Staufner, C., Graf, E., Zschocke, J., Strom, T.M., Traub, 
T., Okun, J.G., et al. (2012). DHTKD1 mutations cause 2-aminoadipic and 2-oxoadipic aciduria. Am. J. Hum. 
Genet. 91, 1082–1087. 
48. Gibson, G.E., Hirsch, J. a., Cirio, R.T., Jordan, B.D., Fonzetti, P., and Elder, J. (2013). Abnormal thiamine-
dependent processes in Alzheimer’s Disease. Lessons from diabetes. Mol. Cell. Neurosci. 55, 17–25. 
 
 
33. Richter, S., Gieldon, L., Pang, Y., Peitzsch, M., Huynh, T., Leton, R., Viana, B., Ercolino, T., Mangelis, A., 
Rapizzi, E., et al. (2018). Metabolome-guided genomics to identify pathogenic variants in isocitrate 
dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and 
paraganglioma. Genet. Med. 0,. 
34. Burr, S.P., Costa, A.S.H., Grice, G.L., Timms, R.T., Lobb, I.T., Freisinger, P., Dodd, R.B., Dougan, G., Lehner, 
P.J., Frezza, C., et al. (2016). Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase 
Complex Controls HIF1α Stability in Aerobic Conditions. Cell Metab. 24, 740–752. 
35. Yang, L., Shi, Q., Ho, D.J., Starkov, A. a., Wille, E.J., Xu, H., Chen, H.L., Zhang, S., Stack, C.M., Calingasan, 
N.Y., et al. (2009). Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to 
mitochondrial toxins. Neurobiol. Dis. 36, 320–330. 
36. Suzuki, J., Yamada, T., Inoue, K., Nabe, S., Kuwahara, M., Takemori, N., Takemori, A., Matsuda, S., Kanoh, 
M., Imai, Y., et al. (2018). The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting 
mTORC1-dependent metabolic activation. Nat. Commun. 9,. 
37. Vatrinet, R., Leone, G., De Luise, M., Girolimetti, G., Vidone, M., Gasparre, G., and Porcelli, A.M. (2017). 
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer Metab. 5, 3. 
38. Yoon, W.H., Sandoval, H., Nagarkar-Jaiswal, S., Jaiswal, M., Yamamoto, S., Haelterman, N.A., Putluri, N., 
Putluri, V., Sreekumar, A., Tos, T., et al. (2017). Loss of Nardilysin, a Mitochondrial Co-chaperone for α-
Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration. Neuron 93, 115–131. 
39. Wang, Y., Guo, Y.R., Liu, K., Yin, Z., Liu, R., Xia, Y., Tan, L., Yang, P., Lee, J.H., Li, X.J., et al. (2017). KAT2A 
coupled with the α-KGDH complex acts as a histone H3 succinyltransferase. Nature 552, 273–277. 
40. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M. a., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, 
S., Keenan, M.C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 
739–744. 
41. Oldham, W.M., Clish, C.B., Yang, Y., and Loscalzo, J. (2015). Hypoxia-Mediated Increases in l-2-
hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab. 22, 291–303. 
42. Intlekofer, A.M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A.S., Salah, S., Gunner, 
M.R., Chodera, J.D., Cross, J.R., et al. (2017). L-2-Hydroxyglutarate production arises from noncanonical 
enzyme function at acidic pH. Nat. Chem. Biol. 13, 494–500. 
43. Kanamori, T., Nishimaki, K., Asoh, S., Ishibashi, Y., Takata, I., Kuwabara, T., Taira, K., Yamaguchi, H., 
Sugihara, S., Yamazaki, T., et al. (2003). Truncated product of the bifunctional DLST gene involved in biogenesis 
of the respiratory chain. EMBO J. 22, 2913–2923. 
44. Schiavi, F., Milne, R.L., Anda, E., Blay, P., Castellano, M., Opocher, G., Robledo, M., and Casc??n, A. (2010). 
Are we overestimating the penetrance of mutations in SDHB? Hum. Mutat. 31, 761–762. 
45. Dénes, J., Swords, F., Rattenberry, E., Stals, K., Owens, M., Cranston, T., Xekouki, P., Moran, L., Kumar, A., 
Wassif, C., et al. (2015). Heterogeneous genetic background of the association of 
pheochromocytoma/paraganglioma and pituitary adenoma: Results from a large patient cohort. J. Clin. 
Endocrinol. Metab. 100, E531–E541. 
46. Odièvre, M.-H., Chretien, D., Munnich, A., Robinson, B.H., Dumoulin, R., Masmoudi, S., Kadhom, N., Rötig, 
A., Rustin, P., and Bonnefont, J.-P. (2005). A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit 
gene (DLD) resulting in an atypical form of α-ketoglutarate dehydrogenase deficiency. Hum. Mutat. 25, 323–
324. 
47. Danhauser, K., Sauer, S.W., Haack, T.B., Wieland, T., Staufner, C., Graf, E., Zschocke, J., Strom, T.M., Traub, 
T., Okun, J.G., et al. (2012). DHTKD1 mutations cause 2-aminoadipic and 2-oxoadipic aciduria. Am. J. Hum. 
Genet. 91, 1082–1087. 
48. Gibson, G.E., Hirsch, J. a., Cirio, R.T., Jordan, B.D., Fonzetti, P., and Elder, J. (2013). Abnormal thiamine-
dependent processes in Alzheimer’s Disease. Lessons from diabetes. Mol. Cell. Neurosci. 55, 17–25. 
 
 
49. Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich,  a., Rötig,  a., 
Landrieu, P., and Rustin, P. (1994). Mutation of the fumarase gene in two siblings with progressive 
encephalopathy and fumarase deficiency. J. Clin. Invest. 93, 2514–2518. 
50. Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich,  a, 
and Rötig,  a (1995). Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory 
chain deficiency. Nat. Genet. 11, 144–149. 
51. Fattal-Valevski, A., Eliyahu, H., Fraenkel, N.I.D., Elmaliach, G., Hausman-Kedem, M., Shaag, A., Mandel, D., 
Pines, O., and Elpeleg, O. (2017). Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate 
dehydrogenase subunit is associated with severe encephalopathy in infancy. Neurogenetics 18, 57–61. 
52. Spiegel, R., Pines, O., Ta-Shma, A., Burak, E., Shaag, A., Halvardson, J., Edvardson, S., Mahajna, M., Zenvirt, 
S., Saada, A., et al. (2012). Infantile cerebellar-retinal degeneration associated with a mutation in 
mitochondrial aconitase, ACO2. Am. J. Hum. Genet. 90, 518–523. 
53. Punzi, G., Porcelli, V., Ruggiu, M., Hossain, M.F., Menga, A., Scarcia, P., Castegna, A., Gorgoglione, R., Pierri, 
C.L., Laera, L., et al. (2017). SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex 
I deficiency. Hum. Mol. Genet. 
54. Flynn, A., Benn, D., Clifton-Bligh, R., Robinson, B., Trainer, A.H., James, P., Hogg, A., Waldeck, K., George, 
J., Li, J., et al. (2015). The genomic landscape of phaeochromocytoma. J. Pathol. 236, 78–89. 
55. Fishbein, L., Leshchiner, I., Walter, V., Danilova, L., Robertson, A.G., Johnson, A.R., Lichtenberg, T.M., 
Murray, B.A., Ghayee, H.K., Else, T., et al. (2017). Comprehensive Molecular Characterization of 
Pheochromocytoma and Paraganglioma. Cancer Cell 31, 181–193. 
56. Raimundo, N., Baysal, B.E., and Shadel, G.S. (2011). Revisiting the TCA cycle: Signaling to tumor formation. 
Trends Mol. Med. 17, 641–649. 
57. Zhou, X., Guo, X., Chen, M., Xie, C., and Jiang, J. (2018). HIF-3α Promotes Metastatic Phenotypes in 
Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling Pathway. Mol. Cancer Res. 16, 
124–134. 
58. Menara, M., Oudijk, L., Badoual, C., Bertherat, J., Lepoutre-Lussey, C., Amar, L., Iturrioz, X., Sibony, M., 
Zinzindohoué, F., De Krijger, R., et al. (2015). SDHD immunohistochemistry: A new tool to validate SDHx 
mutations in pheochromocytoma/paraganglioma. J. Clin. Endocrinol. Metab. 100, E287–E291. 
 
 
 
  
Ta
bl
e 
1.
 C
lin
ica
l d
at
a 
of
 th
e 
in
di
vi
du
al
s w
ith
 D
LS
T 
m
ut
at
io
ns
 
  Bg
: b
en
ig
n;
 F:
 fe
m
al
e;
 H
&
N:
 h
ea
d 
an
d 
ne
ck
 P
GL
; I
HC
: i
m
m
un
oh
ist
oc
he
m
ist
ry
; L
OH
: l
os
s o
f h
et
er
oz
yg
os
ity
; M
: m
al
e;
 M
g:
 m
al
ig
na
nt
, M
TC
: m
ed
ul
la
ry
 
th
yr
oi
d 
ca
rc
in
om
a;
 N
A:
 n
ot
 a
va
ila
bl
e;
 N
M
: n
or
m
et
an
ep
hr
in
e;
 N
S:
 n
on
-s
ec
re
to
ry
; P
CC
: p
he
oc
hr
om
oc
yt
om
a;
 P
RL
: p
ro
la
ct
in
om
a;
 T
AP
: t
ho
ra
cic
-
ab
do
m
in
al
-p
el
vi
c 
PG
L;
 U
PD
: 
un
ip
ar
en
ta
l d
iso
m
y;
 +
 =
 w
ea
k 
im
m
un
os
ta
in
in
g;
 +
++
 =
 s
tr
on
g 
im
m
un
os
ta
in
in
g.
 a
: 
in
di
vi
du
al
 s
tu
di
ed
 b
y 
ex
om
e 
se
qu
en
cin
g.
 D
LS
T 
cD
NA
 m
ut
at
io
ns
 a
re
 n
um
be
re
d 
ac
co
rd
in
g 
to
 h
um
an
 cD
NA
 re
fe
re
nc
e 
se
qu
en
ce
 N
M
_0
01
93
3.
 
ID
 
Tu
m
or
s 
an
al
yz
ed
 
Ge
nd
er
 
Ag
e 
(y
r.)
 
Tu
m
or
s 
Ot
he
r 
tu
m
or
s 
Bi
oc
he
m
ica
l 
Ph
en
ot
yp
e 
Be
ha
vi
or
 
cD
NA
 
va
ria
nt
 
Pr
ot
ei
n 
ch
an
ge
 
Pr
ed
ict
SN
P 
LO
H 
DL
ST
 
IH
C 
#1
 
#1
 
M
 
45
 
PC
C 
- 
NM
 
M
g 
c.
69
2G
>A
 
p.
Ar
g2
31
Gl
n 
De
le
te
rio
us
 
No
 
+ 
#2
 
- 
F 
63
 
H&
N 
(n
=2
) 
- 
NS
 
Bg
 
c.
91
0G
>A
 
p.
As
p3
04
As
n 
Ne
ut
ra
l 
NA
 
NA
 
#3
 
#3
a,
b,
c 
F 
27
 
TA
P 
(n
=7
) 
Ut
er
in
e 
en
do
m
et
rio
id
 
ca
rc
in
om
a 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
++
+ 
#4
 
#4
 
M
 
38
 
TA
P 
(n
=3
) 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
++
+ 
#5
 
#5
a,
b 
F 
24
 
TA
P,
 P
CC
 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
NA
 
#6
a  
- 
M
 
29
 
TA
P 
(n
=4
) 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
NA
 
NA
 
#7
 
- 
M
 
29
 
TA
P 
(n
=3
) 
- 
NM
 
Bg
 
c.
12
65
A>
G 
p.
Ty
r4
22
Cy
s 
De
le
te
rio
us
 
NA
 
NA
 
#8
 
#8
 
M
 
54
 
PC
C 
(n
=2
) 
Pi
tu
ita
ry
 
ad
en
om
a 
(P
RL
) 
NM
 
Bg
 
c.
10
60
-3
T>
A 
- 
- 
No
 
++
+ 
 
  
Ta
bl
e 
1.
 C
lin
ica
l d
at
a 
of
 th
e 
in
di
vi
du
al
s w
ith
 D
LS
T 
m
ut
at
io
ns
 
  Bg
: b
en
ig
n;
 F:
 fe
m
al
e;
 H
&
N:
 h
ea
d 
an
d 
ne
ck
 P
GL
; I
HC
: i
m
m
un
oh
ist
oc
he
m
ist
ry
; L
OH
: l
os
s o
f h
et
er
oz
yg
os
ity
; M
: m
al
e;
 M
g:
 m
al
ig
na
nt
, M
TC
: m
ed
ul
la
ry
 
th
yr
oi
d 
ca
rc
in
om
a;
 N
A:
 n
ot
 a
va
ila
bl
e;
 N
M
: n
or
m
et
an
ep
hr
in
e;
 N
S:
 n
on
-s
ec
re
to
ry
; P
CC
: p
he
oc
hr
om
oc
yt
om
a;
 P
RL
: p
ro
la
ct
in
om
a;
 T
AP
: t
ho
ra
cic
-
ab
do
m
in
al
-p
el
vi
c 
PG
L;
 U
PD
: 
un
ip
ar
en
ta
l d
iso
m
y;
 +
 =
 w
ea
k 
im
m
un
os
ta
in
in
g;
 +
++
 =
 s
tr
on
g 
im
m
un
os
ta
in
in
g.
 a
: 
in
di
vi
du
al
 s
tu
di
ed
 b
y 
ex
om
e 
se
qu
en
cin
g.
 D
LS
T 
cD
NA
 m
ut
at
io
ns
 a
re
 n
um
be
re
d 
ac
co
rd
in
g 
to
 h
um
an
 cD
NA
 re
fe
re
nc
e 
se
qu
en
ce
 N
M
_0
01
93
3.
 
ID
 
Tu
m
or
s 
an
al
yz
ed
 
Ge
nd
er
 
Ag
e 
(y
r.)
 
Tu
m
or
s 
Ot
he
r 
tu
m
or
s 
Bi
oc
he
m
ica
l 
Ph
en
ot
yp
e 
Be
ha
vi
or
 
cD
NA
 
va
ria
nt
 
Pr
ot
ei
n 
ch
an
ge
 
Pr
ed
ict
SN
P 
LO
H 
DL
ST
 
IH
C 
#1
 
#1
 
M
 
45
 
PC
C 
- 
NM
 
M
g 
c.
69
2G
>A
 
p.
Ar
g2
31
Gl
n 
De
le
te
rio
us
 
No
 
+ 
#2
 
- 
F 
63
 
H&
N 
(n
=2
) 
- 
NS
 
Bg
 
c.
91
0G
>A
 
p.
As
p3
04
As
n 
Ne
ut
ra
l 
NA
 
NA
 
#3
 
#3
a,
b,
c 
F 
27
 
TA
P 
(n
=7
) 
Ut
er
in
e 
en
do
m
et
rio
id
 
ca
rc
in
om
a 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
++
+ 
#4
 
#4
 
M
 
38
 
TA
P 
(n
=3
) 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
++
+ 
#5
 
#5
a,
b 
F 
24
 
TA
P,
 P
CC
 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
Ye
s (
UP
D)
 
NA
 
#6
a  
- 
M
 
29
 
TA
P 
(n
=4
) 
- 
NM
 
Bg
 
c.
11
21
G>
A 
p.
Gl
y3
74
Gl
u 
De
le
te
rio
us
 
NA
 
NA
 
#7
 
- 
M
 
29
 
TA
P 
(n
=3
) 
- 
NM
 
Bg
 
c.
12
65
A>
G 
p.
Ty
r4
22
Cy
s 
De
le
te
rio
us
 
NA
 
NA
 
#8
 
#8
 
M
 
54
 
PC
C 
(n
=2
) 
Pi
tu
ita
ry
 
ad
en
om
a 
(P
RL
) 
NM
 
Bg
 
c.
10
60
-3
T>
A 
- 
- 
No
 
++
+ 
E. coli
S. cerevisiae
C. elegans
Fruitfly
Zebra fish 
Tetraodon
Mouse
Rat
Human
Chimpanzee
Pig
Dog
Xenopus
Tilapia
Consensus
Tyr422Gly374Asp304Arg231
…
…
…
…
…
…
…
…
…
…
...
…
…
…
…
…
…
…
…
…
…
…
…
…
...
…
…
…
…
…
…
…
…
…
…
…
…
…
...
…
…
…
… … …• •• • • •
B
p.Gly374Glu
p.Arg231Gln
p.Asp304Asn
p.Tyr422Cys
Ser372
His424Arg430
Asp428
228
453
C
A
c.1060-3T>A
In
di
vi
du
al
s
0
4
Catalytic domain
Biotin/Lipoyl
attachment domain
E1    E2     E3    E4    E5    E6    E7    E8    E9  E10    E11    E12    E13    E14    E15
FIGURES
DLST
2
1
0
2
1
0
2
1
0
Tumor #5a
Tumor #3c
Tumor #4N
um
be
r o
f a
lle
le
s
MEG3
Chr 14
Paternal allele
Maternal allele
:c.1121G>A (p.Gly374Glu)
:methylation of MEG3
2
1
0
Control tumor

A0,0
0,1
1,0
10,0
100,0
p.Gly374Glu-
DLST 
PPGLs
WT-
DLST 
PPGLs
ke
to
gl
ut
ar
at
e/
fu
m
ar
at
e
***
0,1
1,0
10,0
100,0
hy
dr
ox
yg
lu
ta
ra
te
/fu
m
ar
at
e
p.Gly374Glu-
DLST 
PPGLs
WT-
DLST 
PPGLs
IDH1
B *
C
-3.0                3.0
Transcriptional cluster
Mutation
Cluster 1
Cluster 2
Unknown
p.Gly374Glu-DLST
VHL
EPAS1
SDHx
RET
TMEM127
HRAS
MAX
NF1
0
50
100
150
200
250
300
350
400
HI
F3
A
m
RN
A
ex
pr
es
sio
n
(R
U)
p.Gly374Glu-DLST 
PPGLs
WT-DLST
PPGLs
**D
TMEM127
NF1
RET
c.1060-3T>A-DLST
SDHA
SDHB
SDHC
SDHD
p.Gly374Glu-DLST
p.Gly374Glu-DLST
p.Gly374Glu-DLST
EPAS1
A
B
0
1
2
3
Controls
(n=46)
TCA-
mutated
(n=33) 
EPAS1-
mutated
(n=9) 
***
***
D
LS
T 
IH
C
 s
co
re
A87% 72% 59% 74% 81% 79% 81%
neutral deleterious % expected accuracy
87% 91% 68% 74% 81% 79% 89%
Mutation PredictSNP MAPP PhD-SNP PolyPhen-1 PolyPhen-2 SIFT SNAP
p.Arg231Asn
p.Asp304Asn
p.Gly374Glu
p.Tyr422Cys
75% 78% 68% 67% 41% 90% 77%
72% 74% 61% 74% 81% 79% 89%
B
SUPPLEMENTAL DATA
AB
Methylation cluster
Mutation
M1 (CIMP)
M3 (hypomethylated)
M2 (intermediate)
Unknown
SDHB
DNMT3A
RET
p.Gly374Glu-DLST
HRAS
NF1
EPAS1
MAX
#3c #4 #5a
#3c #5a #4
Methylation cluster
Mutation
C
-3.0 3.0
#3a
#3b
c.1121G>G/A
(p.Gly374Glu)
c.1121G>A/A
#3c
Blood
#5b
c.1121G>G/A
(p.Gly374Glu)
c.1121G>A/A
#5a#5
#4
c.1121G>G/A
(p.Gly374Glu)
c.1121G>A/A
#4
#3
Tumor
Blood Tumor
Fatty acid 
biosynthesis
αKG
αKGαKG
αKG
Acetyl-
coA
Oxalo-
acetate
mTORC1inactive
Survival Cell growth and 
proliferation
nucleus
Overall gene 
expression 
alteration
αKG
Su Su
mTORC1active
OGDH
DLD DLST
FH
CS
ACO2
SDHA SDHB 
SDHC  SDHD
SUCLG1
SUCLA2/ 
SUCLG2
IDH3A 
IDH3B 
IDH3G
MDH2
IDH2
TCA 
cycle
mitochondrion cytosol
Citrate
1
2
3
4
Succinyl-
coA
Oxalo-
acetate
OGDH
DLD
KAT2A
Succinyl
-coA
DLST
PGL para-aortic (27y) + PGL renal and PGL pelvic (35y)
+ PGL pre-sacrum (41y) + PGL Zuckerkandl (49y) + PGL
para-aortic and PGL iliac (53y, operated with 66y) +
uterine endometrioid carcinoma (66y) - p.Gly374Glu
99y
67y
#3
#3
81y
45y48y 39y
PGL para-adrenal (38y) + PGL para-aortic (62y) + PGL para-
vertebral (69y) - p.Gly374Glu
78y 76y
#4
#4
PGL para-adrenal + PGL retroperitoneal (24y) + PGL
para-adrenal vs recidivation (29y) - p.Gly374Glu
72y
46y 42y30y 41y
70y
#5
#5 PGL pre-sacrum + two PGLs para-aortic +
PGL renal (29y) - p.Gly374Glu
48y
#6
#6
Table S1. Clinical data of the PPGL patients included in the study
Number 
of cases 
Gender 
Median age 
at onset 
(range) 
Patients with single 
(S) or multiple (M) 
tumors 
Location of 
tumors 
Catecholamine 
phenotype 
Metastatic 
cases 
104 
m: 43 
f: 59 
U: 2 
49y 
(8-82) 
S: 77 
M: 27 
PCC: 57 
TAP: 22 
H&N: 14 
Misc: 9 
U: 2 
NORA: 34 
ADR: 17 
NF: 14 
DOPA: 8 
11 
m: male; f: female; U: unknown; PCC: pheochromocytoma; TAP: thoracic-abdominal-pelvic 
paraganglioma; H&N: head and neck paraganglioma; Misc: miscellaneous; NORA: noradrenergic; 
ADR: adrenergic; NF= non functional, DOPA: dopaminergic 
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Table S4. Genes differentially expressed in p.Gly374Glu DLST tumors and PPGLs carrying other mutations
Gene Name unadj.p FDR_indep Obs_stat
1 A_23_P338534_HIF3A < 0.0000001 < 0.0000001 11,895879
2 A_23_P374339_HIF3A < 0.0000001 < 0.0000001 11,361279
3 A_23_P423853_ERBB4 < 0.0000001 < 0.0000001 9,223138
4 A_24_P188037_HIF3A < 0.0000001 < 0.0000001 10,153642
5 A_23_P142187_HIF3A < 0.0000001 < 0.0000001 9,056168
6 A_24_P252895_TSPAN32 < 0.0000001 1,00E-06 7,73081
7 A_24_P229638_ENST00000373295 < 0.0000001 1,00E-06 7,67991
8 A_32_P125542_THC2384778 < 0.0000001 1,10E-06 7,628959
9 A_24_P308096_JAK3 < 0.0000001 5,60E-06 7,178493
10 A_23_P152082_SPTBN5 < 0.0000001 1,81E-05 6,854214
11 A_23_P98671_C11orf21 < 0.0000001 3,91E-05 6,632856
12 A_23_P255298_GUP1 < 0.0000001 4,51E-05 6,560255
13 A_23_P56855_ENST00000343518 < 0.0000001 4,51E-05 -6,553498
14 A_23_P119337_ATF5 < 0.0000001 5,36E-05 6,49
15 A_32_P163306_KIAA1822 < 0.0000001 0,0001973 6,136795
16 A_23_P5301_TFCP2L1 < 0.0000001 0,0002109 6,102869
17 A_32_P126222_AW302758 1,00E-07 0,0003477 5,957344
18 A_23_P56883_GABRA4 2,00E-07 0,000349 5,94149
19 A_32_P234414_THC2441719 3,00E-07 0,0005559 5,805845
20 A_23_P42322_COL11A2 3,00E-07 0,0006285 5,760247
21 A_23_P363174_HIST1H2AL 4,00E-07 0,0008435 -5,670126
22 A_24_P217834_HIST1H3D 5,00E-07 0,0008452 -5,657366
23 A_24_P305050_CD300LG 8,00E-07 0,0013812 5,515835
24 A_24_P66780_FAM83B 9,00E-07 0,0014752 -5,487073
25 A_23_P250385_HIST1H1B 1,20E-06 0,0019022 -5,408592
26 A_32_P394951_LOC126147 1,30E-06 0,0019881 5,386356
27 A_23_P164057_MFAP4 1,50E-06 0,0020354 5,342249
28 A_24_P751492_C9orf128 1,50E-06 0,0020354 5,338875
29 A_23_P334857_ZNF533 1,40E-06 0,0020354 5,349056
30 A_24_P380311_CAMK2A 1,40E-06 0,0020354 5,364493
31 A_32_P86533_AF038185 1,50E-06 0,0020354 -5,333054
32 A_24_P217306_ZIC4 1,80E-06 0,0022184 5,285947
33 A_23_P145514_IL20RA 1,80E-06 0,0022184 -5,285214
34 A_23_P311818_GHRH 1,70E-06 0,0022184 5,299217
35 A_32_P919718_TMEM105 1,90E-06 0,002251 5,273515
36 A_24_P943301_ENST00000292357 2,10E-06 0,0023956 5,249219
37 A_23_P60627_ALOX15B 2,30E-06 0,0025415 5,225927
38 A_23_P501722_TSPAN32 2,90E-06 0,0030667 5,161023
39 A_24_P148026_AK024190 2,90E-06 0,0030667 5,163282
40 A_32_P170397_ENST00000309874 3,30E-06 0,0033812 5,127741
41 A_24_P934975_A_24_P934975 3,70E-06 0,0037187 5,095233
42 A_23_P168130_IHPK3 4,00E-06 0,0039241 5,074075
43 A_24_P758010_AJ318805 4,40E-06 0,0042372 5,046776
44 A_23_P126658_PRAMEF8 4,60E-06 0,004254 -5,039431
45 A_32_P129669_FRMPD3 5,20E-06 0,0046159 5,005025
46 A_23_P257263_ODZ1 5,10E-06 0,0046159 5,009052
47 A_24_P230948_PER3 6,20E-06 0,005374 4,957521
48 A_23_P75024_MSMB 6,80E-06 0,0057918 -4,931205
49 A_24_P942404_THC2412411 7,60E-06 0,0062365 4,899641
50 A_32_P14253_AW950828 7,50E-06 0,0062365 4,904229
51 A_24_P617427_AF339787 7,90E-06 0,0063173 4,89064
52 A_23_P394836_C14orf173 8,30E-06 0,0065346 4,87597
53 A_24_P920851_DKFZp667G2110 9,00E-06 0,0069743 4,852739
54 A_24_P174924_HIST1H3B 9,60E-06 0,0073094 -4,834599
55 A_24_P38572_NOL6 9,80E-06 0,0073368 4,828487
56 A_23_P161135_LEPR 1,11E-05 0,0081176 4,79547
57 A_24_P299469_GPR116 1,20E-05 0,0086071 4,773048
58 A_24_P76512_FLJ30064 1,22E-05 0,0086071 4,769459
59 A_24_P15834_TNXB 1,48E-05 0,0102808 4,715188
60 A_23_P333484_HIST1H3H 1,56E-05 0,0106304 -4,701148
61 A_23_P321935_OSBP2 1,76E-05 0,0114627 4,666383
62 A_23_P34376_TCEA3 1,75E-05 0,0114627 4,667707
63 A_24_P924920_ABHD2 1,72E-05 0,0114627 4,673638
64 A_24_P159548_HCP1 1,82E-05 0,0116609 4,657156
65 A_24_P372643_SLC22A18AS 1,92E-05 0,0121094 4,642206
66 A_24_P76313_FAM43B 1,96E-05 0,0121715 4,636477
67 A_23_P421483_CEACAM6 2,08E-05 0,0123123 -4,61913
68 A_24_P146683_MSMB 2,07E-05 0,0123123 -4,620543
69 A_24_P332314_FAM111B 2,04E-05 0,0123123 -4,624571
70 A_24_P3627_A_24_P3627 2,10E-05 0,0123123 4,616689
71 A_24_P258235_OR5L2 2,23E-05 0,012849 4,600669
72 A_23_P58407_UGT2B15 2,33E-05 0,0132591 -4,587858
73 A_24_P209389_MLXIPL 2,38E-05 0,0133918 4,581151
74 A_23_P215435_POM121 2,44E-05 0,0135422 4,574151
75 A_23_P1029_MFAP2 2,89E-05 0,0158164 4,526379
76 A_23_P30799_HIST1H3F 2,94E-05 0,015871 -4,521641
77 A_23_P79769_BIRC7 3,13E-05 0,0166818 4,503764
78 A_23_P309250_FLJ30719 3,35E-05 0,0175864 4,485057
79 A_24_P37253_MGC52057 3,52E-05 0,0181442 4,470179
80 A_24_P136905_AF116713 3,63E-05 0,0181442 -4,461909
81 A_24_P925490_AF086115 3,63E-05 0,0181442 -4,461885
82 A_32_P498899_KIAA1244 3,61E-05 0,0181442 4,463654
83 A_24_P154914_ZNF588 3,95E-05 0,0195169 -4,437569
84 A_32_P73151_AK124778 4,08E-05 0,0199111 4,428413
85 A_23_P151297_TENC1 4,41E-05 0,0212642 4,406164
86 A_23_P352226_MAPKBP1 4,48E-05 0,021323 4,401412
87 A_23_P51639_KIAA0467 4,52E-05 0,021323 4,398692
88 A_24_P8116_CCDC80 4,59E-05 0,0213987 4,39439
89 A_24_P172600_AK091555 4,71E-05 0,0216847 4,387322
90 A_23_P24555_PHLDB1 4,91E-05 0,0223809 4,375012
91 A_23_P71810_BAAT 5,28E-05 0,0237887 -4,354242
92 A_23_P129334_CLCN7 5,45E-05 0,024198 4,345077
93 A_23_P500010_KLK12 5,49E-05 0,024198 -4,343038
94 A_23_P166779_LOH3CR2A 5,89E-05 0,0256795 4,32276
95 A_23_P501754_CSF3 6,15E-05 0,0265373 4,310176
96 A_23_P331908_PRDM11 6,46E-05 0,0272858 4,296064
97 A_23_P368154_PODN 6,44E-05 0,0272858 4,296722
98 A_32_P59792_THC2444579 6,53E-05 0,0273035 4,292898
99 A_23_P416821_MGC42090 6,67E-05 0,0275859 4,286618
100 A_24_P248079_BC031319 6,73E-05 0,0275859 4,284039
101 A_24_P384469_A_24_P384469 7,66E-05 0,0302033 4,246218
102 A_23_P104275_SLC16A12 7,65E-05 0,0302033 4,246693
103 A_24_P945165_ENST00000371316 7,52E-05 0,0302033 4,25183
104 A_32_P79351_THC2440217 7,50E-05 0,0302033 4,252519
105 A_23_P115762_ECD 7,87E-05 0,0306682 -4,238417
106 A_23_P149075_RPRC1 7,93E-05 0,0306682 4,236196
107 A_32_P75867_THC2376729 8,28E-05 0,0317259 -4,223539
108 A_24_P934008_AY358789 8,90E-05 0,0334761 4,202389
109 A_32_P22401_RPRC1 8,84E-05 0,0334761 4,204285
110 A_32_P74391_SIRPD 8,98E-05 0,033482 -4,19966
111 A_32_P204740_BC065754 9,07E-05 0,0334911 4,196926
112 A_32_P336776_RP6-213H19.2 9,42E-05 0,034181 4,185698
113 A_23_P350396_CDSN 9,39E-05 0,034181 -4,186754
114 A_32_P221799_HIST1H2AM 9,68E-05 0,0347974 -4,177857
115 A_24_P15898_C1orf145 0,0001002 0,0357083 4,167687
116 A_32_P195793_THC2369621 0,0001026 0,0362757 4,160496
117 A_24_P943026_EPB41L4A 0,0001036 0,0363045 4,157734
118 A_23_P41021_NISCH 0,0001047 0,0363784 4,154626
119 A_23_P157338_UNQ739 0,0001141 0,0393221 4,129168
120 A_24_P119685_OBSCN 0,0001216 0,0415474 4,110403
121 A_23_P11644_SPRR2D 0,0001258 0,0419311 -4,10036
122 A_24_P393644_GYPB 0,000125 0,0419311 -4,102142
123 A_32_P223017_MAP3K6 0,0001255 0,0419311 4,101081
124 A_24_P353905_MXRA8 0,0001302 0,0430352 4,090245
125 A_23_P254254_SGSH 0,0001318 0,0432246 4,086556
126 A_32_P183765_AK126298 0,0001346 0,0434618 4,080213
127 A_24_P367864_BC038983 0,0001346 0,0434618 4,080324
128 A_24_P548297_AF086154 0,0001427 0,0450205 4,062782
129 A_23_P343927_HIST2H2AB 0,0001417 0,0450205 -4,065075
130 A_24_P94222_FBLIM1 0,0001415 0,0450205 4,065455
131 A_23_P159893_CHRDL1 0,0001501 0,0469876 4,047748
132 A_32_P144072_THC2305770 0,0001605 0,0498402 4,02787
133 A_23_P215431_POM121 0,0001627 0,0501653 4,023667
134 A_32_P215621_AK094991 0,000169 0,0516257 4,012276
135 A_23_P125435_GABRB1 0,00017 0,0516257 4,010603
136 A_32_P210622_THC2440737 0,0001724 0,0519612 4,006449
137 A_23_P134991_C9orf38 0,0001807 0,0540776 3,992269
138 A_23_P66432_TTYH2 0,0001853 0,0550448 3,984756
139 A_23_P131801_SGK2 0,0001892 0,0558163 3,978399
140 A_23_P133694_SLC29A1 0,0001921 0,056248 3,973922
141 A_23_P10077_PNPLA2 0,0002011 0,0584663 3,960123
142 A_23_P425990_KIAA0774 0,0002029 0,0585914 3,957347
143 A_23_P80752_PLXND1 0,0002049 0,0587555 3,954386
144 A_24_P153215_AL601841 0,0002076 0,0590969 3,950534
145 A_23_P151895_CILP 0,000211 0,059666 3,94555
146 A_24_P9321_HIST1H3I 0,0002146 0,0602608 -3,940475
147 A_23_P23191_HSPG2 0,0002166 0,0604167 3,93763
148 A_23_P89589_PER1 0,0002182 0,0604368 3,935479
149 A_23_P208340_SLC44A2 0,0002285 0,0628684 3,921499
150 A_23_P141946_LTBP4 0,0002311 0,0630143 3,918031
151 A_24_P933458_NAV2 0,0002321 0,0630143 3,916755
152 A_23_P140454_A_23_P140454 0,0002366 0,0638235 3,910883
153 A_23_P342641_SLC44A5 0,0002429 0,0650875 3,902939
154 A_24_P151032_MYL4 0,0002464 0,0656046 -3,898555
155 A_23_P89529_A_23_P89529 0,0002499 0,066109 3,89426
156 A_23_P83579_ARNT2 0,0002522 0,0662936 -3,891456
157 A_24_P489695_ENST00000340455 0,0002554 0,0666886 3,887705
158 A_24_P489690_FLJ46111 0,0002572 0,0667508 3,885488
159 A_23_P166336_DKFZp434N035 0,0002608 0,0672617 -3,881246
160 A_23_P112564_KCND2 0,0002676 0,0673074 3,873489
161 A_23_P312840_SEMA6A 0,0002692 0,0673074 3,871603
162 A_23_P351342_PLEKHM2 0,0002689 0,0673074 3,871973
163 A_32_P135385_CTB-1048E9.5 0,0002653 0,0673074 -3,876046
164 A_32_P41153_BM929882 0,0002676 0,0673074 3,873492
165 A_32_P142960_CR618217 0,000272 0,0675886 3,868477
166 A_23_P42198_HIST1H3G 0,0002839 0,0701163 -3,855422
167 A_23_P78888_FBL 0,0002938 0,072142 -3,844876
168 A_23_P218884_DVL3 0,0002969 0,0721833 3,841737
169 A_23_P397208_GSTM2 0,0002975 0,0721833 3,841057
170 A_24_P228978_C1QTNF3 0,0003117 0,0751822 3,826775
171 A_23_P43079_INTS8 0,0003217 0,0767445 -3,817135
172 A_24_P320796_FKBP9L 0,0003226 0,0767445 3,816286
173 A_24_P394510_HIST1H2AJ 0,0003238 0,0767445 -3,815092
174 A_23_P500034_GLI2 0,0003306 0,0770164 3,808721
175 A_24_P76158_DOCK11 0,0003274 0,0770164 3,811764
176 A_32_P104063_AF275804 0,0003289 0,0770164 -3,810324
177 A_23_P204721_AQP2 0,0003328 0,0770881 3,806692
178 A_23_P200999_ST3GAL3 0,0003392 0,0777033 3,800789
179 A_32_P204101_THC2439736 0,0003382 0,0777033 3,801746
180 A_23_P85783_PHGDH 0,000343 0,0778084 3,797385
181 A_24_P293192_FXYD3 0,0003469 0,0778084 -3,793902
182 A_24_P347310_P11 0,0003438 0,0778084 3,796661
183 A_24_P928217_AK026155 0,0003473 0,0778084 3,793568
184 A_24_P664939_AK021693 0,0003628 0,0808308 3,780136
185 A_23_P26154_PLIN 0,0003666 0,0812498 3,776866
186 A_24_P143301_KAAG1 0,0003725 0,0821024 3,771977
187 A_23_P126241_EIF4G3 0,0003752 0,0822691 3,769692
188 A_23_P119390_EHD2 0,0003786 0,0825633 3,76694
189 A_23_P10172_TSP50 0,0003829 0,0826363 3,763394
190 A_23_P57474_OSBP2 0,0003829 0,0826363 3,763414
191 A_23_P152344_GTF3C1 0,0003871 0,0830885 3,760081
192 A_23_P207967_KIAA0427 0,0003909 0,0834721 3,757039
193 A_24_P252130_PPARD 0,0003948 0,0838628 3,753984
194 A_23_P139260_SLC22A18 0,0004075 0,0852371 3,744165
195 A_23_P153767_AKAP8L 0,0004071 0,0852371 3,744463
196 A_32_P198325_LOC388886 0,0004052 0,0852371 3,745867
197 A_24_P922631_LOC133874 0,0004138 0,0861144 3,739409
198 A_24_P225339_MOBKL2C 0,0004298 0,0890031 3,727587
199 A_23_P85460_CDKN2C 0,000439 0,0899867 -3,721042
200 A_23_P86164_ZUBR1 0,000437 0,0899867 3,722437
201 A_24_P7021_KRT8P19 0,0004495 0,091689 3,713655
202 A_24_P384239_A_24_P384239 0,0004523 0,0918134 3,711687
203 A_24_P350683_SLC9A1 0,0004558 0,0920612 3,709308
204 A_32_P59516_BC041979 0,0004619 0,0928409 3,705147
205 A_23_P91970_AADACL2 0,0004749 0,0945177 3,696517
206 A_24_P383850_EIF4G3 0,0004745 0,0945177 3,696744
207 A_24_P375728_LOC92154 0,0004947 0,0952371 3,683744
208 A_23_P103310_S100A7 0,0004851 0,0952371 -3,68987
209 A_23_P215459_ELN 0,0004897 0,0952371 3,686944
210 A_23_P81640_KIAA1909 0,0004948 0,0952371 -3,683704
211 A_24_P255628_PACS2 0,0004939 0,0952371 3,684281
212 A_24_P257579_EPB41L4A 0,000494 0,0952371 3,684213
213 A_32_P114535_THC2288392 0,0004897 0,0952371 3,686898
214 A_23_P212854_GYPB 0,0005103 0,0977647 -3,674038
215 A_24_P409230_OR10A2 0,0005342 0,098209 3,6597
216 A_23_P121813_ENPP6 0,0005334 0,098209 3,660147
217 A_23_P98369_GRIA4 0,0005269 0,098209 3,664008
218 A_24_P120147_LOC284948 0,0005258 0,098209 3,664629
219 A_24_P226508_HS3ST5 0,0005325 0,098209 3,660687
220 A_24_P393449_DAPK1 0,0005286 0,098209 3,663011
221 A_24_P671875_THC2428713 0,0005318 0,098209 3,661062
222 A_24_P683917_FLNB 0,0005163 0,098209 3,670385
223 A_32_P231346_THC2458855 0,0005289 0,098209 3,662801
224 A_32_P184448_C18orf34 0,0005584 0,1022038 3,645767
225 A_23_P340338_LCE3E 0,0005676 0,1034289 3,640616
226 A_23_P208369_ITPKC 0,0005715 0,1036803 3,638456
227 A_23_P106371_GOLGA 0,0005803 0,1044194 3,633653
228 A_23_P84910_ZNF157 0,0005825 0,1044194 3,632433
229 A_24_P217520_EREG 0,0005832 0,1044194 -3,632065
230 A_23_P207125_NLGN2 0,0005895 0,1050766 3,628714
231 A_24_P105733_TNS1 0,0006033 0,1061715 3,621375
232 A_24_P113815_SLC35E2 0,0006034 0,1061715 3,621356
233 A_24_P264031_AK126415 0,0006033 0,1061715 3,621373
234 A_32_P179910_THC2315966 0,0006069 0,1063416 3,619499
235 A_23_P114381_STK23 0,0006104 0,1064947 3,617698
236 A_23_P68487_BMP7 0,0006177 0,107317 -3,613927
237 A_23_P317200_ATXN7L2 0,0006276 0,1085721 3,608915
238 A_23_P95359_DNAJC6 0,000635 0,1093941 3,605198
239 A_23_P18123_NLGN1 0,0006377 0,1094021 -3,603848
240 A_23_P203053_AK054929 0,0006414 0,1095648 3,602019
241 A_24_P43826_EBF2 0,000644 0,1095648 3,60074
242 A_23_P110266_FLJ23191 0,0006488 0,1099134 3,598423
243 A_23_P93258_HIST1H3B 0,000662 0,110339 -3,592004
244 A_24_P348265_FCAR 0,0006594 0,110339 3,593281
245 A_24_P407645_SPN 0,0006615 0,110339 -3,592265
246 A_32_P75299_AK125697 0,0006569 0,110339 -3,594492
247 A_32_P124887_A_32_P124887 0,0006658 0,1105195 -3,5902
248 A_32_P16989_A_32_P16989 0,0006705 0,1108493 3,587974
249 A_24_P307599_AF210649 0,0006836 0,1113555 3,581857
250 A_23_P118894_ATAD4 0,0006871 0,1113555 -3,580193
251 A_23_P157109_ADCYAP1R1 0,0006861 0,1113555 3,580692
252 A_23_P68327_CCDC104 0,000685 0,1113555 -3,581176
253 A_24_P358976_TMEM19 0,000687 0,1113555 -3,580258
254 A_23_P167389_CENTD3 0,000698 0,1126708 3,57521
255 A_24_P45651_HIST2H3A 0,000722 0,1156298 -3,56447
256 A_24_P942600_ENST00000349097 0,0007207 0,1156298 3,565048
257 A_23_P121945_SNCB 0,0007394 0,1179658 3,556859
258 A_23_P218442_CEACAM6 0,0007484 0,1184712 -3,553025
259 A_23_P427075_CTNS 0,0007476 0,1184712 3,553356
260 A_23_P406478_FLJ32784 0,0007557 0,1190867 3,549913
261 A_23_P82000_TEAD3 0,0007581 0,1190867 3,548919
262 A_23_P124335_LOC642299 0,0007746 0,1210102 -3,542027
263 A_23_P84952_TFE3 0,0007762 0,1210102 3,541367
264 A_32_P150382_VWF 0,00078 0,121139 3,539815
265 A_23_P12423_ATP13A2 0,0008041 0,1221739 3,530098
266 A_23_P13425_CD81 0,0008143 0,1221739 3,526057
267 A_23_P201596_AMPD2 0,0008116 0,1221739 3,527102
268 A_23_P412476_GREB1 0,0008091 0,1221739 -3,528105
269 A_23_P46639_C8A 0,0008078 0,1221739 -3,528619
270 A_23_P71867_IL11RA 0,0008125 0,1221739 3,526752
271 A_24_P140621_CCNJL 0,0008107 0,1221739 3,527459
272 A_24_P164505_FAM106A 0,0008165 0,1221739 3,525202
273 A_24_P276983_STK25 0,0008138 0,1221739 3,526251
274 A_32_P9816_AI857589 0,0008145 0,1221739 -3,525998
275 A_23_P367899_EPOR 0,0008255 0,1230766 3,521678
276 A_23_P128967_ALDH6A1 0,0008331 0,1233125 3,518742
277 A_24_P228667_MRPL40 0,0008305 0,1233125 -3,519753
278 A_23_P121783_SRD5A2L 0,000866 0,1263981 -3,506317
279 A_23_P200598_C1orf166 0,0008604 0,1263981 3,508421
280 A_23_P24414_EFEMP2 0,0008689 0,1263981 3,505233
281 A_23_P351295_HS3ST5 0,0008604 0,1263981 3,508386
282 A_32_P225768_A_32_P225768 0,0008694 0,1263981 3,505072
283 A_23_P136196_TBC1D19 0,0008774 0,1271151 -3,502117
284 A_23_P404045_MTHFR 0,0008856 0,1274089 3,499112
285 A_32_P215676_AL049990 0,000885 0,1274089 3,499331
286 A_23_P143981_FBLN2 0,0008899 0,127578 3,497559
287 A_23_P150979_SBEM 0,0009138 0,1300911 -3,48904
288 A_23_P73097_RGS20 0,0009134 0,1300911 3,489197
289 A_23_P101434_NALP12 0,0009204 0,1305777 3,486721
290 A_24_P161973_ATP11A 0,0009305 0,1315534 3,483209
291 A_23_P373598_MAFK 0,0009415 0,1326575 3,479405
292 A_23_P396800_NEGR1 0,0009499 0,1329834 3,476552
293 A_24_P254965_HDAC8 0,0009503 0,1329834 -3,476404
294 A_24_P269624_ENST00000381854 0,0009541 0,1330533 -3,475135
295 A_23_P66827_FAM106A 0,0009818 0,1364593 3,465876
296 A_23_P34375_TCEA3 0,0009945 0,1377525 3,461733
297 A_23_P104876_SPA17 0,0010199 0,137967 -3,453582
298 A_23_P107116_ZNF179 0,0010137 0,137967 3,455551
299 A_23_P126008_MAST2 0,0010191 0,137967 3,453843
300 A_23_P156953_IGF2R 0,0010247 0,137967 3,452049
301 A_23_P30805_HIST1H4J 0,0010216 0,137967 -3,453048
302 A_24_P410610_DPYD 0,0010238 0,137967 3,452349
303 A_24_P630640_CENTB1 0,0010216 0,137967 3,453042
304 A_32_P146382_BG181407 0,0010007 0,137967 -3,459715
305 A_32_P32923_A_32_P32923 0,0010263 0,137967 -3,451535
306 A_23_P47546_A_23_P47546 0,0010329 0,1383988 3,449463
307 A_32_P71675_ENST00000378266 0,001038 0,1386291 3,447866
308 A_24_P186936_ELN 0,0010523 0,1400787 3,44344
309 A_23_P121702_OCIAD2 0,0010668 0,1415467 -3,439005
310 A_24_P938508_AK022228 0,0010777 0,1425338 3,4357
311 A_23_P300484_BC061909 0,0010927 0,1439584 3,431217
312 A_32_P173955_A_32_P173955 0,0010955 0,1439584 -3,430381
313 A_32_P71571_FAM19A4 0,0011143 0,1459655 3,424838
314 A_32_P175198_ACTG1 0,0011302 0,1475676 3,420248
315 A_23_P252653_STK25 0,0011435 0,148059 3,416432
316 A_23_P78762_DHRS10 0,0011447 0,148059 3,416069
317 A_24_P127063_A_24_P127063 0,0011384 0,148059 -3,417894
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PPGLs are paradigmatic for illustrating the importance of genetics in cancer development. These 
tumours show a high degree of heritability, around 40% carry a germline mutation, and they exhibit a 
great genetic heterogeneity with seventeen major susceptibility genes identified so far involved in the 
disease. Amongst them, SDHD was defined as the earliest metabolic gene involved in the TCA cycle 
and the respiratory chain whose mutations led to cancer development103. Since then, mutations in nine 
additional metabolic genes, all of them directly or indirectly related to the TCA cycle (SDHA, SDHAF2, 
SDHB, SDHC, FH, MDH2, IDH1, IDH2, and SLC25A11), have been reported to cause PPGL development 
with a characteristic CIMP profile, highlighting the relevance of this pathway in the disease. Despite 
recent genetic findings, there is still a percentage of hereditary PPGL cases that do not have a mutation 
in any of the known susceptibility genes, and for whom we were eager to get a genetic diagnosis.
Therefore, the overall purpose of this thesis was to implement NGS (WES and targeted gene panels) in 
genetically undiagnosed PPGL cases to identify new susceptibility genes. In order to avoid problems of 
data interpretation related to the aforementioned genetic heterogeneity, a proper selection of the patients 
to be included in the study was crucial. Thus, PPGL patients were classified according to molecular 
markers, like a CIMP profile, or based on relevant clinical features, such as tumour location and 
multiplicity.
• ARTICLE 1: Candidate Cancer–Predisposing Mutations in TCA cycle genes.
In this first study, we performed a selection of genetically undiagnosed PPGL cases according to the 
low expression and methylation of RBP1, a strategy for avoiding genetic heterogeneity that allowed 
us to focus exclusively on tumours with a CIMP profile, and therefore candidates to harbour genetic 
alterations in a TCA cycle-related gene. After the sampling phase, we applied to the selected series of 
cases a targeted exome sequencing panel that included 37 genes directly or indirectly involved in the 
TCA cycle.  In addition, we carried out high-throughput DNA methylation profiling of selected tumours. 
Following this rational, we were able to identify various PPGL samples harbouring candidate variants 
affecting several genes TCA-related.
Firstly, we found mutations that although rare are already in the literature, such as the third reported 
pathogenic mutation in IDH1 (c.394C>T; p.Arg132Cys) that affects mainly older patients (>61 years) 
with extra-adrenal PGLs76,121. In our study, we confirmed this cancer-prone alteration as the driver event 
in one PGL, diagnosed in a 78 years-old woman, by showing an accumulation of the oncometabolite 
2HG in the mutated tumour that it is known to cause the inhibition of αKG-dependent dioxygenases, and 
therefore a characteristic CIMP profile. This finding further confirms a more predominant role of IDH1 
in PPGL pathogenesis than previously expected170. Additionally, although aberrant hypermethylation 
of the SDHC promoter has been reported in PGLs110, GIST171, and Carney triad patients111, the case 
described in our study was the first example of a SDHC epimutation affecting a patient with Carney-
Stratakis syndrome. These two examples of rare genetic events leading to PPGL development highlight 
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the need to apply well designed and comprehensive NGS panels and omics analysis for genetic testing in 
this multi-genetic disease, since diagnostic algorithms do not include the analysis of these low prevalent 
variants by conventional methods.
Secondly, we identified two new candidate genes (GOT2 and IDH3B) involved in the hereditary 
predisposition to PPGL. GOT2 is a mitochondrial enzyme implicated in the malate-aspartate shuttle, the 
amino acid metabolism and the urea cycle. It also plays a role in the TCA cycle by converting oxaloacetate 
to aspartate and consequently glutamate to αKG, thus providing metabolic intermediates that are lacking 
due to the truncation of the TCA cycle, for instance in SDH-deficient cells172. The increase in GOT2 
expression and the enhanced enzymatic activity found in the tissues carrying the c.357A>T (p.Glu119Asp) 
mutation suggested an activating role of this variant, fact that was supported by the increment of αKG 
levels and the following oncogenic accumulation of succinate observed in the GOT2-mutated tumour. 
The finding of a mutation affecting GOT2, a gene involved in the malate-aspartate shuttle and therefore 
in anaplerotic reactions, extended the PPGL susceptibility genes spectrum towards other genes not 
directly involved in the TCA cycle. Interestingly, the recent finding of mutations in SLC25A11, encoding 
a mitochondrial membrane carrier of αKG, points to the special relevance of the malate–aspartate shuttle 
in PPGL development173 (Figure 4).
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Figure 4. The malate-aspartate shuttle. PPGL susceptibility genes found activated are denoted in 
red (GOT2) while those inactivated are represented in blue (SLC25A11 and MDH2). Red arrows 
indicate altered pathways due to mutated genes and metabolite accumulation is denoted by red circles.
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Upon extension of the series analysed, a novel truncating germline mutation in the gene IDH3B 
(c.128_138delTGAGGGTGGAG) was detected in a patient with a single PGL. IDH3B-mutated tumour 
exhibited a CIMP-like profile in concordance with a negative 5-hmC IHC as well as an altered αKG/
isocitrate ratio, thus suggesting a driver role of the variant in the tumorigenesis. IDH3B plays a structural 
role facilitating the assembly of the heterodimer and ensuring the full activity of the enzyme that catalyses 
the decarboxylation of isocitrate into αKG in the TCA cycle. Although extremely rare, somatic mutations 
in the gene IDH3B have been recently found in acute myeloid leukaemia (AML) tumours with a FLT3 
internal tandem duplication174, and homozygous loss-of-function mutations have been identified in 
two families with retinitis pigmentosa175. Despite the prevalence in PPGL is very low, the oncogenic 
role of IDH1 and IDH2 mutations in many cancers is well known for more than ten years176–178. As 
previously mentioned, IDH1/2 mutations lead to a neomorphic activity and the concomitant loss of the 
enzyme’s normal catalytic activity. Therefore, our finding of an inactivating mutation in IDH3B, with the 
consequent loss of the activity of IDH3, is in agreement with the relevant role of isocitrate dehydrogenase 
alterations in tumour development.
In summary, taking advantage of a selection of PPGL cases based on the expression of a methylation 
marker, we were able to identify different candidate mutations affecting TCA cycle-related genes (IDH1, 
IDH3B and SDHC), thus highlighting the relevance of this metabolic pathway in PPGL pathogenesis. In 
addition, we have also found altered an enzyme involved in metabolite exchange across the mitochondria 
(GOT2) which, as occurs with the finding of SLC25A11 mutations in PPGL patients, points towards the 
involvement of mitochondrial shuttles in disease development.
• ARTICLE 2: Identification of gain-of-function mutations in an epigenetic regulator.
Among the PPGL patients with a CIMP profile that were included for the analysis with the TCA cycle 
panel (Article 1), there was a very interesting case: a young woman (22 yr.) with multiple PGLs (>7), but 
without family history of the disease, who tested negative not only for the canonical PPGL susceptibility 
genes, but also for any of the candidate genes included in our TCA cycle panel. For this particular patient 
there were different genetic scenarios accounting for the disease, being the main ones the presence of 
a de novo mutation, following a recessive model of inheritance, or an autosomal dominant model with 
incomplete penetrance.
Following a trio-based approach, WES was applied to germline samples from the two parents and the 
proband, identifying a single de novo missense variant in the gene DNMT3A (c.896A>T; p.Lys299Ile). 
De novo highly deleterious mutations play a prominent role in neurodevelopmental diseases. These 
mutations are individually rare with a rate of one de novo mutation per exome179, so our trio-based 
strategy allowed us to probably find the only coding de novo variant and the causal mutation of the 
patient.
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DNMT3A is a DNA methyltransferase that, together with DNMT3B, is in charge of the establishment 
of methylation patterns early in mammal embryogenesis through de novo methylation of unmethylated 
CpG sites180,181 (Figure 5A). The p.Lys299Ile variant affects a highly conserved residue within the PWWP 
domain of DNMT3A that binds to the DNA and targets the protein to trimethyl lysines in histone 
H3182,183 (Figure 5B). In silico predictors classified the variant as deleterious and it was found neither 
in public databases such as gnomAD and the database of Epigenetic Modifiers nor in more than 570 
Spanish exomes from the CIBERER Spanish Variant Server. 
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Figure 5. DNMT3A role and structure. (A) Role of the different DNA methyltransferases (DNMT1, 
DNMT3A, and DNMT3B) in the DNA methylation process. (B) Structural domains of the DNMT3A protein: 
a proline-tryptophan-tryptophan-proline (PWWP) domain, an ATRX, DNMT3, and DNMT3L-type zinc 
finger (ADD) domain, and the methyltransferase (MTase) domain. The DNMT3A mutations (Lys299Ile; 
K299I and p.Arg318Trp; R318W) as well as the hotspot R882 appear indicated in the different domains.
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A characteristic hypermethylation of several Hox genes and other homeobox-containing genes, all 
targets for DNMT3A-dependent methylation, was observed in p.Lys299Ile-DNMT3A tissues, meaning 
both tumours available and lymphocytes extracted from patient’s blood. This finding suggested that 
the p.Lys299Ile variant is associated with a transcriptional repression role due to a gain-of-function 
of DNMT3A, rather than an inactivation of the protein. Hypermethylation of homeobox-containing 
genes and specifically Hox genes with a tumour suppressor role has been widely reported in different 
cancer types including neuroblastoma and PPGL184,185. In fact, aberrant expression of many members of 
this transcription factors superfamily has been related to tumorigenesis and loss-of-function DNMT3A 
mutations186. Of note, the effect on global DNA methylation caused by the introduction of the p.Lys299Ile 
mutation in our CRISPR/Cas9 model of HeLa cells supports the gain-of-function role of this mutation, 
being consistent with the hypermethylated profile observed in the tumours. A high immunostaining of 
H3K9me3 was observed in all DNMT3A-mutated tumours available, something also found in SDH- and 
FH-mutated PPGLs187, thus providing further evidence for the gain-of-function role of the DNMT3A 
mutations.
Somatic loss-of-function mutations in DNMT3A are highly recurrent in patients with AML and many 
other haematological malignancies188,189; with a hotspot for variants affecting the arginine 882 (Figure 
5B). In the same way, germline de novo inactivating genetic alterations in DNMT3A have been commonly 
reported for overgrowth syndrome patients190,191. So far, the index patient carrying the p.Lys299Ile mutation 
is free of AML or any haematological malignancy and overgrowth syndrome. In addition, the p.Lys299Ile 
DNMT3A variant was not found in AML or overgrowth syndrome patients. Somatic mutations in other 
epigenetic modifying genes involved in chromatin-remodelling have been also reported not only in 
overgrowth syndromes (EZH2192, NSD1193 and SETD2) but also in many solid tumours including PPGL 
cases79. In addition, overexpression of DNMT3A has been related to tumorigenesis and progression 
of different tumours194,195, supporting an oncogenic role for the DNMT family proteins. Although not 
curative, the success of DNA hypomethylating agents, including azacitidine and decitabine, in the 
treatment of multiple hematologic malignancies further supports the oncogenic role of DNMT3A181,196. 
Despite there is a well-reported existence of a crosstalk between genomic alterations and deregulation of 
epigenetics as a cause of different cancer types, the case reported herein would be the first example of a 
mutation in an epigenetic regulator causing a hereditary cancer.
Considering the recurrence of activating mutations affecting oncogenes, a screening of the PWWP 
domain of DNMT3A in a series of additional PPGL patients was performed. This way, we were able 
to identify a second germline DNMT3A mutation (c.952C>T; p.Arg318Trp) in a woman with multiple 
HN-PGLs and family history of the disease. The p.Arg318Trp substitution was also affecting a highly 
conserved residue within the PWWP domain of DNMT3A. In the same manner, we were able to identify 
the mutation p.Lys299Ile with a subclonal somatic character in six HN-PGLs (6.4% of PPGLs studied). 
However, we consider that the DNMT3A mutation is not the cancer driver event in these sporadic 
patients due to the low allele frequencies observed.
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To summarize, in this second study DNMT3A appears as a new PGL related gene. Despite altered DNA 
methylation is one of the most common epigenetic changes in human cancers, this would be the first 
example of a gain-of-function mutation affecting DNMT3A. Additionally, DNMT3A sub-clonal somatic 
mutations seems to be relatively frequent in HN-PGLs although the biological meaning of these non-
driver alterations remains unknown.
• ARTICLE 3: Identification of a recurrent germline mutation in a TCA cycle gene in patients 
with multiple PPGLs.
The TCA cycle has become one of the most relevant pathways in PPGL development since more than 
ten different genes (including GOT2 and IDH3B) directly or indirectly involved in this key metabolic 
pathway have been found altered. In this third study, upon extension of the series of samples analysed 
through the TCA cycle-related genes panel (Article 1), we could identify five germline variants affecting 
DLST in seven unrelated patients (~7% of the patients included in the analysis) without mutations in any 
of the known susceptibility genes.
The DLST gene encodes one of the three subunits of the mitochondrial oxoglutarate dehydrogenase 
(OGDH) complex in charge of the conversion of αKG to succinyl-CoA, CO2 and NADH (Figure 6).
As it happens with the SDH complex, depletion of any of the OGDH complex subunits leads to impaired 
enzymatic activity and αKG accumulation. Among the DLST variants identified, c.1121G>A; p.Gly374Glu 
Figure  6. OGDH complex structure. E1: OGDH (2-oxoglutarate dehydrogenase), E2: DLST (dihydrolipoamide 
S-succinyltransferase), E3: DLD (dihydrolipoamide dehydrogenase). The E1 subunit contains tightly bound 
TPP (thiamine pyrophosphate) and catalyses the decarboxylation of 2-oxoglutarate and the formation of 
TPP-hydroxysuccinate, followed by the conversion of oxidized lipoate (covalently linked to the E2 subunits) 
into succinate dihydrolipoate. The E2 subunit induces the formation of succinyl-CoA by transesterification 
as well as the E3 subunit catalyses the transference of H+ (from FADH2) to NAD+ to form NADH and the 
regeneration of oxidized lipoate.
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appeared as a recurrent mutation in four unrelated PPGL patients (three individuals identified with the 
panel and an additional one by WES). The Gly374 residue locates within the pocket of the enzyme that 
is also a region of monomers interaction, so the Glu-containing substitution may interfere not only with 
the binding to the succinyl group, but also in the oligomerization of the protein.
Upon disruption of the OGDH complex activity, high levels of accumulated αKG may be converted to 
the L enantiomer of 2HG by promiscuous enzymatic activity of both malate dehydrogenase enzymes 
(MDH1 and MDH2), and especially by lactate dehydrogenase A in hypoxic cells197. This production 
has been seen enhanced by acidic pH even under normoxic conditions198. Therefore, the increased 
αKG to fumarate, and 2HG to fumarate ratios observed in p.Gly374Glu-DLST tumours, as well as the 
accumulation of significant levels of L-2HG in DLST-KO cells reconstituted with the mutant protein, 
suggests that this mutation is leading to a DLST functional impairment.
Six available tumours carrying the recurrent p.Gly374Glu variant showed LOH by paternal UPD, 
suggesting a tumour suppressor role for DLST. This unusual second hit mechanism was already reported 
for the PPGL susceptibility gene MAX199 which is also located in chromosome 14q, therefore underscoring 
the relevance of this mechanism for PPGL pathogenesis. A detailed omics study showed a homogeneous 
expression profile within p.Gly374Glu-DLST tumours, and alike to the one exhibited by MAX-mutated 
tumours, being a presumably consequence of the 14q chromosomal loss. However, absence of gross 
deletions, alterations in the promotor, and deep intronic mutations in MAX ruled out this gene as the 
disease-causing and confirmed the main driver role of DLST.
When we analysed the expression data from a large series of PPGLs carrying known mutations 
using a previously reported list of 451 genes differentially expressed in PPGLs with different genetic 
backgrounds128, the p.Gly374Glu-DLST cases were grouped in Cluster 1 together with all, except 
one, tumours carrying mutations in EPAS1. This result confirmed the homogeneous profile of the 
p.Gly374Glu-DLST tumours, as well as it suggested a link between DLST disruption and pseudohypoxia, 
and further supported the differences between these tumours and tumours carrying mutations in MAX. 
Among the significant differentially expressed genes, the hypoxic transcriptional factor HIF3A appeared 
overexpressed in DLST-mutated tumours. Although the functional implications of the overexpression 
of this hypoxic factor is unknown, it is though that HIF3A acts as a dominant-negative regulator of the 
hypoxia-inducible gene expression200.
Moreover, p.Gly374Glu-DLST tumours also exhibited characteristic homogeneous methylation profiles, 
that although not hypermethylated as occurred in SDHx-mutated tumours, indicate that a similar 
mutational status account for all of them, therefore pointing to a DLST driver role in the pathogenesis of 
these tumours. To note, the absence of a CIMP profile in p.Gly374Glu-DLST tumours explains why these 
samples were not selected in the first study presented in this thesis focused on hypermethylated PPGLs.
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Regarding the clinical features of mutation carriers, there was a predominance of multiple tumours 
within the DLST-mutated patients (six out of seven, p<0.001), which was especially relevant in the 
thoracic-abdominal region (p<0.0003). This multiplicity supports the pathogenic role of DLST in PPGL 
development, as it is a common feature among hereditary cancer syndromes. In addition, the lack of 
family history of the disease in mutation carriers points towards de novo or low penetrant mutations, 
being both mechanisms already reported for PPGL118,201,202.
Concerning the remaining DLST substitutions (c.692G>A, p.Arg231Gln; c.910G>A, p.Asp304Asn; and 
c.1265A>G, p.Tyr422Cys), although two of them affect highly conserved residues within the protein 
and were predicted as deleterious, displayed a similar behaviour to WT-DLST in our cellular model. 
Similarly, it was not possible to determine a pathogenic role for the DLST intronic splice site variant 
(c.1060-3T>A) since there was not enough tissue to work with.
Finally, we observed a highly positive DLST immunostaining not only in DLST-mutated tumours but 
also in any other PPGL with mutations in TCA cycle-associated genes, as well as in EPAS1-mutated 
PPGLs, highlighting once more, the possible association between DLST mutations and a pseudo-hypoxic 
profile. This observation may suggest that, as occurs with SDHD and the SDH complex203, the presence of 
disrupting mutations in TCA cycle genes or DLST itself obstructs OGDH complex assembly making the 
DLST epitope more accessible. Although still unexplained, DLST IHC may be helpful in the classification 
of VUS in genes from the pseudohypoxic Cluster 1, either in TCA cycle-related genes or in EPAS1. 
To the best of our knowledge, this is the first example of OGDH complex mutations leading to 
cancer. However, mutations in the OGDH complex and related genes, as well as alterations in enzyme 
functionality have been linked to neurodegeneration204–206, something also frequently observed in other 
TCA cycle–related PPGL susceptibility genes207–211.
In summary, this third study highlights DLST as a new candidate PPGL susceptibility gene. Four 
unrelated patients were found carrying a recurrent germline mutation (p.Gly374Glu) that functionally 
compromises DLST function. Tumours and cells harbouring this mutation display elevated αKG and 
2HG to fumarate ratios and consequently altered and characteristic methylation and transcriptional 
profiles. 
• GENERAL DISCUSSION
Advances in sequencing technologies within the past few years led a majority of genetics laboratories to 
embrace NGS as the new gold standard not only for routine diagnosis but also for identification of new 
susceptibility genes, due to that NGS is especially pertinent for disorders such as hereditary PPGLs with 
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a highly genetic heterogeneity37. 
In this thesis, we have developed three projects with the aim of identify new PPGL susceptibility genes 
employing NGS. Taking into consideration the relevance of TCA cycle in PPGL pathogenesis, we applied 
a targeted sequencing panel of genes related to this key metabolic pathway to PPGL samples without 
mutations in any of the already known predisposing genes. Selection of samples was key as we could 
just focus on genetically undiagnosed PPGL patients with similar molecular features, such as a CIMP 
profile. This strategy let us to discover mutations in genes that so far had not been implicated in disease 
development such as GOT2 and IDH3B, and to select for WES another patient the finally carried a 
mutation in the epigenetic modifier DNMT3A. Additionally, we could identify extremely rare mutations 
in already known PPGL susceptibility genes such as IDH1 and an epimutation in SDHC. Finally, upon 
extension of the PPGL samples series to be analysed for alterations in the TCA cycle, a potentially 
pathogenic variant in the DLST gene was unravelled, appearing it as a new candidate PPGL driver gene.
These three studies add invaluable data to a growing list of potential susceptibility genes for PPGL. 
However, segregation analyses and testing of large populations of PPGL patients will be required in 
future studies in order to uncover the prevalence of mutations in these genes, as well as a complete 
understanding of the variants’ penetrance. Moreover, clinicians must act cautiously when rare variants 
are identified in PPGL patients since clinical action is only recommended for truly established pathogenic 
genes and variants212.
Despite all genetic discoveries achieved during the past years, therapeutics development against M-PPGL 
has been very unsuccessful for three main reasons: difficulty of patient enrolment in large clinical trials, 
paucity of preclinical animal models, and lack of efficiency of molecular targeted drugs41. Therefore, 
identification of clinically effective treatments for M-PPGL is for sure the most important unmet clinical 
need nowadays. Although the patients carrying TCA cycle-related mutations identified in this thesis have 
not developed metastases so far, the association of alterations in this metabolic pathway and metastases is 
well known in PPGL. The results gathered in our studies uncover new possible druggable targets which 
can be used in the near future for the development of novel personalized PPGL targeted therapies.
CONCLUSIONES/CONCLUSIONS
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CONCLUSIONES
1. El hallazgo de diversas variantes candidatas en genes relacionados con el ciclo de los ácidos 
tricarboxílicos (TCA), apoya la relevancia de esta vía metabólica central en la patogénesis del PPGL. 
También pone de manifiesto el éxito de una estrategia de selección de muestras basada en marcadores, 
para evitar problemas de interpretación relacionados con la presencia de heterogeneidad genética.
2. La mutación c.357A>T GOT2, asociada a una mayor expresión y actividad de la proteína, así 
como a ratios de metabolitos alterados, tiene un papel directo en el desarrollo de PPGL, lo que incrementa 
el número de genes de susceptibilidad involucrados en la enfermedad. Pese a que la prevalencia de 
mutaciones en GOT2 parece ser baja en pacientes con PPGL, este hallazgo apunta hacia la implicación de 
la lanzadera de malato-aspartato en la enfermedad, como ya se ha visto para otras enzimas relacionadas 
con el intercambio metabólico a través de la mitocondria.
3. El empleo de paneles de genes para la secuenciación masiva, combinado con perfiles de 
metilación, permitió la identificación de alteraciones patológicas raras en genes de susceptibilidad a 
desarrollar PPGL ya conocidos (IDH1 y SDHC) e identificó a IDH3B como un nuevo gen candidato 
responsable de la enfermedad.
4. Mutaciones germinales en el dominio PWWP del gen DNMT3A causan un fenotipo metilado en 
aquellos tejidos mutados y confiere susceptibilidad hereditaria a desarrollar PPGL. Hasta ahora, este es 
el primer ejemplo de mutaciones activadoras en un gen con actividad ADN metiltransferasa involucrado 
en una predisposición a desarrollar cáncer. Además, las mutaciones somáticas subclonales en DNMT3A 
son relativamente frecuentes en PPGLs de cabeza y cuello, lo que subraya por tanto la importancia de las 
alteraciones en DNMT3A en el desarrollo de PPGL.
5. DLST, otro gen que codifica una enzima crucial del ciclo TCA, aparece mutado hasta en un 
7% de los pacientes con PPGL que no presentaban alteraciones en ninguno de los principales genes de 
susceptibilidad de la enfermedad. En presencia de la variante germinal recurrente p.Gly374Glu-DLST, y 
después de una pérdida de heterocigosidad por disomía uniparental, se produce una interrupción de la 
actividad del complejo OGDH dando lugar a una acumulación de αKG así como a una producción de 
2HG.
6. Los tumores portadores de la variante recurrente p.Gly374Glu-DLST exhiben un perfil de 
metilación homogéneo, pero no hipermetilado, y una marca de expresión pseudohipóxica, como ocurre 
en los tumores con mutación en EPAS1, en la cual parece estar involucrado HIF3A.
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7. La inmunohistoquímica de DLST se vislumbra como una nueva herramienta que podría ayudar 
a discernir entre mutaciones y variantes de significado desconocido (VUS), no sólo en el gen DLST sino 
también en EPAS1 y en los genes pseudohipóxicos del Cluster 1A. 
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Conclusiones/Conclusions
CONCLUSIONS
1. The finding of several candidate variants affecting TCA cycle-related genes further attests the 
relevance of this key metabolic pathway in PPGL pathogenesis, as well as it highlights the success of an 
appropriate marker-based sample selection strategy in order to avoid the interpretation problems related 
to the presence of genetic heterogeneity.
2. The c.357A>T GOT2 mutation, that is associated with a higher expression and activity of the 
protein, and with altered metabolite ratios, has a driver role in PPGL development, which increases the 
number of susceptibility genes involved in the disease. Although the prevalence of GOT2 mutations 
seems to be low across PPGL patients, this finding points towards the involvement of the malate-aspartate 
shuttle in the disease, as it has already been seen for other enzymes related to metabolite exchange across 
the mitochondria.
3. The use of targeted gene panel sequencing, combined with methylation profiling, allowed the 
identification of rare pathological alterations in known PPGL susceptibility genes (IDH1 and SDHC), as 
well as uncovered IDH3B as a new candidate gene responsible for the disease.
4. Germline mutations in the PWWP domain of the DNMT3A gene cause a methylated phenotype 
in mutated tissues, and confer hereditary susceptibility to develop PGLs. This is the first example of gain-
of-function mutations in a DNA methyltransferase gene involved in cancer predisposition reported so 
far. Moreover, DNMT3A subclonal somatic mutations are relatively frequent in HN-PGLs highlighting 
the importance of DNMT3A alterations in PGL development.
5. DLST, another gene encoding a pivotal enzyme of the TCA cycle, is found mutated in up to 7% 
of the PPGL patients without alterations in the main PPGL susceptibility genes. Upon the presence of 
the recurrent p.Gly374Glu-DLST germline variant, and after LOH caused by UPD, there is a disruption 
of OGDH complex activity leading to accumulation of αKG and production of 2HG.
6. Tumours carrying the recurrent p.Gly374Glu-DLST variant exhibit a homogeneous but not 
hypermethylated profile, and a pseudohypoxic expression signature, close to EPAS1-mutated tumours, 
in which HIF3A seems to play a role.  
7. DLST IHC appears as a new tool that may be useful in order to discern between mutations and 
VUS not only in the DLST gene, but also in EPAS1 and pseudohypoxic Cluster 1A genes.
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1. ATRX driver mutation in a composite malignant phaeochromocytoma
Comino-Méndez I, Tejera ÁM, Currás-Freixes M, Remacha L, Gonzalvo P, Tonda R, Letón R, Blasco 
MA, Robledo M, Cascón A.
Published in Cancer Genetics, 2016 Jun;209(6):272-7.
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are tumors arising from the adrenal medulla 
and sympathetic/parasympathetic paraganglia, respectively. Approximately 40% of PCCs/PGLs are due 
to germline mutations in one of 16 susceptibility genes, and a further 30% are due to somatic alterations 
in 5 main genes. Recently, somatic ATRX mutations have been found in succinate dehydrogenase (SDH)-
associated hereditary PCCs/PGLs. In the present study we applied whole-exome sequencing to the 
germline and tumor DNA of a patient with metastatic composite PCC and no alterations in known PCC/
PGL susceptibility genes. A somatic loss-of-function mutation affecting ATRX was identified in tumor 
DNA. Transcriptional profiling analysis classified the tumor within cluster 2 of PCCs/PGLs (without 
SDH gene mutations) and identified downregulation of genes involved in neuronal development and 
homeostasis (NLGN4, CD99 and CSF2RA) as well as upregulation of Drosha, an important gene involved 
in miRNA and rRNA processing. CpG island methylator phenotype typical of SDH gene-mutated tumors 
was ruled out, and SNP array data revealed a unique profile of gains and losses. Finally, we demonstrated 
the presence of alternative lengthening of telomeres in the tumor, probably associated with the failure 
of ATRX functions. In conclusion, somatic variants affecting ATRX may play a driver role in sporadic 
PCC/PGL.
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2. PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and 
Paraganglioma Diagnostics
Currás-Freixes M, Piñeiro-Yañez E, Montero-Conde C, Apellániz-Ruiz M, Calsina B, Mancikova V, 
Remacha L, Richter S, Ercolino T, Rogowski-Lehmann N, Deutschbein T, Calatayud M, Guadalix S, 
Álvarez-Escolá C, Lamas C, Aller J, Sastre-Marcos J, Lázaro C, Galofré JC, Patiño-García A, Meoro-Avilés 
A, Balmaña-Gelpi J, De Miguel-Novoa P, Balbín M, Matías-Guiu X, Letón R, Inglada-Pérez L, Torres-
Pérez R, Roldán-Romero JM, Rodríguez-Antona C, Fliedner SMJ, Opocher G, Pacak K, Korpershoek E, 
de Krijger RR, Vroonen L, Mannelli M, Fassnacht M, Beuschlein F, Eisenhofer G, Cascón A, Al-Shahrour 
F, Robledo M.
Published in the Journal of Molecular Diagnostics, 2017 Jul;19(4):575-588.
Genetic diagnosis is recommended for all pheochromocytoma and paraganglioma (PPGL) cases, as 
driver mutations are identified in approximately 80% of the cases. As the list of related genes expands, 
genetic diagnosis becomes more time-consuming, and targeted next-generation sequencing (NGS) has 
emerged as a cost-effective tool. This study aimed to optimize targeted NGS in PPGL genetic diagnostics. 
A workflow based on two customized targeted NGS assays was validated to study the 18 main PPGL 
genes in germline and frozen tumor DNA, with one of them specifically directed toward formalin-fixed 
paraffin-embedded tissue. The series involved 453 unrelated PPGL patients, of whom 30 had known 
mutations and were used as controls. Partial screening using Sanger had been performed in 275 patients. 
NGS results were complemented with the study of gross deletions. NGS assay showed a sensitivity 
≥99.4%, regardless of DNA source. We identified 45 variants of unknown significance and 89 pathogenic 
mutations, the latter being germline in 29 (7.2%) and somatic in 58 (31.7%) of the 183 tumors studied. 
In 37 patients previously studied by Sanger sequencing, the causal mutation could be identified. We 
demonstrated that both assays are an efficient and accurate alternative to conventional sequencing. Their 
application facilitates the study of minor PPGL genes, and enables genetic diagnoses in patients with 
incongruent or missing clinical data, who would otherwise be missed.
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3. Role of MDH2 pathogenic variant in phaeochromocytoma and paraganglioma patients
Calsina B, Currás-Freixes M, Buffet A, Pons T, Contreras L, Letón R, Comino-Méndez I, Remacha L, 
Calatayud M, Obispo B, Martin A, Cohen R, Richter S, Balmaña J, Korpershoek E, Rapizzi E, Deutschbein 
T, Vroonen L, Favier J, de Krijger RR, Fassnacht M, Beuschlein F, Timmers HJ, Eisenhofer G, Mannelli 
M, Pacak K, Satrústegui J, Rodríguez-Antona C, Amar L, Cascón A, Dölker N, Gimenez-Roqueplo AP, 
Robledo M. 
Published in Genetics in Medicine, 2018 Dec;20(12):1652-1662.
Purpose: MDH2 (malate dehydrogenase 2) has recently been proposed as a novel potential 
pheochromocytoma/paraganglioma (PPGL) susceptibility gene, but its role in the disease has not been 
addressed. This study aimed to determine the prevalence of MDH2 pathogenic variants among PPGL 
patients and determine the associated phenotype.
Methods: Eight hundred thirty patients with PPGLs, negative for the main PPGL driver genes, were 
included in the study. Interpretation of variants of unknown significance (VUS) was performed using 
an algorithm based on 20 computational predictions, by implementing cell-based enzymatic and 
immunofluorescence assays, and/or by using a molecular dynamics simulation approach.
Results: Five variants with potential involvement in pathogenicity were identified: three missense 
(p.Arg104Gly, p.Val160Met and p.Ala256Thr), one in-frame deletion (p.Lys314del), and a splice-site 
variant (c.429+1G>T). All were germline and those with available biochemical data, corresponded to 
noradrenergic PPGL.
Conclusion: This study suggests that MDH2 pathogenic variants may play a role in PPGL susceptibility 
and that they might be responsible for less than 1% of PPGLs in patients without pathogenic variants in 
other major PPGL driver genes, a prevalence similar to the one recently described for other PPGL genes. 
However, more epidemiological data are needed to recommend MDH2 testing in patients negative for 
other major PPGL genes.
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4. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy
Sánchez-Barroso L, Apellaniz-Ruiz M, Gutiérrez-Gutiérrez G, Santos M, Roldán-Romero JM, Curras 
M, Remacha L, Calsina B, Calvo I, Sereno M, Merino M, García-Donas J, Castelo B, Guerra E, Letón R, 
Montero-Conde C, Cascón A, Inglada-Pérez L, Robledo M, Rodríguez-Antona C.
Published in The Oncologist, 2018 Nov 23. doi: 10.1634/theoncologist.2018-0418.
Background. Peripheral neuropathy is the dose-limiting toxicity of many oncology drugs, including 
paclitaxel. There is large interindividual variability in the neuropathy, and several risk factors have been 
proposed; however, many have not been replicated. Here we present a comprehensive study aimed at 
identifying treatment and physiopathology-related paclitaxel-induced neuropathy risk factors in a large 
cohort of well-characterized patients.
Patients and Methods. Analyses included 503 patients with breast or ovarian cancer who received 
paclitaxel treatment. Paclitaxel dose modifications caused by the neuropathy were extracted from 
medical records and patients self-reported neuropathy symptoms were collected. Multivariate logistic 
regression analyses were performed to identify concomitant medications and comorbidities associated 
with paclitaxel-induced neuropathy.
Results. Older patients had higher neuropathy: for each increase of 1 year of age, the risk of dose 
modifications and grade 3 neuropathy increased 4% and 5%, respectively. Cardiovascular drugs increased 
the risk of paclitaxel dose reductions (odds ratio [OR], 2.51; p = .006), with a stronger association for 
beta-adrenergic antagonists. The total number of concomitant medications also showed an association 
with dose modifications (OR, 1.25; p = .012 for each concomitant drug increase). A dose modification 
predictive model that included the new identified factors gave an area under the curve of 0.74 (p = 1.07 
× 10-10). Preexisting nerve compression syndromes seemed to increase neuropathy risk.
Conclusion. Baseline characteristics of the patients, including age and concomitant medications, could 
be used to identify individuals at high risk of neuropathy, personalizing chemotherapy treatment and 
reducing the risk of severe neuropathy.
